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Abstract 
In humans, several dendritic cell (DC) subsets have been identified, including the CD1c+ DCs, 
CD141+ DCs and plasmacytoid DC (pDC). It has been suggested that human CD141+ DCs play a 
role in cross-presentation leading to the induction of cytotoxic T lymphocyte (CTL) responses that 
are important for immunity against tumours and intracellular pathogens. pDCs are known to be 
major responders against viruses through secretion of Type I interferons (IFNs). The role of CD1c+ 
DCs remains to be established, although there is some evidence that CD1c+ DCs prime regulatory 
responses against E. coli and Th2 type responses against allergens. As the putative equivalent of the 
human CD1c+ DCs, mouse CD11b+ DCs are efficient in priming Th2 and Th17 responses. Th2 cells 
are known to play a role against parasitic infections and aiding B cells in producing antibodies. 
Th17 cells are potent inducers of inflammation and play a role in bacterial and fungal clearance. 
DCs, upon activation, produce a range of cytokines including IL-12p70 and IL-23 which are known 
to reactivate memory CD4+ T cells. However, the specific conditions of which CD1c+ DCs produce 
these cytokines remains to be established.  
Using TLR agonists as our model stimuli, our first aim was to characterise the cytokine secretory 
profile of CD1c+ DCs in response to LPS (TLR 4 agonist), poly:IC (PIC – TLR 3 agonist) and R848 
(TLR 7/8 agonist) either alone or in combination. CD1c+ DCs displayed greater IL-1β, IL-6, IL-23 
and IL-12p70 secretion compared to other DC subsets in response to combinational TLR 
stimulation. Ankylosing spondylitis (AS) is an autoimmune disease where IL-23 has been reported 
to play an important role in its pathology. Notably, CD1c+ DCs have been identified in peripheral 
blood and synovial fluid in AS patients; however, their functional properties remain to be 
established. We observed that CD1c+ DCs derived from active, AS patients expressed significantly 
higher CD80 and CD86 compared to the CD1c+ DCs from healthy controls in response to LPS plus 
R848 stimulation. AS-derived monocytes expressed significantly higher levels of the activation 
marker CD83 compared to monocytes from healthy controls. Importantly, we demonstrated that 
AS-derived monocytes produced significantly higher TNF-α and CXCL10 compared to monocytes 
from healthy controls. Notably, we observed elevated levels of IL-12p70 produced by AS-derived 
CD1c+ DCs compared to those derived from healthy controls upon LPS plus R848 stimulation, 
although with the limited sample size this did not reach significance at a p < 0.05 level.  
Having demonstrated that CD1c+ DCs are the major producers of IL-23, we examined the 
functional consequences of IL-23 signalling using STAT3 phosphorylation as readout. We found 
protein expression of the IL-23 receptor (IL-23R) on a small percentage of memory CD4+ T cells, 
NK cells and γδ T cells and focussed on the role of CD1c+ DCs in activating these populations. 
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Th17 cells that transition towards Th1 phenotype is referred as Th17.1 cells; which have been 
reported to play a pathogenic role in multiple human autoimmune diseases. Arising from the 
memory CD4+ T cell pool, pathogenic Th17.1 cells respond to IL-1β, IL-12p70 and IL-23, leading 
to induction of IFN-γ, IL-17A, IL-17F, IL-22, GM-CSF and IL-6. Due to their pathogenic cytokine 
secretory profile and with the ability to repel corticosteroid treatments, these cells have been 
hypothesised to be the major players in autoimmunity. We demonstrated that TLR-activated CD1c+ 
DCs and monocytes were equivalent to driving the proliferation of polyclonal memory CD4+ T 
cells. Compared to monocytes, LPS plus R848-activated CD1c+ DCs induced significantly higher 
IFN-γ production by polyclonal memory CD4+ T cells. We noted that plus R848-activated CD1c+ 
DCs induced elevated levels of IL-17F by polyclonal memory CD4+ T cells compared to monocytes 
under identical conditions. We observed that CD1c+ DC derived factors, but not monocyte-derived 
soluble factors induced STAT3 phosphorylation γδ T cells, CD3intermediate and CD3negative 
populations. 
Taken together, CD1c+ DCs are major producers of IL-12p70 and IL-23 amongst peripheral blood 
myeloid cells in response R848 ligation, which was enhanced in the presence of PIC or LPS. LPS 
plus R848-stimulated CD1c+ DCs reactivated polyclonal memory CD4+ T cells to produce higher 
levels of IFN-γ, along with elevated levels of IL-17F compared to monocytes. Finally, soluble 
factors derived from LPS plus R848-activated CD1c+ DCs may play a role in activating innate and 
adaptive cell populations by triggering STAT3 phosphorylation.  
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Chapter 1 - Introduction 
1.1) Dendritic cell (DC) biology 
The human body is frequently exposed to foreign pathogens which can be harmful to the host. To 
effectively counter these pathogens, the human body is equipped with a biological network known 
as the immune system. Our immune system comprises of a large structure, linking multiple cell 
types, tissues and organs which function in unison. The immune system can be divided into two 
categories, innate and adaptive immunity. The innate immune system consists of granulocytes 
(basophils, eosinophils, neutrophils), natural killer (NK) cells, natural killer T (NKT) cells, innate 
lymphoid cells (ILCs), mucosal-associated invariant T (MAIT) cells and monocytes which respond 
rapidly and represents the first line of defence against pathogens. The adaptive immune system 
consists of B and T cells, which upon activation, results in antibody production and cell-mediated 
killing, respectively. As part of the innate immune system, dendritic cells (DCs) are strategically 
localised in lymphoid and non-lymphoid organs allowing them to constantly survey their 
environment for pathogens. DCs possess a remarkable capacity to stimulate naive T cells in a mixed 
lymphocyte reaction (MLR) and their phenotypes are different from macrophages which can be 
distinguished using immunohistochemistry, phenotypic markers as well as transcriptome expression 
(Angel et al., 2007, Banchereau and Steinman, 1998, Nussenzweig et al., 1980). In an immature 
state, DCs display superior capabilities in antigen (Ag) recognition and uptake. Upon recognition of 
foreign Ag, immature DCs then differentiate into a mature state by down-regulating its Ag uptake 
capacity and up-regulating co-stimulatory molecules and initiating cytokine production. 
1.2) DC function  
DCs are regarded as professional antigen presenting cells (APCs). DCs are well-equipped with a 
wide array of pathogen-recognition receptors (PRRs) which include toll-like receptors (TLRs), C-
type lectin receptors (CLRs) and nucleotide-binding oligomerisation domain (NOD)-like receptors 
(NLRs) (Olive, 2012). All these receptors are crucial for immature DCs to constantly survey for 
danger- or pathogen-associated molecular patterns (DAMPs or PAMPs), respectively which can be 
found on bacteria, viruses, parasites and tumours. DCs also express CLRs such as DEC-205 and 
CLEC9A which facilitate Ag uptake, while NLRs including NLRP3 facilitates recognition of 
intracellular bacterial-associated PAMPs (Geijtenbeek and Gringhuis, 2009). 
1.2.1) Toll-like receptors (TLRs) 
DCs express a wide range of extracellular TLRs which mainly recognise bacterial DAMPs and 
PAMPs, while intracellular TLRs recognise nucleic acids (Olive, 2012). Extracellular TLR 4 
recognises lipopolysaccharide (LPS) which is present on Gram-negative bacteria (Hoshino et al., 
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1999). TLR 3 recognises double-stranded (ds) RNA from viruses as well as poly:IC, a synthetic 
dsRNA analogue (Botos et al., 2009). TLRs 7 and 8 are also viral sensors that recognise single-
stranded (ss) RNA as well as imidazoquinoline derivatives including imiquimod and resiquimod 
(Hemmi et al., 2002). Imiquimod otherwise known as R837 is specifically recognised by TLR 7, 
while resiquimod or R848 triggers both TLRs 7 and 8 (Hemmi et al., 2002). Resiquimod is 
currently being investigated as a human vaccine adjuvant (Hurst et al., 2009, Vasilakos and Tomai, 
2013). Finally, TLR 9 recognises CpG motives on bacterial DNA as well as oligodeoxynucleotides 
(ODNs) (Klinman et al., 1996). Upon recognition of their cognate ligands, TLRs initiate signalling 
cascades, which promote cytokine production such as IL-1β, IL-12p70, and TNF-α which are 
crucial in T cell priming as well as activation of innate cell populations.  
 
Table 1.1: Expression of toll-like receptors on human DC subsets along with their cognate ligands. 
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1.2.2) T cell priming 
Interactions between DCs and T cells play a crucial role in priming immune responses. The priming 
of immune responses requires three signals (Reis e Sousa, 2006). Upon recognition of PAMPs or 
DAMPs, immature DCs down-regulate their Ag uptake capacity and differentiate into their mature 
state. Mature DCs then process the Ag which can be presented to two classes of major 
histocompatibility molecules (MHC), which represent signal one. Upon recognition of Ag presented 
onto class I MHC, naïve CD8+ T cells are primed to generate cytotoxic T lymphocyte (CTL) 
responses which play a crucial role against tumours and intracellular pathogens. Upon recognition 
of Ag presented onto class II MHC, naïve CD4+ T cells are primed to generate T helper (Th) 
responses. DCs then up-regulate co-stimulatory molecules (i.e CD40, CD80, CD86 and HLA-DR) 
which represents signal two. The types of Th responses being generated is highly dependent on the 
polarising cytokines such as IL-1β, IL-6, IL-10 and IL-12p70. These cytokines are produced by 
DCs, which represents signal three, Signals two and three are triggered by recognition of PAMPs or 
DAMPs via PRR.  
IL-12p70 is a heterodimeric cytokine consisting of IL-12p35 and IL-1240 subunits (Oppmann et al., 
2000). In the presence of IL-12p70, DCs can prime the differentiation of naïve CD4+ T cells into 
Th1 cells. Th1 cells characteristically produce IFN-γ, which plays a role in anti-tumour responses 
and clearance of intracellular pathogens (Figure 1.1). In addition, IL-12p70 acts on other cell types 
including NK cells leading to the production of IFN-γ, further fuelling Th1 responses. The 
cytokines which polarise naïve CD4+ T cell towards Th2 profile remains to be established. The 
generation of Th2 responses has been attributed to the presence of epithelial proteins including 
thymic stromal lymphopoieitin (TSLP) which is recognised by TSLP receptor (TSLPR) expressed 
by lung DCs in the context of asthma (Froidure et al., 2014, Kitajima and Ziegler, 2013, Larson et 
al., 2013, Melum et al., 2014). Naïve CD4+ T cells then differentiate into Th2 cells that produce IL-
4, IL-5 and IL-13, which play a role in parasitic infections and humoral responses (Geginat et al., 
2014) (Figure 1.1).  
DCs are capable of producing inflammatory cytokines including IL-1β and IL-6 which favour Th17 
cell differentiation. IL-23 is a member of the IL-12 family of cytokines, consists of IL-23p19 and 
IL-12p40 subunits, where the latter is shared with IL-12p70 (Oppmann et al., 2000). While IL-23 is 
dispensable at priming Th17 responses (Manel et al., 2008, Yang et al., 2008a, Zhou et al., 2008), 
IL-23 is required for sustaining and stabilisation of Th17 phenotype (McGeachy et al., 2009) 
(Figure 1.1). Th17 cells play a crucial role in inducing inflammation by producing their signature 
IL-17A and IL-17F cytokines, as well as IL-21 and IL-22. Th17 cells play a major role in anti-
fungal and bacterial immunity (Korn et al., 2009). Dysregulated Th17/IL-23 signalling has been 
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widely recognised in numerous autoimmune diseases including ankylosing spondylitis (AS), 
Crohn’s Disease (CD) and inflammatory bowel disease (IBD) (Izcue et al., 2008, Langrish et al., 
2005, Sherlock et al., 2012, Cua et al., 2003, D'Elios et al., 2010). IL-23 triggers the downstream 
production of IL-17A and IL-17F, which further induce expression of chemokine ligands including 
CXCL1, CXCL2 and CXCL5; promoting neutrophil and monocyte chemotaxis. Furthermore, IL-
17A and IL-17F trigger the NF-κB pathway, which enhances the production of inflammatory 
cytokines such as TNF-α (Isailovic et al., 2015). Excessive levels of these cytokines along with 
activation of numerous cell types may be a mechanism of potentiating autoimmune pathology. 
Genome-wide screens revealed IL23R gene single nucleotide polymorphisms (SNPs) variants 
including R381Q and L310P have been associated with CD, psoriasis, AS, ulcerative colitis (Di 
Meglio et al., 2013, Duerr et al., 2006, McGovern et al., 2014, Rueda et al., 2008). Furthermore, a 
recent phase I clinical trial with a monoclonal antibody, tildrakizumab (also known as MK-3222 or 
SCH 900222) that specifically binds to the IL-23p19 subunit demonstrated clinical improvement of 
psoriasis (Kopp et al., 2015). These findings, therefore strengthen the idea that IL-23 signalling is 
critically involved in human autoimmune diseases. 
Th17 cells are capable of transitioning towards a Th1 cell phenotype, and these cells are now 
referred to as Th17/1 or Th17.1 cells (Annunziato et al., 2007, Duhen and Campbell, 2014, Ramesh 
et al., 2014). Th17.1 cells which have been hypothesised as the major player in human autoimmune 
diseases arise from memory CD4+ T cell pool in the presence of IL-1β, TNF-α, IL-12p70 and IL-23 
(Figure 1.1). These cells produce a wide range of cytokines including IFN-γ IL-17A, IL-17F, IL-
21, IL-22, granulocyte colony-macrophage stimulating factor (GM-CSF) and IL-6. Dysregulated 
immune responses are harmful to the host, therefore in addition to their priming capabilities, DCs 
also play a role in maintaining immune tolerance and regulating tissue homeostasis. Production of 
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Figure 1.1: Polarisation of naïve CD4+ T cells by human DCs towards memory Th phenotypes. 
Human DCs express extracellular and endosomal TLRs which are capable of detecting PAMPs and 
DAMPs. Upon recognition, DCs produce a wide array of cytokines and are able to polarise naïve 
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1.3) Human blood DCs 
Human DCs comprise approximately 1% of haematopoietic cells in the blood or any lymphoid 
organs. Human DCs arise from CD34+ haematopoietic stem cells (HSCs) in the bone marrow 
giving rise to monocyte-DC progenitor with the ability to develop into monocytes or common DC 
progenitor (Liu and Nussenzweig, 2010). Unlike B or T cells which unequivocally express surface 
immunoglobulin or TCR respectively, there is no cell surface marker that uniquely identifies all 
DCs. Human blood DCs do not express lineage (lin) markers including CD3, CD14, CD16, CD19, 
CD20, CD34, CD56, but express high levels of HLA-DR (lin- HLA-DR+), along with potent 
capabilities at inducing allogeneic MLR (Hoshino et al., 1999, Izcue et al., 2008). Human DCs can 
be further sub-divided into CD11c- plasmacytoid (p) and CD11c+ conventional (c) DCs. pDCs are 
further subsided into two subsets based on the expression of CD2 (Matsui et al., 2009). The CD11c+ 
cDCs comprise of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ DCs. The alignment of human and 
mouse DCs has proven difficult because markers defining mouse DCs including CD8 on murine 
lymphoid DCs are absent on human DCs. Furthermore, myeloid markers CD1c and CD141 are 
absent on mouse DCs. Transcriptional and functional analyses have aligned the human CD141+ 
DCs with mouse CD8+/CD103+ DCs, while the human CD1c+ DCs closely resemble mouse 
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Table 1.2 – Functional and phenotype of human DC subsets. Adapted and modified from (O’Keeffe 
et al., 2015).  
 
1.3.1) Human monocyte-derived DCs (MoDCs) 
Due to difficulties of working with ex vivo-isolated human DCs such as their low frequency in the 
circulation, studies of human DC have relied heavily on in vitro-generated DCs. Functional DCs 
can be derived from classical CD14+ monocytes as well as human CD34+ progenitors cultured in 
vitro using IL-4 and granulocyte macrophage-colony stimulating factor (GM-CSF), termed MoDCs 
(Sallusto and Lanzavecchia, 1994). MoDCs have been heavily employed in multiple clinical trials 
of DC immunotherapy against cancer (Radford et al., 2014, Palucka et al., 2006). Recently, Segura 
et al. reported that inflammatory DC (infDC) isolated from tumour ascites of cancer patients and 
synovial fluid from rheumatoid arthritis (RA) patients ex vivo are the equivalent of in vitro-derived 
MoDCs (Segura et al., 2013b). These findings that indicated MoDCs derived from monocytes rather 
than DC precursors. Human MoDCs express HLA-DR, CD11b, CD11c, CD1c, CD206, FcεRI, 
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Sirpα, CD1a and CD14 markers (Guttman-Yassky et al., 2007, Segura et al., 2013b, Wollenberg et 
al., 2002).  
Human MoDCs express CSF1R and ZBTB46 transcription factors; which are important for the 
development of mouse MoDCs in vivo (Greter et al., 2012, Meredith et al., 2012, Satpathy et al., 
2012). Previously, human DCs expressing markers CD11c and CD1c were identified in synovial 
fluid of RA patients (Jongbloed et al., 2006, Moret et al., 2013, Moret et al., 2014), detailed 
transcriptome analyses have now demonstrated that this DC population closely aligned to in vitro-
derived MoDCs [33]. Furthermore, Segura et al. and Van Beelen et al. reported that MoDCs were 
able to induce Th17 responses due to their ability to secrete IL-1β, IL-6 and IL-23 in response to 
PamCSK (TLR 1/2 agonist) but not in response to peptidoglycan (Segura et al., 2013b, van Beelen 
et al., 2007). Segura et al. demonstrated that MoDCs isolated from tumour ascites induced naive 
CD4+ T cells to produce IFN-γ, IL-17A, IL-5 and IL-13 ex vivo, although the role of this DC subset 
at priming Th1, Th2 and Th17 responses remains to be confirmed (Segura et al., 2013b). 
Furthermore, when incubated with Staphylococcus aureus Enterotoxin B (SEB), human MoDCs 
reactivated autologous memory CD4+ T cells to produce IFN-γ and IL-17A (Segura et al., 2013b). 
Taken together, these findings suggest that the induction of Th17 responses may not be an exclusive 
ability of one DC subset, but rather redundant in an inflammatory environment.  
1.3.2) Plasmacytoid DCs 
pDCs are defined as Lin- CD11c- CD123 (IL-3Rα)+ CD303 (BDCA-2)+ CD304 (BDCA-4)+ 
CD45RA+ cells (Reizis et al., 2011). IL-3 mediates the survival of human pDCs in vitro (Cella et 
al., 1999). pDCs are located in the blood and lymphoid organs, while they are absent in the non-
lymphoid organs in the absence of inflammation. The recognition of foreign nucleic acids is 
mediated by the expression of endosomal TLRs, specifically TLR 7 and 9 (Heil et al., 2004, 
Kadowaki et al., 2001). Activation of these TLRs results in secretion of Type I interferon (IFN) via 
the myeloid differentiation primary response protein 88 (MyD88)-IRF 7 pathway. This further leads 
to the production of inflammatory cytokines including TNF-α and IL-6 via the MYD88-nuclear 
factor κB (NF-κB) pathway. Due to their constitutive expression of IRF7 and Type I IFN 
production, pDCs play an important role in mediating anti-viral immunity against human immune 
deficiency virus (HIV), herpes simplex virus (HSV) and influenza virus (Gilliet et al., 2008).   
pDCs are important inducers of Type I interferon (IFN) responses. Type I IFNs derived from pDCs 
were previously demonstrated to trigger IL-12, IL-18 and IL-23 production from MoDCs, 
indicating crosstalk between DC subsets to elicit optimal immune responses (Santini et al., 2000). 
One study has reported that pDCs stimulated with R837 (a strictly TLR 7 agonist) up-regulated IL-
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23p19 mRNA, although their production of IL-23 protein remains to be determined (Yu et al., 
2010). Similarly, the ability of pDCs to produce IL-12p70 remains to be established. pDCs express 
blood DC antigen 2 (BDCA-2) and ligation of BDCA-2 with a monoclonal antibody suppressed the 
production of Type I IFNs in response to TLR stimulation (Dzionek et al., 2001). Furthermore, the 
association of BDCA-2 and immunoglobulin-line transcript 7 (ILT7) with the γ-chain of high-
affinity Fc receptor for IgE (FcεRIγ), results in the activation of the immunoreceptor-based tyrosine 
activation motif (ITAM) signalling pathway inhibits Type I IFN production (Cao et al., 2006, Cao 
et al., 2007). Stimulation of pDCs with R848 (TLR 7 and 8 agonists) inhibits IFN-α production by 
down-regulating the IRF7 and IFN-α mRNA expression (Marshall et al., 2007).   
 
1.3.3) Human CD141+ DCs – phenotype and cytokine production 
CD141+ DCs comprise approximately 0.03% of peripheral blood mononuclear cells (PBMCs) and 
are localised within the blood, liver, skin, lung, spleen, tonsils and lymph node (Bamboat et al., 
2009, Haniffa et al., 2012, Jongbloed et al., 2010, Poulin et al., 2012, Poulin et al., 2010). Due to 
their rarity in numbers, detailed functional analyses have been limited. Transcriptional and 
functional analyses have now aligned human CD141+ DCs with mouse CD8+/CD103+ DCs (Haniffa 
et al., 2012, Robbins et al., 2008) Like their murine counterpart, CD141+ DCs express fms-like 
tyrosine kinase 3 (Flt3) and can be expanded in vitro (Jongbloed et al., 2010, Poulin et al., 2010) 
and in vivo (Ding et al., 2014) in the presence of Flt3 ligand (Flt3L) (Jongbloed et al., 2010). These 
data suggested the importance of Flt3L in their development. 
Like their murine counterparts, CD141+ DCs selectively express C-type lectin CLEC9A (Caminschi 
et al., 2008, Huysamen et al., 2008, Sancho et al., 2009), nectin-like protein 2 (NELC2) (Galibert et 
al., 2005) and chemokine receptor XCR1 (Bachem et al., 2010, Crozat et al., 2010), express high 
levels of toll-like receptor (TLR) 3 which recognises double-stranded (ds) RNA (Hemont et al., 
2013, Jongbloed et al., 2010) and express TLR 8 which recognises single-stranded (ss) RNA 
(Jongbloed et al., 2010). Furthermore, CD141+ DCs are the major producers of IFN-λ in response to 
dsRNA, a feature uniquely shared with its mouse CD8+/CD103+ counterpart (Lauterbach et al., 
2010). CD8+ CD103+ DCs in mice that express TLRs 3, 4 and 9 and produce IL-12p70 upon 
stimulation with poly:IC (PIC – a TLR 3 agonist), LPS (a TLR 4 agonist) and CpG (a TLR 9 
agonist) respectively (Hochrein et al., 2001). However, stimulation of CD141+ DCs with a wide 
range of TLR agonists including PIC and R848 or employment of secondary T cell-mediated 
signals including CD40 ligand (CD40L) fail to enhance IL-12p70 production (Hemont et al., 2013, 
Jongbloed et al., 2010, Nizzoli et al., 2013, Poulin et al., 2010). Taken together, current studies to 
26 | P a g e  
 
date suggest that this DC subset is not the major producer of IL-12p70. However, it remains a 
possibility that CD141+ DCs may produce IL-12p70 through a yet, unidentified mechanism which 
may not be TLR-dependent. Haniffa et al. previously reported that stimulation of CD141+ DCs with 
PIC up-regulated IL-23p19 mRNA; however, its secretion of IL-23 protein remains to be 
determined (Haniffa et al., 2012).  Furthermore, CD141+ DCs stimulated either with PIC alone or 
R848 alone do not produce IL-1β, but are capable at producing IL-6 in response to these TLR 
agonists (Haniffa et al., 2012, Hemont et al., 2013, Jongbloed et al., 2010).  
1.3.3.2) Role of human CD141+ DCs in T cell responses 
Like their mouse counterpart, CD141+ DCs excel at cross-presentation, a process where exogenous 
Ag is processed and presented to class I MHC machinery, leading to the generation of cytotoxic T 
lymphocyte (CTL) as well as Th1 responses (Haniffa et al., 2012, Hemont et al., 2013, Jongbloed et 
al., 2010). Therefore, CD141+ DCs are proposed to play a major role in tumour and intracellular 
pathogen clearance. CD141+ DCs are known to be potent stimulators of allogeneic (donor HLA 
mismatch) naïve CD4+ T cell proliferation (Hemont et al., 2013, Jongbloed et al., 2010, 
Watchmaker et al., 2014, Yu et al., 2014). Upon stimulation with PIC, CD141+ DCs excel at 
inducing IFN-γ production by CD4+ T cells. Studies to date show that CD141+ DCs are the major 
inducers of Th1 responses upon stimulation with PIC. Given that CD141+ DCs do not produce high 
levels of IL-12p70 in response to PIC stimulation (Hemont et al., 2013, Jongbloed et al., 2010, 
Nizzoli et al., 2013), Th1 priming by this DC subset may occur independently of this cytokine much 
like the murine CD8+ DC counterpart via the expression of CD70 (Soares et al., 2007).  
Furthermore, CD141+ DCs produce high levels of CXCL10 and CCL5 upon PIC stimulation, 
suggesting their capability in Th1-priming (Hemont et al., 2013, Jongbloed et al., 2010).  
In response to live-attenuated influenza virus (LAIV), CD141+ DCs primed Th2 responses and 
induced allogeneic, naïve CD4+ T cells to produce IL-5 and IL-13 (Yu et al., 2014). Few studies 
have reported the role of CD141+ DCs at activating autologous, memory CD4+ T cells (Ding et al., 
2014, Schlitzer et al., 2013). Furthermore, lung CD141+ DCs primed autologous CD4+ T cells to 
produce IFN-γ in response to Aspergillus fumigatus (Schlitzer et al., 2013).  
1.3.4) Human CD1c+ DCs 
Human CD1c+ DCs localise in lymphoid and non-lymphoid tissues, including blood, lymph nodes, 
tonsils, spleen, skin, liver, kidneys, lungs and gut (Demedts et al., 2005, Haniffa et al., 2012, 
Jongbloed et al., 2010, Kassianos et al., 2012, Klechevsky, 2013, Masten et al., 2006, Mittag et al., 
2011, Segura et al., 2013a, Watchmaker et al., 2014). Transcriptional and functional analyses have 
aligned human CD1c+ DCs with mouse CD11b+ DCs as their murine homologues (Haniffa et al., 
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2012, Robbins et al., 2008, Watchmaker et al., 2014). In humans, circulating CD1c+ DCs are 
characterised by expression of CD11c, CD11b, CD1c, MHC-II, CD45RO and Signal regulatory 
protein-α (SIRPα or CD172α) (Dzionek et al., 2000, MacDonald et al., 2002, Mittag et al., 2011). In 
the dermis, CD1c+ DCs co-express CD1a, while intestinal CD1c
+ DCs express CD103 
(Watchmaker et al., 2014). It is worth mentioning that dermal CD1a+ DCs can be further subdivided 
into two subsets based on the expression of Langerin (Bigley et al., 2015). Blood CD1c+ DCs are 
closely related to Langerin+ dermal DCs that express CD1a, CD11b, CD11c as well as a lower level 
of Langerin expression (Bigley et al., 2015). Similarly, McGovern et al. previously reported that 
CD1c+ DCs with a lower CD14 expression are localised within the human dermal tissue (McGovern 
et al., 2014).  
The CD1c marker does not exclusively identify this DC subset, as it is also expressed by B cells, 
monocytes and can be induced on MoDCs and CD141+ DCs (Ding et al., 2014, Dzionek et al., 
2000, Poulin et al., 2010). In an inflammatory setting, CD1c+ DCs are difficult to discern from 
human MoDCs, as the latter DC subset also express CD1c, MHC-II, CD11c and CD11b (Segura et 
al., 2013b). However, the identification of new markers including Flt3, interferon regulatory factor 
(IRF) 4 and the absence of monocytic markers including CD64 (FcγRI), will allow a more precise 
segregation of bonafide human CD1c+ DCs from MoDCs (Langlet et al., 2012, Plantinga et al., 
2013, Schlitzer et al., 2013, Tamoutounour et al., 2012).  
Similar to CD141+ DCs, CD1c+ DCs can be expanded in response to Flt3L (Breton et al., 2015, 
Ding et al., 2014, Jefford et al., 2003, Maraskovsky et al., 2000, Pulendran et al., 2000). 
Furthermore, like CD11b+ DC in mice, CD1c+ DCs express IRF4 which is crucial for their 
development (Schlitzer et al., 2013, Vander Lugt et al., 2014, Watchmaker et al., 2014). In addition, 
IRF8 appears to be important for CD1c+ DC development. Individuals with IRF8 mutations at 
K108E and T80A exhibit a dramatic reduction in their numbers (Hambleton et al., 2011). 
Interestingly, the same study highlighted that the specific loss of CD1c+ DCs increased the 
susceptibility of patients towards mycobacterial infections, indicating a specific role of CD1c+ DCs 
in inducing anti-mycobacterial immunity [62]. This notion was further supported by another study 
by Lozza et al., whereby CD1c+ DCs but not other DC subsets were the main responders against 
Mycobacterium tuberculosis, via production of TNF and IL-6 (Lozza et al., 2014a).  
1.3.4.1) Toll-like receptor expression and cytokine production by CD1c+ DCs  
CD1c+ DCs express TLRs 1, 2, 3, 4, 5, 7 and 8 (Hemont et al., 2013). Stimulation of CD1c+ DCs 
through TLRs 1, 2, 5 do not induce production of IL-1β, IL-6 and IL-12p70 (Hemont et al., 2013). 
However, stimulation of CD1c+ DCs with TLR 3, 4, 7 and 8 agonists induced production of IL-1β, 
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IL-6, TNF-α and IL-12p70 (Hemont et al., 2013, Jongbloed et al., 2010, Acosta-Rodriguez et al., 
2007a, Napolitani et al., 2005). These findings, therefore indicate that cytokine production by 
CD1c+ DCs is induced upon TLR 3, 4, 7 and 8 stimulations. The ability of CD1c
+ DCs to produce 
IL-1β and IL-6 in response PIC, LPS and R848 has been reported (Dillon et al., 2010, Hemont et 
al., 2013). Of note, IL-1β and IL-6 production upon TLR 3 and 4 ligation are lower compared to 
TLR 7 and 8 ligation (Hemont et al., 2013).  
IL-12p70 is a heterodimeric cytokine consisting of IL-12p35 and IL-12p40 subunits (Oppmann et 
al., 2000). Stimulation of CD1c+ DCs with other stimuli including PIC, LPS, PamCSK (TLR 1/2 
agonist) do not induce IL-12p70 production (Hemont et al., 2013, Jongbloed et al., 2010, Napolitani 
et al., 2005, Nizzoli et al., 2013). CD1c+ DCs produce minimal IL-12p70 in response to R848, 
which can be significantly enhanced in response to LPS (Acosta-Rodriguez et al., 2007a, Napolitani 
et al., 2005, Nizzoli et al., 2013), suggesting a possible role for CD1c+ DCs in priming Th1 
responses (Acosta-Rodriguez et al., 2007a). This is due to the cooperative mechanism between TLR 
8 and with TIR-domain-containing adaptor protein inducing IFNβ (TRIF)-coupled TLRs including 
TLRs 3 and 4. These findings are in contrast with the mouse system as murine CD11b+ DCs are 
known to not produce IL-12p70 or prime Th1 responses [115-117]. These findings, therefore 
highlight a species-to-species difference in DC biology. Importantly, the enhancement of IL-12p70 
levels in the presence of multiple TLR agonists seems to be specific to CD1c+ DCs, but not CD141+ 
DCs or pDCs (Napolitani et al., 2005, Nizzoli et al., 2013).  
IL-23 is a heterodimeric cytokine consisting of IL-23p19 and IL-12p40 subunits (Oppmann et al., 
2000). IL-23 predominantly signals via STAT3, which is crucial for the induction of retinoic-acid-
receptor-related orphan receptor-γ (RORγt) and IL-17A (Durant et al., 2010, Fischer, 2008). Murine 
CD11b+ DCs are the major producers of IL-23 in response to flagellin which was dependent on 
TLR 5 signalling (Kinnebrew et al., 2012). Additionally, murine CD11b+ DCs were the obligate 
source of IL-23 in response to Citrobacter rodentium infection in vivo (Satpathy et al., 2013). The 
ability of CD1c+ DCs to produce IL-23 remains controversial. Previous studies also reported that 
CD1c+ DCs lack IL-23-producing capabilities in response to various stimuli including CD40L, E. 
coli, a combination of TNF-α, IFN-α with prostaglandin E2 (PGE2) (Jefford et al., 2003). Gerosa et 
al. previously reported that R848 alone does not trigger IL-23 production by CD1c+ DCs (Gerosa et 
al., 2008). However, CD1c+ DCs used in that study were pre-treated with IL-4 prior to R848 
stimulation whereby IL-4 has been reported to inhibit IL-23 production (Guenova et al., 2015). 
Therefore, the ability of R848 to stimulate IL-23 production from CD1c+ DCs directly ex vivo 
remains to be determined.  
29 | P a g e  
 
R848 can significantly enhance IL-23 levels induced by Mycobacterium tuberculosis (Mtb), 
indicating that IL-23 production by CD1c+ DCs can be enhanced in the presence of additional 
stimuli (Gerosa et al., 2008). Additionally, unstimulated lung CD1c+ DCs express the highest level 
of IL-23p19 mRNA transcript [76]. While Acosta-Rodriguez et al. reported that CD1c+ DCs 
produced IL-23 in response to LPS plus R848 stimulation, but the conditions in which they do so 
remains to be fully established (Acosta-Rodriguez et al., 2007a). Furthermore, the enhancement of 
IL-23 production in the concurrent presence of other TLR agonists remains to be established. 
Finally, the ability of other DC subsets including pDCs and CD141+ DCs to produce IL-23 has yet 
to be addressed. This thesis will therefore, examine the ability of R848 to induce IL-23 by CD1c+ 
DCs and the effects of PIC and LPS at augmenting its levels; and whether CD1c+ DCs are the major 
DC subset at producing IL-23 and IL-12p70.  
1.3.4.2) TLR 8 and human autoimmunity  
Intracellular TLRs including TLRs 7 and 8 play a crucial role in RNA recognition, providing a 
platform for identifying RNA viruses. In addition to their protective role, several reports have 
highlighted the role of TLR 7 in promoting autoimmunity in mice (Deane et al., 2007, Walsh et al., 
2012). Furthermore, TLR 8 in the mouse system is non-functional and does not recognise ssRNA 
ligands, RNA viruses or any agonists which engage human TLR 8 (Heil et al., 2004, Hemmi et al., 
2002). Of note, stimulation of TLR 7 and TLR 8 is a sequence-dependent process. For example, 
TLR 7 recognises guanine-uridine (GU)-rich sequences, while TLR 8 recognises adenosine-uridine 
(AU) rich sequences (Forsbach et al., 2008). Furthermore, TLR 8 deficient mice showed increased 
TLR 7 up-regulation as well as increased serum levels of autoantibodies (Demaria et al., 2010). 
This finding suggests a regulatory role of mouse TLR 8 in TLR 7 expression. Following that, the 
role of human TLR 8 in autoimmune diseases largely derived from on work performed on mouse 
TLR7 (Deane et al., 2007, Walsh et al., 2012). There is circumstantial evidence pointing a role of 
TLR 8 in human autoimmunity including RA (Sacre et al., 2008) and inflammatory gastrointestinal 
disorders (Parronchi et al., 1997, Prinz et al., 2011), whereby elevated levels of IL-12 and IL-23 
have been reported. Importantly, TLR 8 mRNA expression is elevated and positively correlated 
with IL-1β transcripts in Still’s Disease patients (Guiducci et al., 2013). Taken together, these 
studies highlight a species-to-species difference in TLR 8 function.  
Resiquimod or R848 has been demonstrated to induce human MoDC maturation via up-regulation 
of co-stimulatory molecules along with the production of IL-12p70 (Paustian et al., 2011, Spranger 
et al., 2010). Utilising R848 in pre-clinical models including mice, rats and pigs have demonstrated 
superior Th1 responses characterised with IFN-γ-producing CD4+ T cells (Vasilakos and Tomai, 
2013). TLR 8 could also recognise self-RNA autoantibody complexes, leading to the induction of 
30 | P a g e  
 
TNF-α and IL-6 by CD11c+ cDCs (Ganguly et al., 2009, Vollmer et al., 2005). Following that, 
CD11c+ cDCs have been identified at sites of inflammation which have been hypothesised to play a 
role in disease pathology (Baumgart et al., 2005, Baumgart et al., 2009, Hart et al., 2005, Jongbloed 
et al., 2006, Moret et al., 2013, Sakuraba et al., 2009, Silva et al., 2004). The marker CD11c is not 
exclusively expressed by MoDCs, but also present on CD1c+ DCs and macrophages (Hume, 2008, 
Segura et al., 2013b, MacDonald et al., 2002). Incorporation of DC-specific markers including Flt3, 
Irf4 and the lack of CD64 expression will allow a more precise identification of CD1c+ DCs as well 
as their potential role in contributing disease pathology. While a direct role of CD1c+ DCs has yet to 
be established, activation of TLR 8 in CD1c+ DCs with R848 or in combination with other stimuli 
would induce dual IL-12p70 and IL-23 may be the key mechanism in promoting human 
autoimmunity.  
1.4.)  Role of CD1c+ DCs at priming CD4+ T cell responses 
The murine CD11b+ DCs are reputedly known for its ability to prime CD4+ T cell responses (Merad 
et al., 2013, Persson et al., 2013, Schlitzer et al., 2013, Vander Lugt et al., 2014). Of note, CD1c+ 
DCs express higher levels of mRNA reputedly associated with MHC Class II processing such as 
Ifi30, HLA-DMA, cathepsin H and cathepsin S, suggesting a role for CD1c+ DCs to prime CD4+ T 
cell responses (Jongbloed et al., 2010). However, it remains to be determined if this DC subset is 
able to prime Th2 and Th17 responses, much like its murine CD11b+ DC counterpart.  
1.4.1) Th1 cells 
Th1 cells arise in response to IL-12p70, and its development is governed by transcription factors; T-
bet and STAT4 (Jacobson et al., 1995). In comparison to CD141+ DCs, CD1c+ DCs are less potent 
at priming Th1 responses upon stimulation with PIC (Hemont et al., 2013, Jongbloed et al., 2010). 
Interestingly, PIC-stimulated CD1c+ DCs produced equal levels of CCL5 and CXCL10, along with 
higher levels of IL-12p70 in response to PIC compared to CD141+ DCs; however, CD141+ DCs 
were superior at priming Th1 responses (Hemont et al., 2013). These results suggested that priming 
of Th1 responses may not be totally dependent on cytokines or chemokines. Similarly, CD1c+ DCs 
stimulated with LPS alone or R848 alone fail to prime Th1 responses (Hemont et al., 2013, Acosta-
Rodriguez et al., 2007a). It is worth noting that CD1c+ DCs in the aforementioned studies were not 
stimulated under conditions in which they would optimally produce IL-12p70. CD1c+ DCs have 
been demonstrated to produce substantial amounts of IL-12p70 in response to LPS plus R848 
combination (Napolitani et al., 2005, Nizzoli et al., 2013, Acosta-Rodriguez et al., 2007a), although 
its role at priming Th1 responses remains to be determined. The mouse CD11b+ DCs do not prime 
or reactivate Th1 responses given its lack of IL-12 production in response to TLR stimulations 
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(Hochrein et al., 2001, Merad et al., 2013). These findings highlight species-to-species difference in 
DC function. However, Napolitani et al. reported that MoDCs stimulated with LPS plus R848 
primed Th1 responses (Napolitani et al., 2005). Taken together, CD1c+ DCs are not the major DC 
subset at priming Th1 responses.   
1.4.2) Th2 cells 
Th2 cells are dependent on transcription factors STAT6 and GATA3 for their development and play 
significant role against parasitic infections as well as promoting humoral B cell responses 
(Finkelman et al., 2000, Geginat et al., 2014, Jin et al., 2014). Murine CD11b+ DCs are specialised 
at inducing Th2 responses (Kitajima and Ziegler, 2013, Larson et al., 2013, Plantinga et al., 2013, 
Vander Lugt et al., 2014). There is some evidence to suggest a similar role for human CD1c+ DCs. 
CD1c+ DCs stimulated either with TSLP or house dust mite allergens induced allogeneic naïve 
CD4+ T cells to produce IL-5, IL-9 and IL-13 (Froidure et al., 2014). In the airway mucosa, CD1c+ 
DCs express the TSLP receptor (TSLPR) (Froidure et al., 2014). Several studies have reported 
elevated levels of TSLP in the airway mucosa of allergic rhinitis patients, thus indicating the 
potential role of CD1c+ DCs at contributing towards allergic responses (Kamekura et al., 2009, 
Ziegler et al., 2013).  
1.4.3) Th17 cells 
Murine CD11b+ DCs are reputedly known to prime Th17 responses (Satpathy et al., 2013, 
Kinnebrew et al., 2012, Persson et al., 2013, Schlitzer et al., 2013, Vander Lugt et al., 2014), 
however the amount evidence to suggest the same for CD1c+ DCs remains lacking. In steady-state, 
unstimulated CD1c+ DCs derived from the gut lamina propria were unable to prime Th17 responses 
(Watchmaker et al., 2014). This finding was attributed to the low expression of IL-6 and IL-23 
mRNA. It will be interesting to revisit CD4+ T cell priming with activated DCs in vitro, as gut 
CD1c+ DCs were previously reported to produce IL-23 but not IL-12p70 upon stimulation with LPS 
plus R848 combination in vitro (Dillon et al., 2010). In response to Aspergillus fumigatus, lung 
CD1c+ DCs but not monocytes or CD141+ DCs reactivated CD4+ T cells to produce IL-17A 
(Schlitzer et al., 2013). It is worth noting that the study utilised total autologous, CD4+ T cells which 
contain Aspergillus-specific memory T cells. Previously, CD1c+ DCs but not MoDCs stimulated 
with peptidoglycan (PGN) primed naïve CD4+ T cells towards Th17 phenotype, attributed to their 
ability to produce IL-1β and IL-6, but not IL-12p70 (Acosta-Rodriguez et al., 2007a, van Beelen et 
al., 2007). These findings were not unexpected as the substantial amount of IL-12p70 being 
produced by CD1c+ DCs upon LPS plus R848 stimulation is known to inhibit Th17 differentiation 
(Acosta-Rodriguez et al., 2007a, Acosta-Rodriguez et al., 2007b, LeibundGut-Landmann et al., 
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2007). Taken together, the ability of CD1c+ DCs to prime Th17 responses may be stimuli-dependent 
or a tissue-specific role.  
1.5) Role of DCs at maintaining memory CD4+ T cell pool 
Upon encounter of foreign Ag presented by mature DCs, naive CD4+ T cells become fully 
stimulated and highly proliferative, leading to differentiation of effector T cells that perform T cell-
mediated killing and release of effector cytokines. This is known as the expansion phase (Gasper et 
al., 2014). This is then followed by a period of contraction, where approximately 90% of the Ag-
specific T cells undergo apoptosis. The remaining pool of T cells further develops into long-lived 
memory T cells, this is known as the memory phase. Upon recognition of the same Ag presented by 
DCs in the context of MHC molecules, memory T cells respond quickly by inducing cytokine 
responses. While the reactivation of memory CD4+ T cells is mediated by Ag-MHC II complex, its 
maintenance by DCs can also occur independently of TCR:MHC interactions. Indeed, Geginat et al. 
previously reported the maintenance of memory CD4+ T cell pool is mediated via IL-7 and IL-15 
(Geginat et al., 2001). This was an important finding given that IL-15 can be produced by human 
DCs themselves (Ferlazzo et al., 2004), while IL-7 is mainly produced by stromal cells (Jiang et al., 
2005). In addition to these homeostatic cytokines, DCs are capable of producing IL-12p70 and IL-
23 which not only contribute to memory CD4+ T cell proliferation, but also their effector responses. 
1.5.1) Effects of IL-12p70 and IL-23 on memory CD4+ T cells 
The IL-23 receptor (IL-23R) is a heterodimer consisting of IL-23R chain, which binds to the IL-
23p19 subunit and IL-12β1 chain, the latter interacts with the IL-12/23 p40 subunit. In humans, 
memory but naïve CD4+ T cells express IL-23R (Oppmann et al., 2000, Wilson et al., 2007). Since 
the initial discovery of IL-23, Oppmann et al. reported that IL-23 act on mouse memory (CD4+ 
CD45RBlow) but not naïve (CD4+ CD45RBhigh) T cells purified from mouse spleen and mesenteric 
lymph node (Oppmann et al., 2000). This was due to the lack of IL-23 receptor (IL-23R) expression 
by mouse CD4+ CD45RBhigh naïve T cells, compared to CD4+ CD45RBlow memory T cells. 
Furthermore, stimulation of human memory but not naïve CD4+ T cells with recombinant IL-23 
induces memory CD4+ T cell proliferation and production of IL-17A and IFN-γ (Oppmann et al., 
2000, Wilson et al., 2007). Importantly, stimulation of IL-23R+ memory T cells induced higher 
expression of IL17A, IL17F and IL22, which define a signature Th17 cytokine profile compared to 
their IL-23Rnegative counterparts (Wilson et al., 2007). Therefore, IL-23 is crucial for maintaining 
memory Th17 cell responses. IL-23 synergises with other cytokines including IL-1β, TNF-α and 
IL-6 to enhance IL-17 production by memory CD4+ T cells (Duhen and Campbell, 2014, van 
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Beelen et al., 2007, Wilson et al., 2007). In addition to that, IL-23 also induces production of IL-21 
which promotes Th17 generation in an autocrine mechanism (Wei et al., 2007).  
The role of IL-23 in promoting autoimmunity is undisputed (Hirota et al., 2011, Izcue et al., 2008, 
Lee et al., 2012, McGeachy et al., 2007, Murphy et al., 2003). IL-23 triggers proliferation of 
memory CD4+ T cells and IL-17A production in a dose-dependent manner (Wilson et al., 2007, 
Oppmann et al., 2000). IL-23 also signals through STAT4 leading to induction of IFN-γ by memory 
CD4+ T cells, albeit to a lesser extent compared to IL-12p70 (Oppmann et al., 2000). The role of IL-
23 in human diseases was further supported by multiple polymorphisms in the IL23R locus, 
indicating that IL-23/IL-23R signalling to be the crucial factor (Di Meglio et al., 2013, Duerr et al., 
2006, McGovern et al., 2014, Rueda et al., 2008). Several studies have now suggested that IL-23 
induces IFN-γ IL-17A-double producing T cells and repression of IL-10 induction (Duhen et al., 
2013, Ramesh et al., 2014) (Figure 1.2). Stimulation of memory CD4+ T cells with IL-12p70 
promotes memory CD4+ T cell proliferation and IFN-γ production (Oppmann et al., 2000). The role 
of IL-12p70 in promoting transition of memory Th17 cells towards Th1 phenotype was previously 
reported (Annunziato et al., 2007, Duhen et al., 2013). Duhen et al. demonstrated that IL-12p70 in 
combination with IL-1β enhanced T-bet and STAT4 expression in memory Th17 cells, leading to 
production of IL-17A, IFN-γ and GM-CSF (Duhen et al., 2013).  
1.6) Memory Th17.1 cells – phenotype  
While naïve CD4+ T cells are able to differentiate into memory Th lineages, and it has become 
increasingly clear that acquisition of a certain phenotype is not irreversible. Memory Th cells are 
known to display functional plasticity and their ability to transition from one phenotype to the other 
is highly influenced by inflammatory stimuli. One such example would be the plasticity of memory 
Th17 cells towards Th1 phenotype which are now known as Th17.1 cells (Annunziato et al., 2007, 
Boniface et al., 2010, Cosmi et al., 2008, Duhen et al., 2013, Ramesh et al., 2014) (Figure 1.2). 
Th17.1 cells which express chemokine receptors; CXCR3, CCR6: C-type lectin; CD161: and IL-
23R (Annunziato et al., 2007, Nistala and Wedderburn, 2009), and have been identified in arthritic 
patients (Cosmi et al., 2008, Maggi et al., 2014, Nistala and Wedderburn, 2009), CD patients 
(Annunziato et al., 2007, Ramesh et al., 2014), IBD patients (Globig et al., 2014), and AS patients 
(Limon-Camacho et al., 2012, Zhang et al., 2012). Th17.1 phenotype can be distinguished from 
classical, memory Th1 cells based on the expression of CD161, where it is not expressed on Th1 
cells (Annunziato et al., 2013, Cosmi et al., 2008). Th17.1 cells comprise approximately 10 – 20% 
of total memory CD4+ T cells within healthy individuals (Duhen et al., 2013). Notably, 
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approximately 4% of Th17.1 cells co-produce IFN-γ and IL-17A have been hypothesised to play a 
pathogenic role in human autoimmune diseases.  
Th17.1 cells isolated from inflamed tissues of CD patients display elevated levels of IL17A, IL17F, 
IL22 and CSF2 compared to Th17.1 cells isolated from non-inflamed tissues (Ramesh et al., 2014). 
Furthermore, pathogenic Th17.1 cells express MDR1, which renders them resistant to corticosteroid 
treatment (Basdeo et al., 2015, Ramesh et al., 2014). To further strengthen the notion that Th17 
cells transition to Th1 phenotype in vivo, the common TCR Vβ (TCRBV) usage was compared 
between CD161+ Th17 and CD161+ Th1 cells (non-classic Th1) and demonstrated that both Th 
subsets were of common origin (Cosmi et al., 2011, Nistala et al., 2010). Furthermore, non-classic 
Th1 and to a lesser extent, Th17.1 cells display weak proliferation capacity due to their high 
expression of interleukin-4 induced gene 1 (IL4I1) (Maggi et al., 2012, Santarlasci et al., 2012), 
which results in down-regulation of TCR ζ chain expression (Boulland et al., 2007). Of note, 
stimulation of pathogenic Th17.1 cells with recombinant IL-12p70 alone or IL-23 alone results in 
production of IFN-γ and IL-17A, respectively (Ramesh et al., 2014). However, the types of 
responses induced by pathogenic Th17.1 cells in the concurrent presence of IL-12p70 and IL-23 
remains to be determined.  
 
Figure 1.2: Cytokines involved in promoting the transition of classical, memory Th17 cells 
towards Th17.1 profile. Memory Th17 cells are capable of transitioning towards Th17.1 phenotype 
in the presence of IL-1β, TNF-α, IL-12p70 and IL-23, leading to its polyfunctional cytokine 
producing capabilities. Adapted and modified from (Annunziato et al., 2013) 
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1.6.1) Memory Th17.1 cells – polarising cytokines 
In humans, it was initially reported by Annunziato et al. that Th17 clones generated from CD 
patients gradually acquired Th1 phenotype when cultured in vitro in the presence of IL-12p70 and 
produced both IFN-γ and IL-17A. Memory CD4+ T cells isolated from the gut of CD patients 
produced significantly higher IFN-γ and IL-17A compared to their peripheral blood counterparts 
(Annunziato et al., 2007). CD4+ CD161+ Th17 cells were discovered in the peripheral blood of 
juvenile idiopathic arthritic patients (JIA) and able to transition towards Th1 phenotype in vitro 
(Cosmi et al., 2011). This transition was partially mediated by IL-12p70 and the neutralisation of 
IL-12p70 reversed this effect. However, other cytokines including IL-1α, IL-1β, IL-6 and IL-8 may 
act in concert with IL-12p70 at promoting the aforementioned transition (Cosmi et al., 2011). 
Furthermore, TNF-α was recently identified as a contributing factor of the Th17 to Th1 transition in 
vitro and treatment of JIA patients with etanercept (TNF-α antagonist) results in reduced proportion 
of Th17 cells (Maggi et al., 2014). This was an important finding as Th17 cells themselves are able 
to produce TNF-α, which might be able to promote their transition towards Th1 phenotype either 
via the autocrine or paracrine mechanism. IL-1β and IL-12p70 can synergistically enhance the 
expression of T-bet as well as STAT4 expression in Th17 cells rendering them sensitive towards 
IL-12p70 stimulation, resulting in co-production of IFN-γ, IL-17A and GM-CSF (Duhen and 
Campbell, 2014). In mice, IL-23 has been suggested to promote autoimmunity partially due to its 
ability to induce IFN-γ, IL-17A and GM-CSF (Cua et al., 2003, El-Behi et al., 2011, Hirota et al., 
2011). Th17.1 cells have been reported to express IL-23R mRNA; while its protein expression 
remains to be determined, stimulation of Th17.1 cells with IL-23 induces production of both IL-
17A and IFN-γ (Ramesh et al., 2014). Of note, ex vivo isolated Th17 cells do not express IL-12Rβ2 
(Lexberg et al., 2010). Interestingly, stimulation of Th17 cells with IFN-γ in combination with IL-
12p70 promotes up-regulation of IL-12Rβ2 expression (Lexberg et al., 2010). Similarly, the 
combined presence of IL-1β and IL-12p70 enhanced STAT4 and T-bet expression in Th17 cells 
(Duhen and Campbell, 2014). These findings, therefore suggest that the presence of both cytokines 
promote the transition of Th17 cells by conferring IL-12p70 responsiveness. DCs stimulated with 
TLR agonists can be induced to produce IL-1β, IL-12p70 and IL-23, therefore this thesis will 
examine which DC subset may be crucial at reactivation of pathogenic Th17.1 cell responses.   
1.6.2) Memory Th17.1 cells – effector cytokines 
The production of IL-17A and IL-17F is triggered upon STAT3 phosphorylation (Korn et al., 
2009). Furthermore, engagement of IL-17 with its receptor triggers NFκB and MAPK pathways, 
leading to induction of IL-1β, IL-6 and TNF-α. The most prominent function of IL-17 is promoting 
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neutrophil chemotaxis, which is necessary for pathogen clearance at the site of infection (Isailovic 
et al., 2015, Ye et al., 2001b). In addition, IL-17 can trigger the production of GM-CSF, 
antimicrobial peptides and defensins as well as maintain epithelial integrity (Isailovic et al., 2015, 
Ye et al., 2001a). In support of this, several studies have demonstrated that IL-17A play a protective 
role in a mouse model of colitis (O'Connor et al., 2009, Ogawa et al., 2004, Yang et al., 2008b). 
Pathogenic Th17.1 cells isolated from inflamed gut tissues of CD patients displayed increased 
expression of IL17A and IL-17F compared to their peripheral blood counterparts (Ramesh et al., 
2014). In an inflammatory environment, the ability of IL-17 to act in concert with these cytokines 
including TNF-α, IL-1β, IL-6 and even, IL-23 would be lead to exacerbation of tissue damage via 
recruitment of inflammatory myeloid cells (Cua et al., 2003, El-Behi et al., 2011).  
IL-21 belongs to the IL-2 family of cytokines and is strongly induced by IL-6 (Suto et al., 2008), 
and dependent on STAT3 signalling (Zhou et al., 2007). IL-21R is expressed on CD4+, CD8+ T 
cells, NK cells, DC, macrophages B cells and keratinocytes, indicating that the IL-21/IL-21R 
signalling would exert multiple effects (Spolski and Leonard, 2008b). IL-21 has been reported to 
promote Th17 differentiation in vitro via an autocrine mechanism (Wei et al., 2007). IL-21 was 
previously reported to contribute to the pathogenesis in the mouse model of RA (Young et al., 
2007). High levels of IL-21 have been detected in sera and synovial fluid of RA patients (Niu et al., 
2010). Furthermore, the same study demonstrated purified CCR6+ CD4+ T cells regulated its own 
IL-21 production in an autocrine manner.  
IL-22 belongs to the IL-10 family of cytokines and signals via STAT3 and MAPK pathways and is 
further up-regulated in response to LPS, IL-1β, TNF-α and IL-23. IL-22R is not expressed on 
immune cells, but on epithelial cells in mucosal tissues (Rueda et al., 2008). IL-22 plays a 
protective role by inducing anti-microbial peptide production from keratinocytes and maintaining 
epithelial barrier integrity (Zheng et al., 2008). In addition to its protective role, IL-22 has been 
reported to induce dermal inflammation and acanthosis in a mouse model of psoriasis which was 
mediated by IL-23 (Zheng et al., 2007). Furthermore, levels of IL-22 in psoriatic patients positively 
correlated with disease severity (Wolk et al., 2006). IL-22 may even promote the migration of 
human Th17 cells through the blood-brain barrier (Kebir et al., 2007). MDR1+ memory T cells 
isolated from inflamed gut tissue of CD patients expressed a higher level of IL22 compared to their 
MDR1negative counterparts, indirectly suggesting a pathogenic role of IL-22 in disease pathology 
(Ramesh et al., 2014).  
GM-CSF was initially reported to be as an essential haematopoietic growth factor promoting 
proliferation and differentiation of macrophages and DC (Shi et al., 2006). In mice, GM-CSF is 
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produced by T cells in response to LPS, IL-1β, TNF-α and IL-23 (Conti and Gessani, 2008, El-Behi 
et al., 2011, Noster et al., 2014). The GM-CSF receptor is expressed on DC, monocytes, 
macrophages, gut epithelial cells and neutrophils. GM-CSF was later demonstrated to promote 
invasion, as well as retention of murine myeloid cells into the central nervous system and enhanced 
IL-23 secretion from mouse CD11c+ DCs (Codarri et al., 2011, El-Behi et al., 2011), thereby 
perpetuating Th17 cell responses and chronic inflammation. Therefore, the missing link between 
IL-23 and pathogenic mouse Th17 responses was hypothesised to be GM-CSF. In humans, the 
induction of GM-CSF seems to be regulated by IL-12p70 and Th1 cells. Noster et al. further 
demonstrated that human memory CD4+ T cells cultured in the presence of IL-1β and IL-23 do not 
induce GM-CSF compared to IL-12p70 alone (Noster et al., 2014). In humans, high levels of GM-
CSF have been documented in RA and multiple sclerosis (Noster et al., 2014, Reynolds et al., 
2015). Duhen et al. reported the synergy between IL-1β and IL-12p70 induced high levels GM-CSF 
from human Th17 cells (Duhen and Campbell, 2014). Furthermore, pathogenic Th17.1 cells 
isolated from gut inflamed tissues of CD patients express high levels of CSF2 mRNA which 
encodes for GM-CSF (Ramesh et al., 2014), indirectly suggesting a pathogenic role of GM-CSF in 
disease pathology. 
1.7) Role of DCs in innate cell activation 
As previously discussed, the generation of memory responses by the host is achieved through three 
different phases; expansion, contraction and memory. During this period, the innate immune system 
is activated to provide protection against foreign pathogens, until the adaptive immune system 
becomes fully activated. The innate immune system comprises of several innate cell types including 
NK cells, NKT cells, MAIT cells, γδ T cells as well as ILCs. Given the strategic localisation in 
lymphoid and non-lymphoid organs along with cytokine production capabilities, DCs could play a 
role in activating innate cell populations.  
γδ T cells were initially discovered by Brenner et al. whereby the TCR was composed of the γ and δ 
chains, unlike the conventional TCRs which are composed of α and β chains (Maldonado-Lopez et 
al., 1999). γδ T cells comprise between 0.5 to 5% of total peripheral CD3+ T cells (Chien et al., 
2014). Unlike the conventional TCR αβ T cells, γδ T cells do not recognise Ag presented in the 
context of class I or II MHC molecules. For example, γδ T cells recognise lipids presented by 
MoDCs in the context of the CD1c molecule (Cui et al., 2009). Additionally, γδ T cells in turn 
secrete TNF-α which promotes maturation of human MoDCs (i.e up-regulation of CD83 and CD86 
markers) as well as the production of IL-12p70 (Leslie et al., 2002). Therefore, these data suggest a 
potential crosstalk between DCs and γδ T cells in mounting optimal immune responses.  
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Natural killer (NK) cells are unique innate cells, distinct from B and T cells. In humans, peripheral 
blood NK cells constitute approximately 5 – 20% of PBMCs. NK cells lack the CD3 marker but 
express CD56 and CD161 (Lanier et al., 1994, Pampena and Levy, 2015). NK cells are known to 
respond towards IL-12p70 given its high expression of IL-12Rβ1 and IL-12Rβ2, leading to the 
induction of IFN-γ (Chognard et al., 2014, Fauriat et al., 2010, Gerosa et al., 2005). Gerosa et al. 
initially reported that human NK cells induced significant IL-12p70 production by MoDCs (Gerosa 
et al., 2005). In addition, IL-2-activated NK cells induced functional maturation of MoDCs by up-
regulating co-stimulatory molecules, indicating a reciprocal relationship. PIC-stimulated CD1c+ 
DCs activated NK cells to produce IFN-γ, a process mediated via IL-12p70 (Gerosa et al., 2005, 
Perrot et al., 2010). Activated NK cells in turn promoted up-regulation of co-stimulatory molecules 
on CD1c+ DC (Gerosa et al., 2005). IL-15 forms a stable complex with IL-15Rα which is later 
presented in trans by dendritic cells towards neighbouring cells that express IL-15Rβ, this process 
is known as trans-presentation. The trans-presentation of IL-15 from MoDCs via IL-15Rα has been 
reported to be a crucial mechanism for the development and function of NK cells (Ferlazzo et al., 
2004).  
MAIT cells are innate-like T cells comprising up to 10% of CD3+ T cells in human peripheral 
blood, lung and intestines, and are selectively enriched in the liver comprising as many as half the 
total T cells (Gold et al., 2013). MAIT cells express CD3 and CD8αβ TCR chain, while devoid of 
CD4 expression, which segregates them into two compartments, the CD8+ or CD8- CD4- double 
negative subsets. MAIT cells also highly express IL-18Rα, IL-12Rβ2, IL-23R and CD161 
(Billerbeck et al., 2010, Dusseaux et al., 2011, Ussher et al., 2014). MAIT cells recognise vitamin B 
metabolites which are presented in the context of the MR1 molecule (Huang et al., 2008). MAIT 
cells are known to react towards IL-12p70 and IL-23 leading to the production of IFN-γ and IL-
17A, respectively (Sattler et al., 2015, Ussher et al., 2014, Cho et al., 2014). The role of human DCs 
at activating MAIT cells remains to be determined.  
1.7.1) Innate cells and their contribution to autoimmunity 
γδ T cells are capable of producing IL-17 which has been detected in synovial fluid of ankylosing 
spondylitis (AS) patients (Kim et al., 2006, Wendling et al., 2007). Kenna et al. reported that blood 
γδ T cells isolated from AS patients displayed higher IL-23R expression and increased the 
proportion of IL-17+ γδ T cells compared to healthy controls (Kenna et al., 2012). From that study, 
purified γδ T cells stimulated with recombinant IL-23 produced higher IL-17 compared to the γδ T 
cells purified from healthy controls. γδ T cells isolated from psoriatic patients displayed a 
significant increase in IL-17 production upon stimulation with IL-23 compared to total CD3+ T cells 
(Cai et al., 2011). Importantly, a combination of IL-1β, IL-6 and IL-23 was previously reported to 
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induce human γδ T cells to co-produce IFN-γ and IL-17A (Caccamo et al., 2011). The physiological 
relevance of this finding remains to be understood; however, the production of multiple cytokines 
may be harmful to the host.  
CD56bright but not CD56
dim
 NK cells have been detected in synovial fluid of RA patients and 
displayed increased activation status, as assessed by CD69 up-regulation (Dalbeth et al., 2004). 
Along with the presence of accessory cells and along with IL-12 and IL-18 within synovial tissues, 
NK cells can be induced to produce IFN-γ, TNF-α (Flodstrom-Tullberg et al., 2009). In RA 
patients, co-culture experiments involving monocytes and autologous CD56bright NK cells 
demonstrated reciprocal relationship (Dalbeth et al., 2004, Zhang et al., 2007). In these studies, NK 
cells induced monocytes to produce TNF-α in a cell-to-cell contact dependent manner; and 
conversely, NK cells were activated by monocytes to produce IFN-γ. While CD1c+ DCs have been 
identified in synovial fluid of RA and AS patients (Jongbloed et al., 2006, Moret et al., 2013, 
Wright et al., 2016), crosstalk between this DC subset and NK cells as well as their contribution in 
disease pathology remains to be determined.  
1.8) Ankylosing spondylitis (AS) 
AS is a disease that belongs to a class of immune-mediated arthropathies known as 
spondyloarthropathies, which includes reactive arthritis and psoriatic arthritis (Brown et al., 2016). 
Genome-wide association studies (GWAS) have identified several other genes other than HLA-
B*27 are associated with AS pathology including IL23R, TYK2, JAK2, STAT3 and IL12B (encodes 
for IL-12p40 subunit) suggest the importance of IL-23 signalling in AS pathology (Cortes et al., 
2015, Ellinghaus et al., 2016, International Genetics of Ankylosing Spondylitis et al., 2013). Given 
the importance of IL-23 in maintaining memory Th17 cells (Wilson et al., 2007), these studies 
implicated that IL-23-Th17 axis in AS pathology. Consistently, increased serum levels of IL-23 and 
IL-17 was detected, as well as increased proportion of IL-23R+ cells within the subchondral bone 
marrow of AS patients compared to controls (Davidson et al., 2011, Zheng et al., 2012). In addition 
to the Th17 cells, several other cell populations have been recognised as important mediators of IL-
23 including γδ T cells, NK cells and mast cells (Kenna and Brown, 2013a). However, it remains to 
be determined if these innate cell populations are able to produce other IL-23-dependent cytokines 
such as IL-17F, IL-21 and IL-22, and which cell population would play a pathogenic or protective 
role in AS pathology. Interestingly, serum IL-12p70 levels have been reported to be elevated in AS 
patients compared to healthy controls (Yang et al., 2007). This finding indirectly suggested the role 
of Th1 cell activation in AS pathology. Macrophages generated from AS patients in vitro displayed 
increased IL-23 production capacity in response to LPS compared to macrophages from healthy 
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controls (Zeng et al., 2011). The role of DCs in AS pathology was initially demonstrated by 
Prevosto et al. whereby in vitro MoDCs stimulated with a combination of PIC and CL097 (TLR 7 
and 8 agonists) demonstrated increased production of IL-12p70 and IL-23 (Prevosto et al., 2012). 
While CD1c+ DCs purified from AS patients were able to drive allogenic MLR in vitro (Wright et 
al., 2016), the study did not characterise their cytokine secretory profile in response to activation in 
comparison with CD1c+ DCs from healthy controls. Therefore, this thesis will compare the cytokine 
profile of AS-derived CD1c+ DCs stimulated with TLR agonists in comparison with the ones from 
healthy controls. 
1.9) Hypothesis  
We hypothesised that the ligation of TLR 8 in CD1c+ DCs induces production of IL-23 which is 
further enhanced in the presence of TLR 3 and 4 agonists. We also hypothesised that the co-
production of IL-1β, IL-12p70 and IL-23 by TLR-stimulated CD1c+ DCs reactivates pathogenic 
memory Th17.1 response to produce IFN-γ, IL-17A, IL-17F, IL-6, GM-CSF and IL-22 as well as 
triggering activation of innate cell populations. 
1.10) Aims 
1. Determine the conditions under which CD1c+ DCs produce IL-12p70 and IL-23 compared to 
other cell types.  
2. Determine the cell types which can be influenced by the dual production of IL-12p70 and IL-23 
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Chapter 2 – Materials and methods 
2.1) Blood collection 
Peripheral blood was obtained with informed consent from healthy volunteers approved by Mater 
Health Services Human Research Ethics Committee (#1407AP/MMRI #45). Six ankylosing 
spondylitis (AS) patients with active disease were recruited in our study according to the BASDAI 
(Bath ankylosing spondylitis disease activity index) score (detailed in Appendix D). Clinical 
measures of inflammation including Erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP) were adopted to score our patients (detailed in Appendix D). Informed, written consent was 
obtained from all AS patients and peripheral blood was drawn into heparin-coated polystyrene tubes 
and CD1c+ DCs and monocytes were isolated as detailed below. AS study approved by Metro South 
Human Research Ethics Committee (HREC/05/QPAH/221) and University of Queensland (UQ 
2006000102).  
2.2) Cell isolations 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood via density 
centrifugation using Ficoll-PaqueTM Plus (Amersham Biosciences) (Jongbloed et al., 2010). Human 
CD1c+ DCs were isolated using human BDCA-1+ kit (Miltenyi Biotec) as per manufacturer’s 
instructions. CD19+ (B cells) were depleted with AutoMACS Pro Separator using the “Depletes” 
program. Human CD1c+ DCs were positively selected with AutoMACS Pro Separator using the 
“Posseld2” program (Jongbloed et al., 2010). The purity of CD1c+ DCs was evaluated by staining 
with anti-human HLA-DR-PeCy7 (clone – L243), CD19-Pacific Blue (PB, clone - HIB19), CD14-
allophycocyanin (APC, clone - HCD14) (all from Biolegend) and CD1c-fluorescein isothiocyanate 
(FITC, clone – B-B5, Abcam). The typical purity of CD1c+ DCs was (84.54% ± 5.653, mean ± s.d 
from 11 experiments). Using the CD1c negative fraction, CD14+ monocytes were isolated from 
PBMCs using human CD14 isolation kit (Miltenyi Biotec), as per manufacturer’s instructions. 
Monocytes were positively selected with AutoMACS Pro Separator using “Possel” program. The 
purity of CD14 monocytes was evaluated by staining with anti-human CD14-APC. The typical 
purity of CD14 monocytes was (98.49% ± 0.6664, mean ± s.d from 11 experiments). To 
simultaneously purify CD1c+ DCs, CD141+ DCs and pDCs, total DCs were enriched from PBMCs 
using a panDC enrichment kit (Stemcell Technologies) according to manufacturer’s instructions. 
Enriched DC fraction was stained with CD3-PB (clone – OKT3), CD14-PB (clone – HCD14), 
CD16 PB (clone 3G8), CD19-PB (clone – HIB19), CD20-PB (clone – 2H7) and CD56-PB (clone – 
HCD56), CD1c-PE (clone – L161), CD141-APC (clone – M80), CD123-Percp cy5.5 (clone – 6H6), 
HLA-DR-Pecy7 (clone – L243) [all from Biolegend] and Live/Dead Aqua Dye (Invitrogen). DC 
subsets were identified as lin- HLA-DR+. All three DC subsets were sorted as the following; CD1c+ 
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DCs (lin- HLA-DR+ CD1c+ CD141-), CD141+ DCs (lin- HLA-DR+ CD141+ CD1c-) and pDCs (lin- 
HLA-DR+ CD123+ CD1c- CD141-) with MoFlow® AstriosTM (Beckman Coulter) into 5ml 
polystyrene tubes cushioned with 500µl of 10% heat-inactivated AB serum. DC subsets were 
resuspended with complete 10% AB media and counted in the presence of trypan blue. Cells were 
then washed again and resuspended with complete 10% AB media for downstream experiments. 
Memory CD4+ T cells were isolated from fresh PBMCs with human Memory CD4+ T cell 
Enrichment Kit (StemCell Technologies) according to manufacturer’s instructions, which depleted 
CD8, CD14, CD16, CD19, CD20, CD36, CD45RA, CD56, CD123, TCRγ/δ, glycophorin A-
expressing cells. The purity of memory CD4+ T cells was evaluated by staining with anti-human 
CD3-PB (clone – OKT3), CD4-APC Cy7 (clone – RPA-T4), CD45RO-APC (clone – UCHL1) and 
CD45RA-PE (clone – HI100) (all from Biolegend). Memory CD4+ T cells were defined as CD3+ 
CD4+ CD45RO+ CD45RA-. The typical purity of isolated memory T cells was 95 ± 3.541% (mean 
± s.d from seven experiments).  Refer to Appendix B for flow plots.  
2.3) Cell stimulation 
Human CD1c+ DCs, pDCs, CD141+ DCs and monocytes were resuspended to a concentration of 1 
x 106 cells per ml with complete AB media containing RPMI 1640, supplemented with 10% FCS, 
100U/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, 0.1mM 
nonessential amino acids, 10mM HEPES buffer solution (all obtained from Invitrogen), and 50µM 
2-mercaptoethanol (Sigma-Aldrich). Cells were plated at 5 x 104 cells per 50µl into each well of a 
96 well V-bottom plate unless stated otherwise. Cells were stimulated with LPS (Sigma Aldrich – 
concentrations at 100, 10, 1, 0.1ng/ml), R848 (Invivogen – concentrations at 2, 1, 0.5µg/ml), 
poly:IC (Invivogen – concentrations at 25, 10, 5, 3 and 1µg/ml, 1µM CpG ODN 2216 (Miltenyi 
Biotec) as previously reported (Heil et al., 2004). All activators were diluted with 10% complete 
AB media for downstream experiments. Cultures were maintained at a final volume of 100µl in 
complete AB media and incubated overnight (20 hours unless stated otherwise) in a 37oC with 5% 
CO2/air atmosphere incubator.  
2.4) Thawing of frozen PBMCs and antibody titration on Cyan ADP Cytometer 
Frozen PBMCs were rapidly thawed at 37C until a small ice crystal was remaining. DNase I was 
added at a working concentration of 20ng/ml. PBMCs were washed with cold, 10% complete FCS 
media by adding it dropwise slowly. Cells were centrifuged at 500g for 5 minutes at 4C. PBMCs 
were resuspended with 5ml cold complete 10% FCS media supplemented with 20µg/ml DNase I. 
PBMCs were incubated for 15 minutes at 37oC. Post-incubation, total volume was made up to 10ml 
with complete 10% FCS media to wash the cells. Cells were harvested and counted using trypan 
43 | P a g e  
 
blue. 1 x 106 PBMCs were aliquoted and stained with titrated concentrations of antibodies (listed in 
Appendix A, pg 163-164) for 15 minutes at 4oC in a final volume of 100µl in cold MACS buffer 
(Miltenyi Biotec). A separate aliquot of cells was set aside as unstained controls. Post-incubation, 
cells were washed with cold MACS buffer and centrifuged for 5 minutes at 500g. Supernatant was 
aspirated and cells were resuspended with cold MACS buffer and analysed on Cyan ADP 
Cytometer with 488nm, 405nm and 642nm laser configuration (Beckman Coulter). The unstained 
cells were used to determine the flow cytometer voltage (i.e to adjust the cells in the first log 
decade). Cells stained with titrated concentrations of antibodies were analysed without changing the 
voltage. The antibody concentration that provided the best separation between positively and 
negatively stained cells were used for future experiments.  
2.5) Optimisation of flow cytometry panel for CFSE labelling on LSR Fortessa X20 
Frozen PBMCs were thawed and counted as described in Section 5.4. 1 x 106 PBMCs were 
aliquoted for CFSE labelling at 0.2µM and cultured overnight (≥ 18 hours) at 37o C in a 48 well 
plate at a cell concentration of 10 x 106 cells/ml. This step was to provide sufficient time for non-
stably incorporated CFSE to dissipate (Quah et al., 2007). A separate aliquot of 1 x 106 PBMCs left 
unlabelled and cultured under the same conditions, which were used as an unstained control for 
voltage configuration on the LSR FortessaX-20 with 375nm, 405nm, 488nm, 561nm and 640nm 
laser configuration (BD Biosciences). Unstained PBMCs were aliquoted and stained individually 
with CD3-PE (clone – OKT3, BD Pharmingen), CD4-APC (clone – RPA-T4, Biolegend), CD4-
APC Cy7 (clone – RPA-T4, Biolegend), CD3-PB (clone – OKT3, Biolegend) for single colour 
controls. CFSE-labelled PBMCs were used validate any spill over into phycoerythrin (PE) detector. 
To minimise significant compensation issues between CFSE and PE, optimisations were conducted 
using the LSR FortessaX-20 with separate lasers and detectors for both parameters. CFSE-labelled 
PBMCs with stained anti-human CD3-PE to confirm the settings were optimal.  
2.6) CFSE labelling of isolated CD4+ T cells  
Purified memory CD4+ T cells were washed and resuspended in PBS at a concentration of 10 x 106 
cells/ml. Purified memory CD4+ T cells were labelled with 0.2µM carboxyfluorescein succinimidyl 
ester (CFSE) from Molecular Probes, vortexed cells for 30 seconds and incubated for 10 minutes at 
37oC. The reaction was quenched by adding 10ml of complete 10% AB medium and centrifuged for 
5 minutes, at 500g. The supernatants were aspirated and cells were washed again with 10ml 
complete 10% FCS medium. Memory CD4+ T cells were resuspended in complete 10% FCS 
medium for downstream experiments.  
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2.7) DC:T cell co-culture experiments 
Human CD1c+ DCs and monocytes were resuspended to a concentration of 1 x 106 cells per ml with 
complete AB medium. Cells were plated in duplicates at 5 x 104 cells per 50µl into each well of a 
96 well V-bottom plate unless stated otherwise. Cells were stimulated with 100ng/ml LPS (Sigma 
Aldrich), 2µg/ml R848 (Invivogen); either alone or in combination. Cultures were maintained at a 
final volume of 100µl in complete AB medium and activated in a 37oC with 5% CO2/air 
atmosphere incubator. Post-incubation, cells were pooled, washed with PBS and recounted using 
trypan blue exclusion dye. Cells were washed again with PBS, then resuspended to 1 x 104 cells per 
10µl with complete AB medium. Purified CD4+ T cells were labelled with 0.2µM CFSE and 
cultured with activated APCs (e.g. monocytes, CD1c+ DCs) at a 10:1 ratio in the presence of 
25ng/ml IL-7 and IL-15 for 7 days (McKinlay et al., 2007). Purified memory CD4+ T cells were 
stimulated with 0.05µg of plate-bound αCD3 and 1µg/ml soluble αCD28 as a positive control for T 
cell function. On day 7, cells were centrifuged at 500g for 5 minutes, and supernatants were 
harvested for cytokine analysis. Cells were washed once with MACS buffer and stained with anti-
human CD4-APC Cy7 (clone – RPA-T4, Biolegend) and proliferation of memory CD4+ T cells was 
evaluated through CFSE dilution.  
2.8) Intracellular cytokine staining (ICS)  
Intracellular stain was performed using fixation/permeabilisation kit (RnD Systems.) On day 7, 
supernatant (SN) was harvested for cytokine analysis. Cells were washed once with PBS and 
restimulated with 50ng/ml phorbol 12-myristate 13-acetate (PMA) and 1µg/ml ionomycin (both 
from Sigma Aldrich) for 4 hours at 37oC. GolgiStop (BD Pharmingen) was added at a final dilution 
of 1:1000 and cultured for 2 more hours. Cells were washed MACS buffer and stained with CD4-
APC Cy7 (Biolegend) for 15 minutes on ice. Cells were washed with MACS buffer and again with 
PBS. Cells were fixed by adding 50µl of cold fixation buffer (RnD Systems) and incubated at room 
temperature for 10 minutes. Cells were washed with PBS, resuspended with Permeabilisation/wash 
buffer (RnD Systems) and cells from each condition were split evenly into two wells. In one well, 
cells were then stained with IL-17A-APC (clone – eBio64DEC17, eBioscience) and IFN-γ-PE 
(clone – B27, BD Pharmingen) at a 1:50 dilution to a final volume of 100µl, which allowed 
detection of IL-17A IFN-γ double-positive T cells. In the other well (control), cells were stained 
with matching isotype-APC (clone – P3.6.2.8.1, eBioscience) and isotype-PE (clone – MOPC-21, 
BD Pharmingen) at a 1:50 dilution to a final volume of 100µl. Cells were incubated for 30 minutes 
at room temperature, in the dark. Post-incubation, cells were washed thrice with cold 
Permeabilisation/wash buffer. Cells were resuspended in PBS and analysed immediately on the 
LSR Fortessa X-20. 
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2.9) Cytokine secretion assays  
Culture supernatants from each condition in duplicates were harvested and levels of IL-1β, IL-23, 
IFN-λ (ELISA kits from R&D Systems), IL-6, IL-12p70 (ELISA kits from BD Biosciences), IFN-α 
(ELISA kits from Interferon Source) were determined using ELISA according to manufacturer’s 
instructions. Optical density was determined using the POLARStar Omega (BMG LabTech) at 
450nm. Wavelength correction was performed on all ELISA readings by deducting the optical data 
of 570nm from 450nm. Data were analysed with GraphPad Prism 5 using a four-parameter 
nonlinear regression. Simultaneous detection of IL-1β, IL-6, IL-12p70, IL-18 IL-23, IL-10, IL-27, 
CCL5, IFN-α, CXCL9, CXCL10, CXCL11, TNF-α production by CD1c+ DCs, CD141+ DCs and 
pDCs was conducted using a customised DC LegendPlex kit (Biolegend). Simultaneous detection 
of IL-2, IL-4, IL-5, IL-6, IL-9, IK-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-γ and TNF-α 
production by memory CD4+ T cells was conducted using a Human T helper LegendPlex kit 
(Biolegend). Data were analysed with VigeneTech software Version7.0 (Biolegend).  
2.10) GM-CSF ELISA 
The levels of GM-CSF were quantified using the DuoSet® ELISA (R&D Systems) according to the 
manufacturer’s instructions. Optical density was determined using the POLARStar Omega (BMG 
LabTech) at 450nm. Wavelength correction was performed by deducting the optical data of 570nm 
from 450nm. Data was analysed with GraphPad Prism 5 using a four parameter nonlinear 
regression.  
2.11) Assessment of MDR1 activity via Rhodamine 123 (Rh123) efflux assay 
This assay is a measure of MDR1 activity, a feature exclusive to pathogenic Th17.1 cells (Ramesh 
et al., 2014). MDR1 activity can be specifically evaluated using a fluorescent substrate, Rh123. 
Purified memory T cells were washed once with PBS and loaded with Rh123 (Sigma-Aldrich) at a 
working concentration of 1µg/ml for 30 minutes on ice, as previously described (Ramesh et al., 
2014). Post-incubation, cells were then washed and moved to a 37oC incubator for 1 hou (efflux 
period). After the efflux period, cells were washed thrice with PBS and stained with anti-human 
CD4 APC Cy7 (Biolegend) for 15 minutes on ice. Cells were washed with MACS buffer, and 
stained cells were analysed with LSR FortessaX20. The fluorescence of Rh123 was evaluated on 
the FITC channel. 
2.12) Flow cytometry analysis of DC viability and co-stimulatory molecule expression 
After stimulation, cells were harvested, washed with cold MACS buffer and stained with anti-
human flow antibodies against CD86-FITC (clone – 2331), CD80-PE (clone – L307.4), CD83-APC 
(clone – HB15e) (all from BD Pharmingen), HLA-DR-PeCy7 (clone – L243, Biolegend), 
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Live/Dead AquaTM (Invitrogen) for 15 minutes on ice (Jongbloed et al., 2010). Cells were washed 
again with cold MACS buffer, resuspended in PBS and analysed on Cyan ADP Cytometer with 
488nm, 405nm and 642nm laser configuration (Beckman Coulter). All primary antibodies used in 
this study were titrated using frozen PBMCs and analysed on Cyan ADP Cytometer (Beckman 
Coulter) with three laser configuration (488nm, 405nm, 643nm). Staining cells with antibodies will 
result in background fluorescence due to Fc receptor-mediated binding and other non-specific 
protein interactions. Therefore, the use of matching isotype control antibodies will confirm the 
specificity of each primary antibody used in our study. Each isotype control antibody was used as 
the same concentration with the antibody used to stain for the antigen of interest. Sorting strategy 
presented in Appendix C. CD141+ DC purity (98.7 ± 0.997%, mean ± sd), CD1c+ DC purity 
(93.98 ± 2.054%, mean ± sd), pDC purity (95.69 ± 1.52%, mean ± sd). MFI and delta (Δ) MFI 
were for each co-stimulatory molecule were calculated using FlowJo version 8.8.7.  
2.13) STAT3 phosphorylation 
Freshly isolated PBMCs were stimulated with three conditions: a) supernatant derived from LPS 
plus R848-stimulated CD1c+ DCs alone, b) LPS plus R848-stimulated CD1c+ DCs alone or c) 
supernatant derived from LPS plus R848-stimulated CD1c+ DCs plus activated CD1c+ DCs for 15 
minutes at 37oC. Supernatant from unstimulated cells were used as negative control. Identical 
conditions were setup in parallel with monocytes. As positive control, PBMCs were stimulated with 
100ng/ml human recombinant IL-6 (RnD Systems). Post-stimulation, cells were washed with cold 
MACS buffer. Cells were stained with flow cytometry antibodies for γδ T cells (γδ TCR-FITC, 
CD3-PB) and NK cells (CD3-PB, CD56-Pecy7, CD161-Percp Cy5.5) for 15 minutes on ice. Cells 
were washed again with MACS buffer and fixed with pre-warmed (37oC) Phosflow fix buffer I (BD 
Pharmingen), and incubated in a 37oC waterbath for 10 minutes. Cells were spun at 250 x g for 10 
minutes, and washed again with FBS stain buffer (BD Pharmingen). Cells were permeabilised with 
pre-chilled (-20oC) Phosflow perm buffer III (BD Pharmingen) with occasional mixing, and 
incubated for 30 minutes on ice. Cells were washed twice with FBS stain buffer and stained with 
STAT3-PE or matching isotype control (both from BD) for 60 minutes in the dark at room 
temperature at 20µl/ per test (according to manufacturer’s instructions). Cells were then washed 
thrice with FBS stain buffer and analysed immediately on Cyan ADP Cytometer (Beckman 
Coulter).  
2.14) Titration of IL-23R antibody 
Frozen PBMCs were thawed and counted as described in Section 3.3.5. 1 x 106 PBMCs were 
aliquoted and stimulated overnight (≥ 18 hours) at 37o C in a 48 well plate at cell concentration of 1 
x 106 cells/ml with 10% AB medium supplemented with 50ng/ml PMA, 200ng/ml ionomycin, 
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200ng/ml LPS, 20ng/ml human recombinant IL-23 and 40ng/ml human recombinant IL-6 (as per 
manufacturer’s instructions). A separate aliquot of 1 x 106 PBMCs cultured only with 10% AB 
medium, which was used as untreated controls. Post-overnight culture, PBMCs were harvested and 
washed with cold MACS buffer. Stimulated PBMCs were then stained with CD4-APC Cy 7 (clone 
– RPA-T4, Biolegend) and titrated concentrations of IL-23R-PE (mouse anti-human IgG2B, clone – 
218213, RnD Systems). Unstimulated PBMCs were stained with CD4-APC Cy7 (clone – RPA-T4, 
Biolegend) and titrated concentrations of anti-human mouse IgG2b-PE (clone – 133303, RnD 
Systems) for 15 minutes on ice. Post-incubation, cells were washed with cold MACS buffer and 
centrifuged at 500g for 5 minutes. PBMCs were harvested and analysed on Cyan ADP Cytometer 
(Beckman Coulter). IL-23R expression on each cell type was calculated as percentage of IL23R+ 
minus the percentage of IL-23R+ in our isotype staining. Cell types that displayed higher percentage 
of IL-23R staining compared to its isotype control were concluded to express IL-23R. If IL-23R 
staining was higher in our isotype controls compared to the IL-23R staining under identical 
conditions and concentrations, it was concluded that no IL-23R expression was observed.  
2.15) Flow staining for IL-23R detection 
Freshly isolated PBMCs were stained with anti-human IL-23R-PE (clone – 218213) or matching 
isotype control (clone - 133303) (both from RnD Systems) in MACS buffer, according to 
manufacturer’s instructions. To determine the expression of IL-23R on specific cell subsets, the 
following antibody cocktails were employed. For γδ T cells (γδ TCR – FITC, clone – B1, CD3-PB, 
clone – OKT3), NK cells (CD3-PB, CD56-Pecy7, clone – B159, CD161-Percp Cy5.5, clone - HP-
3G10), B cells (CD19-PB, clone - HIB19, HCD56, respectively, CD27-APC, clone - L128), 
CD11c+ cDCs (CD3, CD14, CD16, CD19, CD56-PB, clones – OKT3, HCD14, 3G8, HIB19, 
HCD56, respectively) HLA-DR-Pecy7, clone – L243, CD11c-APC, clone - B-ly6), pDCs (CD3, 
CD14, CD16, CD19, CD56-PB, HLA-DR -Pecy7, CD123-Percp Cy5.5, clone – 6H6). All 
antibodies were obtained from Biolegend except for CD11c-APC (clone – B-ly6), CD27-APC 
(clone – M-T271) (both from BD Pharmingen). PBMCs were stained for 15 minutes on ice, washed 
with MACS buffer and resuspended in PBS for analysis on CyAN ADP Cytometer (Beckman 
Coulter). IL-23R expression on each cell type was calculated as a percentage of IL23R+ minus the 
percentage of IL-23R+ in our isotype staining. Cell types that displayed a higher percentage of IL-
23R staining compared to its isotype control were concluded to express IL-23R. If IL-23R staining 
was higher in our isotype controls compared to the IL-23R staining under identical conditions and 
concentrations, it was concluded that no IL-23R expression was observed. To assess the up-
regulation of IL-23R, PBMCs were cultured in 10% AB medium supplemented with 20ng/ml 
human recombinant IL-23 [a kind gift from Dr. Rohan Lourie - Mater Research – UQ (RnD 
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Systems)]. This concentration was previously reported to up-regulate IL-23R mRNA in human γδ T 
cells (Maggi et al., 2010, Kenna et al., 2012). 
2.16) Natural killer T (NKT) cell expansion 
Freshly isolated PBMCs are stained with CD3 PB, Vα24-Jα18 APC (clone – 6B11) (both from 
Biolegend) to identify the initial proportion of NKT cells. Cells were washed with PBS and 
resuspended with complete 10% AB medium at a concentration of 1 x 106 cells/ml in the presence 
of 100ng/ml α-Galcer (KRN7000 [Avanti Polar Lipids] – kind gift from Stephen Mattarollo (UQ 
Diamantina Institute), 10ng/ml IL-7 (Biosource) and 10ng/ml IL-15 (Peprotech) for 7 days at 37oC. 
On day 7, cells were harvested, washed, stained again with CD3-PB and Vα24-Jα18-APC in the 
presence of IL-23R-PE or isotype control.  
2.17) Statistical analysis 
Data were analysed using GraphPad Prism 5. Comparison between two different groups with 
nonparametric samples was conducted with Wilcoxon matched paired t test. Comparison between 
multiple groups was conducted using repeated measures, two-way ANOVA with Bonferroni post-














49 | P a g e  
 
Chapter 3 - Cytokine profile by CD1c+ DC in response to toll-like receptor (TLR) agonists 
3.1) Introduction 
Murine CD11b+ DCs do not produce IL-12p70 in response to TLR agonists including PIC (TLR 3 
agonist), CpG (TLR 9 agonist) and LPS (TLR 4 agonist) (Hochrein et al., 2001). Human CD1c+ 
DCs however, are known to produce IL-12p70 in response to R848 (TLR 7 and 8 agonists), which 
is significantly enhanced in response to LPS (Acosta-Rodriguez et al., 2007a, Napolitani et al., 
2005, Nizzoli et al., 2013). These findings indicate their potential role at priming Th1 responses 
(Acosta-Rodriguez et al., 2007a). Murine CD11b+ DCs are the major producers of IL-23 in 
response to flagellin as well as Citrobacter rodentium (Kinnebrew et al., 2012, Satpathy et al., 
2013). The ability of CD1c+ DCs to produce IL-23 however, remains controversial. CD1c+ DCs do 
not produce IL-23 in response to CD40L, E. coli, PamCSK, LPS, peptidoglycan or combination of 
TNF-α, IFN-α plus PGE2 (Acosta-Rodriguez et al., 2007a, Gerosa et al., 2008, Jefford et al., 2003). 
To date, one study reported that CD1c+ DCs produce IL-23 in response to LPS plus R848; however, 
the conditions in which they do so remain to be fully established. Human CD141+ DCs were 
previously reported to produce IL-23p19 subunit in response to PIC, while pDCs were previously 
reported to express IL-23p19 mRNA in response to R837 (a strictly TLR 7 agonist). However, the 
secretion of a full-length IL-23 protein by pDCs and CD141+ DCs has yet to be determined.  
AS is a disease that belongs to a class of immune-mediated arthropathies known as 
spondyloarthropathies, which includes reactive arthritis and psoriatic arthritis (Brown et al., 2016). 
GWAS have identified several other genes other than HLA-B*27 are associated with AS pathology 
including IL23R, TYK2, JAK2, STAT3 and IL12B (encodes for IL-12p40 subunit) suggest the 
importance of IL-23 signalling in AS pathology (Cortes et al., 2015, Ellinghaus et al., 2016, 
International Genetics of Ankylosing Spondylitis et al., 2013). Furthermore, a proof-of-concept 
clinical trial of ustekinumab (IL-12p40 neutralising monoclonal antibody) was recently conducted 
and demonstrated effectiveness in AS patients (Poddubnyy et al., 2014). Additionally, the serum 
level of IL-12p70 was significantly elevated in AS patients compared to healthy controls (Yang et 
al., 2007). To date, the role of DCs in AS pathology was derived from in vitro-generated MoDCs 
(Prevosto et al., 2012). However, the relevance of this DC subset at contributing AS pathology in 
vivo is currently unclear. Therefore, it is of utmost importance to determine the contributions of 
bonafide DCs and other myeloid populations in AS pathology. It was recently reported that the 
proportion of CD1c+ DCs between AS patients and healthy controls was not significantly different 
(Wright et al., 2016). While AS-derived CD1c+ DCs can stimulate allogeneic MLR in vitro, their 
functional properties have not been fully elucidated (Wright et al., 2016). CD14+ monocytes have 
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been reported to be elevated in the circulation of AS patients compared to healthy controls; 
however, their cytokine profile has yet to be fully established (Wright et al., 2016).  
To ascertain the role of CD1c+ DCs in AS pathology, highly purified CD1c+ DCs were isolated 
from peripheral blood of active AS patients and evaluated their cytokine production in response to 
TLR stimulation in comparison with healthy individuals. In this chapter, we isolated human CD1c+ 
DCs, monocytes, CD141+ DCs and pDCs and stimulated them with an optimal concentration of 
TLR agonists using PIC, LPS, CpG ODN2216 and R848, either alone or in combination. We 
compared their ability at producing IL-1β, IL-6, IL-12p70 and IL-23 in response to combinational 
TLR agonists. Additionally, we isolated CD1c+ DCs and monocytes from peripheral blood of 
active, AS patients and determined their cytokine profile in response to TLR stimulation, in 
comparison with healthy controls. Here, we hypothesised that CD1c+ DCs would produce IL-12p70 
and IL-23 in response to TLR 8 stimulation, which are enhanced in the presence of TLR 3 and 4 
agonists. Therefore, our results would provide an insight into human DC subset specific functions.  
3.2) Major aim 
Determine the conditions under which CD1c+ DCs would produce IL-12p70 and IL-23 compared to 
monocytes, CD141+ DCs and pDCs  
3.2.1) Sub-aims 
1. Determine the conditions that can stimulate CD1c+ DCs to produce IL-1β, IL-6, IL-12p70 and 
IL-23   
2. Compare the levels of cytokine production by CD1c+ DCs with monocytes, pDCs and CD141+ 
DCs in response to TLR stimulation 
3. Determine the levels of IL-1β, IL-6, IL-12p70 and IL-23 production by AS-derived CD1c+ DCs 
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3.3) Results 
3.3.1) Titration of TLR agonists 
In this pilot experiment, we optimised the doses of each TLR agonists used in our study by 
analysing cytokine secretion and cell viability as readouts. Cytokine secretion by CD1c+ DCs and 
monocytes were evaluated using ELISA, while cell viabilities were analysed using flow cytometry. 
However, it is worth mentioning that comparisons between CD1c+ DCs and monocytes should be 
performed on a larger scale using the optimal TLR concentrations. We showed that CD1c+ DCs 
produced IL-1β in response to TLR 8 ligation (Figure 3.1a). Monocytes produced significantly 
higher IL-1β compared to CD1c+ DCs in response to all R848 concentrations (Figure 3.1a, p < 
0.01). Next, CD1c+ DCs produced IL-6 in response 0.5, 1 and 2µg/ml R848 in a dose-dependent 
manner (Figure 3.1b). Monocytes were capable of producing IL-6 in response to different R848 
concentrations. As shown in Figure 3.1b, no significant difference in IL-6 production was observed 
between monocytes and CD1c+ DCs in response to all R848 concentrations (paired, repeated 
measures, two-way ANOVA).   
CD1c+ DCs produced IL-23 in response to all R848 concentrations while IL-23 was not detected 
from monocytes (Figure 3.1c, limit of detection = 62.5 pg/ml). CD1c+ DCs produced detectable 
levels of IL-12p70 in response to 2µg/ml R848 while IL-12p70 was undetected in monocytes 
(Figure 3.1d, limit of detection = 7.8 pg/ml). Taken together, 2µg/ml R848 induced highest levels 
of IL-1β, IL-6, IL-12p70 and IL-23 production in CD1c+ DCs. Furthermore, the viability of CD1c+ 
DCs stimulated with titrated concentrations of R848 ranged between 60 – 80% (Figure 3.3b). 
While the viability of monocytes was lower (30 – 60%) compared to CD1c+ DCs, there was no 
significant difference between both cell types. The absence of IL-12p70 and IL-23 production may 
be attributed to its low viability post-stimulation. Subsequent stimulatory experiments were 
conducted using 2µg/ml R848.  
Next, we observed that in response to 100ng/ml LPS, monocytes produced significantly higher IL-
1β compared to CD1c+ DCs (Figure 3.2a, p < 0.01). Furthermore, monocytes produced 
significantly higher IL-6 compared to CD1c+ DCs in response to all LPS concentrations (0.1, 1, 10, 
100ng/ml) (Figure 3.2a, b, p < 0.05, p < 0.0001, p < 0.01, p < 0.0001, respectively). Taken 
together, 100ng/ml LPS induced highest levels of IL-1β and IL-23 production in monocytes. 
Furthermore, no statistical difference was observed in the percentage of live CD1c+ DCs and 
monocytes in response to multiple LPS titrations (Figure 3.3a). Therefore, subsequent stimulatory 
experiments were conducted using 100ng/ml LPS.  
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Figure 3.1: Titration of R848 using CD1c+ DCs and monocytes. 1 x 104 CD1c+ DCs or monocytes 
were incubated with R848 in duplicates at different titrations (2, 1, 0.5µg/ml) for 20 hours at 37oC. 
Post-incubation, supernatants were harvested and levels of (a) IL-1β, (b) IL-6, (c) IL-23 and (d) IL-
12p70 were evaluated using ELISA. Data were analysed with matching, paired t-test, presented as 
the mean from a total of three independent experiments. Statistical difference in cytokine 
production between stimulated CD1c+ DCs and monocytes was analysed with paired, repeated 
measures two-way ANOVA with ** p < 0.01. Red plots represented CD1c+ DCs, blue plots 
represent monocytes. Each plot represents data obtained with cells from one donor. 
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Figure 3.2: Titration of LPS using CD1c+ DCs and monocytes. 1 x 104 CD1c+ DCs or monocytes 
per 100µl culture volume in duplicates were incubated with LPS at different titrations (100, 10, 1, 
0.1ng/ml) for 20 hours at 37oC. Post-incubation, supernatants were harvested and levels of (a) IL-
1β, (b) IL-6, (c) IL-23 and (d) IL-12p70 were evaluated using ELISA. Statistical difference in 
cytokine production between stimulated CD1c+ DCs and monocytes analysed with paired, repeated 
measures two-way ANOVA with ** p < 0.01, *** p < 0.001, presented as the mean from a total of 
three independent experiments. Red plots represented CD1c+ DCs, blue plots represent monocytes. 
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Figure 3.3: Percentage of live CD1c+ DCs and monocytes post-stimulation with titrated 
concentrations of LPS and R848. (a) Top panel – gating strategy for CD1c+ DCs, bottom panel – 
gating strategy for monocytes. 1 x 104 CD1c+ DCs or monocytes per 100 µl culture volume in 
duplicates were incubated with (b) LPS at different titrations (100, 10, 1, 0.1ng/ml) or R848 (c) 
(0.5, 1, 2 µg/ml) for 20 hours at 37oC. Post-incubation, cells were harvested, washed, stained with 
Live/dead aqua and cell viability was analysed using flow cytometry with Cyan ADP cytometer. 
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Finally, we titrated the PIC using CD1c+ DCs as this DC subset expresses TLR 3. Human 
monocytes are known to not express TLR 3 (Matsumoto et al., 2003, Muzio et al., 2000, Visintin et 
al., 2001). Furthermore, our experiments demonstrated that stimulation of monocytes with titrated 
concentrations of PIC do not induce production of IL-1β, IL-12p70 and IL-23. Interestingly, we 
detected IL-6 from monocytes upon stimulation with PIC. We stimulated purified CD1c+ DCs with 
a range of PIC concentrations (25, 10, 5 and 1µg/ml) for 20 hours and evaluated its viability. As 
shown in Figure 3.4, CD1c+ DCs stimulated with 25µg/ml PIC displayed reduced viability 
compared to unstimulated controls. Similarly, CD1c+ DCs stimulated with 10µg/ml PIC also 
resulted in a loss of viability, albeit to a lesser extent when compared to 25µg/ml. CD1c+ DCs 
stimulated with 5, 3 and 1µg/ml remained viable. We next evaluated the production of IL-6, along 
with IL-1β, IL-12p70 and IL-23 by in response to a range of PIC concentrations. We observed that 
25µg/ml PIC stimulated CD1c+ DCs to produce IL-1β, IL-6, IL-12p70 and IL-23 at high levels 
(Figure 3.4). 10µg/ml PIC managed to induce CD1c+ DCs to produce IL-1β, IL-6 and IL-23, albeit 
to a lesser extent compared 25µg/ml PIC (Figure 3.4). Given the poor viability as a result of 
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Figure 3.4: Percentage of live CD1c+ DCs and cytokine secretion post-stimulation with titrated 
concentrations of PIC. 1 x 104 CD1c+ DCs per 100µl culture volume were incubated with PIC at 
different titrations (25, 10, 5, 3, 1µg/ml) for 20 hours at 37oC. Post-incubation, cells were harvested, 
washed, stained with Live/dead aqua and cell viability was analysed using flow cytometry with 
Cyan ADP cytometer. Levels of IL-1β, IL-6, IL-23 and IL-12p70 were evaluated using ELISA. 














57 | P a g e  
 
3.3.2) Comparable production of IL-1β and IL-6 between CD1c+ DCs and monocytes in 
response to TLR agonists  
Having identified the optimal concentrations of LPS, R848 and PIC (100ng/ml, 2µg/ml and 
10µg/ml, respectively), we next determined the effects of combinational TLR stimulations on both 
CD1c+ DCs and monocytes on their cytokine production. Cytokine production by both cell types 
were evaluated using ELISA. We demonstrated that monocytes produced IL-1β and IL-6 in 
response R848 and in response to R848 in combination with LPS. Monocytes produced 
significantly higher levels of IL-1β compared to CD1c+ DCs in response to LPS alone (p < 0.001) 
and the combination of LPS with PIC (p < 0.001) (Figure 3.5a). Similarly, monocytes produced 
significantly higher levels of IL-6 compared to CD1c+ DCs in response to LPS alone (p < 0.05) and 
the combination of LPS plus PIC (p < 0.01). Monocytes stimulated with LPS either alone or in 
combination with PIC produced similar levels of IL-1β and IL-6 (Figure 3.5a, b). While monocytes 
lack TLR 3, monocytes may express PRRs which are able to recognise dsRNA leading to cytokine 
production.  
Next, we observed that R848 alone, but not LPS alone or PIC alone induced IL-1β production in 
CD1c+ DCs (Figure 3.5a). Levels of IL-1β induced by R848 was significantly enhanced in the 
presence of LPS by CD1c+ DCs (Figure 3.5a, p < 0.05, 3075 ± 1034.828 pg/ml vs 5430 ± 1229 
pg/ml, mean ± sem). R848 plus PIC combination significantly enhanced IL-1β production in 
CD1c+ DCs compared to PIC alone (Figure 3.5a, p < 0.01, 4958 ± 1190 vs 401.2 ± 224.9 pg/ml, 
mean ± sem). Although no significance was observed, we noted elevated levels of IL-1β production 
by CD1c+ DCs stimulated with R848 plus PIC compared to R848 alone (Figure 3.5a, 4958 ± 1190 
vs 3045 ± 1035 pg/ml, mean ± sem). Notably, the combination of LPS plus PIC failed to enhance 
IL-1β production by CD1c+ DCs.  
We observed IL-6 production by CD1c+ DCs in response to PIC alone or R848 alone (2095 ± 611 
pg/ml vs 5157 ± 1509 pg/ml, mean ± sem). R848 plus PIC combination did not significantly 
enhance IL-6 production by CD1c+ DCs compared to R848 alone or PIC alone. Additionally, we 
confirmed that CD1c+ DCs were capable of producing IL-6 in response to LPS plus R848 condition 
(Figure 3.5b). Using the same combination, we observed significant enhancement IL-6 levels in 
CD1c+ DCs compared to LPS alone; (Figure 3.5b, p < 0.01, 6712 ± 1719 vs 2517 ± 703.9 pg/ml, 
mean ± sem). IL-6 production by CD1c+ DCs stimulated with LPS plus R848 compared to R848 
alone did not achieve significance (Figure 3.5b, 5157 ± 1509 pg/ml vs 6712 ± 1719 pg/ml, mean ± 
sem). While monocytes were capable of producing IL-6 in response to all TLR agonists, we did not 
observe any enhancing effect when comparing single with dual TLR combinations. Taken together, 
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the production of IL-1β by CD1c+ DCs was induced by R848 and further enhanced in the presence 
of either LPS or PIC. The production of IL-6 by CD1c+ DCs was induced in response to R848 or 
PIC alone, and the levels of IL-6 production by CD1c+ DCs have only enhanced in the presence of 
LPS plus R848 combination. 
 
3.3.3) Significant IL-23 and IL-12p70 production by CD1c+ DC compared to monocytes in 
response to TLR agonists 
Next, we showed that R848 but not LPS or PIC alone induced IL-12p70 production by CD1c+ DCs 
(Figure 3.5d) using ELISA. We confirmed that IL-12p70 production by CD1c+ DCs in response to 
LPS plus R848 (2299.755 ± 229.655 pg/ml, mean ± sem) combination, which was significantly 
higher compared to CD1c+ DCs stimulated with LPS alone (0pg/ml) or R848 alone (490.072 ± 
178.960 pg/ml, mean ± sem (Figure 3.5d, p < 0.001). While PIC alone failed to activate CD1c+ 
DCs to produce IL-12p70, PIC was able to enhance IL-12p70 induced by R848 in CD1c+ DCs 
(2227.512 ± 297.334 pg/ml, mean ± sem Figure 3.5d). Following that, CD1c+ DCs stimulated with 
R848 plus PIC produced significantly higher IL-12p70 compared to R848 alone (490.072 ± 178.960 
pg/ml, mean ± sem p < 0.01) or PIC alone (p < 0.001) (Figure 3.5d). Notably, the combination of 
LPS plus PIC did not induce IL-12p70 secretion by CD1c+ DCs. Finally, we observed low levels of 
IL-12p70 production by monocytes in response to TLR stimulation. These data indicated that IL-
12p70 production by CD1c+ DCs was induced upon TLR 8 ligation, and further enhanced in the 
presence of TLR 3 and 4 agonists. Additionally, IL-12p70 was not detected from monocytes in 
response to TLR agonists. Previously, Acosta-Rodriguez reported that CD1c+ DCs produced IL-23 
in response to LPS plus R848 combination (Acosta-Rodriguez et al., 2007a); however, its 
conditions remained to be fully defined. We asked if the production of IL-23, like IL-12p70 by 
CD1c+ DCs was induced in response to R848 and further enhanced in the presence of LPS or PIC.  
Here, our study demonstrated that R848 induced IL-23 production from freshly isolated CD1c+ 
DCs, but not in response to LPS or PIC (Figure 3.5c, detection limit = 62.5 pg/ml using ELISA). 
We observed significant IL-23 production by CD1c+ DCs in response to R848 alone compared to 
monocytes (Figure 3.5c, p < 0.001, 905.4 ± 218.3 vs 174.6 ± 164.9 pg/ml, mean ± sem). We 
further demonstrated that the levels of IL-23 induced by R848 in CD1c+ DCs were enhanced in the 
presence of LPS alone (5209 ± 959.2 vs 18.33 ± 18.33 pg/ml, mean ± sem) or PIC alone (5209 ± 
959.2 vs 205.4 ± 218.3 pg/ml, mean ± sem), suggesting a synergistic mechanism. We did not 
observe any significant difference in IL-12p70 production by CD1c+ DCs upon stimulation with 
R848 alone or PIC alone. 
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Similarly, IL-23 production by CD1c+ DCs in response to R848 was further enhanced in the 
presence of PIC (3960.009 ± 903.453 pg/ml, mean ± sem Figure 3.5c). Following that, R848 plus 
PIC combination stimulated CD1c+ DCs to produce significantly higher IL-23 compared to R848 (p 
< 0.001) or PIC (p < 0.01) alone. The combination of LPS plus PIC did not enhance IL-23 
production by CD1c+ DCs, further indicated that stimulation of TLR 8 was paramount for its 
induction. We did not observe a further increase in IL-23 production by CD1c+ DCs in response to 
triple TLR engagement.  
These data therefore, suggested that R848 is crucial for IL-23 induction, which was enhanced in the 
presence of LPS or PIC, a feature absent in monocytes. These data indicated that the production of 
IL-12p70 and IL-23 by CD1c+ DCs was induced by R848, and further enhanced by LPS or PIC. 
LPS plus R848 combination seemed to be the best combination at inducing IL-1β, IL-6, IL-12p70 
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Figure 3.5: Induction of IL-23 and IL-12p70 in CD1c+ DCs but not monocytes by a combination 
of TLR agonists. IL-1β (a), IL-6 (b), IL-23 (c) and IL-12p70 (d) production by human 5 x 104 
CD1c+ DCs and monocytes in 100µl volume stimulated with 100ng/ml LPS, 2µg/ml R848, 10µg/ml 
PIC alone or in combination. Cytokines were measured in a 20-hour culture supernatants using 
ELISA. Data presented as mean ± sem from a total of eight human donors. Paired analysis was 
performed using repeated measures, two-way ANOVA with *p < 0.05, ** p < 0.01, *** p < 0.001. 
Cytokine levels presented as pg/ml per 5 x 104 cells.  Red plots represented CD1c+ DCs, blue plots 
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3.3.4) CD1c+ DCs are the major DC subset producing IL-1β, IL-6, IL-23 and IL-12p70 
compared to pDCs and CD141+ DCs in response to TLR stimulation 
Human CD141+ DCs express TLRs 3 and 8, while pDCs express TLRs 7 and 9 (Jongbloed et al., 
2010, Kadowaki et al., 2001). Our previous data demonstrated that R848 was the main inducer of 
IL-23 and IL-12p70 in CD1c+ DCs, we next investigated the effects of R848 on CD141+ DCs and 
pDC cytokine production. Given their TLR expressions, CD141+ DCs were stimulated with R848, 
PIC while pDCs were stimulated with R848 and CpG ODN 2216, either alone or in combination. 
To ensure CD141+ DCs and pDCs were viable post-TLR stimulation, we evaluated their viability 
using flow cytometry by staining them with Live/DeadTM Fixable Dead Cell Stain and analysed 
total live cells using flow cytometry. As shown in Figure 3.6, we observed no significant difference 
in CD1c+ DC and CD141+ DC viability in response to while the R848 plus PIC combination when 
compared to untreated controls. CD1c+ DCs stimulated with R848 alone or PIC alone did not affect 
cell viability when compared to untreated controls. Similarly, CD141+ DCs stimulated with R848 
alone or PIC alone did not affect cell viability when compared to untreated controls. Finally, no 
significant difference was observed in pDC viability in response to CpG or R848, either alone or in 
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Figure 3.6: Viability of pDCs, CD141+ DCs and CD1c+ DCs post-TLR stimulation. (a) Purified 
CD141+ DCs, (b) CD1c+ DCs and (c) pDCs were stimulated with R848, CpG ODN 2216 or PIC, 
either alone or in combination for 20 hours at 37oC. pDCs were stimulated either with R848 or CpG 
ODN2216, either alone or in combination for 20 hours at 37oC in the presence of 25ng/ml human 
recombinant IL-3. Post-incubation, DCs were harvested, washed, stained with live/dead aqua dye 
and cell viability was analysed using flow cytometry on Cyan ADP Cytometer. (d) Total live DCs 
were calculated using FlowJo version 8.8.7 and presented as mean ± SEM. Data from three 
experiments, except PIC condition (two experiments).  
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Next, we determined the expression co-stimulatory molecules by CD141+, CD1c+ DCs and pDCs 
upon TLR stimulation, which were analysed using flow cytometry. As shown in Figure 3.7a, b, we 
observed that unstimulated CD1c+ and CD141+ DCs expressed CD83, CD86 and HLA-DR. Upon 
stimulation with R848 or PIC either alone or in combination, we observed a slight up-regulation of 
CD86, while the expression of HLA-DR was sustained on CD141+ DCs. In response to PIC and its 
combination with R848, we observed CD83 expression on CD141+ DCs was not significantly 
different compared to untreated controls (p > 0.5540, Figure 3.7d). We observed significant up-
regulation of CD86 by CD1c+ DCs in response to R848 plus PIC combination compared to 
unstimulated controls (p < 0.05, Figure 3.7b). As expected, the expression of CD83 and HLA-DR 
on CD1c+ DCs was sustained in response to TLR stimulation. The expression of CD86 on pDCs 
was not significantly up-regulated in response to TLR 7 and 9 stimulations when compared to 
untreated controls (Figure 3.7c). Similarly, pDCs stimulated with CpG or R848, either alone or in 
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Figure 3.7: Expression of co-stimulatory molecules by CD141+ DC and CD1c+ DCs in response 
to TLR stimulation. Purified (a) CD141+ DCs, (b) CD1c+ DCs and (c) pDCs were stimulated with 
R848, CpG or PIC, either alone or in combination for 20 hours at 37oC. pDC cultures were 
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supplemented with 25ng/ml human recombinant IL-3. Post-incubation, DCs were harvested, 
washed, stained with CD80, CD83, HLA-DR and analysed using flow cytometry using Cyan ADP 
Cytometer in comparison to their matching isotype controls. However, the HLA-DR-PeCy7 
antibody which was used to sort the DC subsets was still present on the surface. Therefore, in this 
Figure, the “PeCy7 isotype control” represents the level of HLA-DR expressed at the 
commencement of the culture rather than a true negative staining, whilst the HLA-DR-PeCy7 
represents the increased HLA-DR surface staining during the culture (as detailed in the Methods 
Chapter, section 2.2). Numbers in each plot represent median fluorescence intensity (MFI) for 
each red histogram. (d) MFI value of each co-stimulatory molecule was determined using Flow Jo 
version 8.8.7. Delta (Δ) MFI was calculated by subtracting MFI value of each staining antibody 
(red histogram) with its matching isotype control (blue histogram). Data were analysed with 
repeated measures, one-way ANOVA with Bonferroni post-tests and presented in log scale as mean 

















67 | P a g e  
 
As a positive control for pDC function, we evaluated the production of IFN-α in response to CpG 
and R848 stimulation, either alone or in combination. We demonstrated that pDCs were able to 
secrete IFN-α in response to CpG stimulation (Figure 3.8). R848 also induced pDCs to produce 
IFN-α, albeit to a lesser extent compared to CpG. Interestingly, we observed diminished IFN-α 
production in response to CpG plus R848 combination which was not attributed to poor pDC 
viability (Figure 3.6). Taken together, our data demonstrated that CD141+ DCs and pDCs used in 
our study were functional and remained viable post-TLR stimulation.  
As a positive control for CD141+ DC function, we evaluated IFN-λ production by in response to 
PIC stimulation. CD141+ DCs stimulated with PIC alone resulted in IFN-λ production (3308 ± 
666.2 pg/ml, mean ± SEM, Figure 3.8). We observed that IFN-λ levels produced by CD1c+ DCs in 
response to PIC alone were significantly lower compared to CD141+ DCs (p < 0.01, 926 ± 98.56 vs 
3308 ± 666.2 pg/ml, mean ± SEM, Figure 3.8). CD141+ DCs were capable of producing IFN-λ in 
response to R848 plus PIC (3713 ± 690.7 pg/ml, mean ± SEM, Figure 3.8). We observed in our 
assay that pDCs derived from one donor secreted IFN-λ in response to CpG; albeit to a lesser extent 
than CD141+ DCs (Figure 3.8). We observed low levels of IFN-λ from CD1c+ DCs when 
stimulated with R848 alone. Taken together, CD141+ DCs remained functional after stimulation 
with R848 plus PIC given their production of IFN-λ. 
Having demonstrated the viability of CD1c+ DCs, CD141+ DCs and pDCs within our culture 
system, we next evaluated their cytokine production in response to TLR stimulations. We 
stimulated CD1c+ DCs, CD141+ DCs and pDCs isolated from the same donors with optimal TLR 
agonist combination and evaluated cytokine production using our customised human DC 
LegendPlex kit. CD141+ DCs only express TLRs 3 and 8, while CD1c
+ DCs express TLRs 3, 4, 7 
and 8. Therefore, we chose the R848 plus PIC combination to stimulate both CD1c+ and CD141+ 
DCs. pDCs selectively express TLRs 7 and 9, therefore the CpG plus R848 combination was 
employed for their stimulation. In response to R848 plus PIC, CD1c+ DCs produced significantly 
higher levels of IL-1β compared to CD141+ DCs (Figure 3.8, p < 0.001, 166.9 ± 27.89 vs 10.57 ± 
10.21 ng/ml, mean ± sem). Here, we did not observe IL-1β from pDCs in response to CpG plus 
R848 (Figure 3.8). We demonstrated that pDCs secreted IL-6 in response to R848 plus CpG 
combination; albeit to a lesser extent compared to CD1c+ DCs and CD141+ DCs that were 
stimulated with R848 plus PIC (Figure 3.8). We further demonstrated CD141+ DCs produced IL-6 
in response to R848 plus PIC, although significantly lower compared CD1c+ DCs (Figure 3.8, p < 
0.01, 154.9 ± 30.17 vs 358.6 ± 94.26 ng/ml, mean ± sem). Furthermore, stimulation of CD1c+ DCs 
with LPS plus R848 plus PIC combination resulted in significant production of IL-1β (p < 0.001) 
and IL-6 (p < 0.01) in comparison with CD141+ DCs under identical conditions (Figure 3.8). 
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Taken together, CD1c+ DCs excelled at IL-1β and IL-6 production in response to TLR stimulation 
compared to pDCs and CD141+ DCs.   
CD1c+ DCs produced significantly higher IL-23 compared to CD141
+
 DCs in response to R848 plus 
PIC combination (Figure 3.8a, p < 0.001, 57.5 ± 12.3 vs 18.02 vs 14.06 ng/ml, mean ± sem). 
CD1c+ DCs stimulated with R848 plus PIC combination produced significantly higher IL-23 
compared to pDCs that were stimulated with CpG plus R848 combination. In a separate set of 
experiments, stimulation of CD1c+ DCs with triple TLR combination consisting of LPS plus R848 
plus PIC produced significantly higher IL-23 compared to CD141+ DCs under identical conditions, 
which was measured using the customised human DC LegendPlex assay (Figure 3.8a, p < 0.001, 
164.583 ± 57.365 ng/ml vs 32.3 ± 17.470 ng/ml). Using R848 plus PIC combination, we observed 
that CD1c+ DCs produced significantly higher IL-12p70 compared CD141+ DCs (Figure 3.8a, p = 
0.0340, 190.488 ± 37.08 ng/ml vs 113.214 ± 45.13, vs mean ± sem). pDCs did not produce IL-
12p70 in response to CpG plus R848 combination (Figure 3.8a). Furthermore, we observed that 
CD1c+ DCs produced significantly higher IL-12p70 compared to pDCs (Figure 3.8a, p < 0.001, 
190.488 ± 37.08 ng/ml vs 0 ng/ml) in response to dual TLR stimulations.  
In a separate set of experiments, we compared the ability of CD1c+ DCs and CD141+ DCs at 
producing IL-12p70 in response to LPS plus R848 plus PIC combination. The levels of IL-12p70 
were measured using ELISA. We observed that CD1c+ DCs produced significantly higher IL-12p70 
compared to CD141+ DCs in response to LPS plus R848 plus PIC combination (Figure 3.8b with p 
0.0245). However due to lack of sufficient supernatants, we were unable to analyse IFN-λ 
production by CD141+ DCs in response to LPS plus R848 plus PIC combination. It is worth 
mentioning that in response to LPS plus R848 plus PIC combination, CD1c+ DCs were superior 
compared to CD141+ DCs in terms of IL-1β, IL-6 and IL-23 production (Figure 3.8b).  
In conclusion, we demonstrated that CD1c+ DCs produced significantly higher IL-12p70 compared 
to CD141+ DCs in response to R848 plus PIC combination as well as LPS plus R848 plus PIC 
combination. Finally, CD1c+ DCs were superior compared to other peripheral blood CD141+ DCs 
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Figure 3.8: IL-1β, IL-6, IL-23, IL-12p70, IFN-λ and IFN-α production by CD1c+ DCs, CD141+ 
DCs and pDCs in response to TLR agonists. (a) IL-1β, IL-6, IL-23, IL-12p70, IFN-λ and IFN-α 
production by human CD1c+ DCs, CD141+ DCs and pDCs from peripheral blood stimulated with 
dual TLR agonists (R848 plus PIC for CD1c+ and CD141+ DCs, CpG 2216 plus R848 for pDCs) 
compared to unstimulated controls. pDC cultures were supplemented with 25ng/ml human 
recombinant IL-3. IL-1β, IL-6, IL-12p70, IL-23, IFN-α and IFN-λ were measured from 20-hour 
culture supernatants using customised human DC LegendPlex assay. Raw data were analysed using 
VigeneTech Software version 7.0 (Biolegend). (b) IL-1β, IL-6, IL-23 and IL-12p70 production by 
human CD1c+ DCs, CD141+ DCs upon stimulation with triple TLR combination consisting of LPS 
plus R848 plus PIC (L + P + R). Supernatants from CD1c+ DCs and CD141+ DCs stimulated with L 
+ P + R were analysed using ELISAs. Raw data were analysed using GraphPad Prism 5 with a four-
parameter nonlinear regression. Data were presented as mean ± SEM from a total of three human 
donors. Data analysed with repeated measures, two-way ANOVA with * p < 0.05, **p < 0.01, *** 
p < 0.001. Cytokine levels presented as ng/ml per 1 x 106 cells. Each donor is represented by a 














71 | P a g e  
 
 3.3.5) AS-derived CD1c+ DCs showed up-regulation of expression of co-stimulatory molecules 
in response to combinational TLR stimulation 
GWAS have identified several genes including IL12B, STAT3 and IL23R in AS pathogenesis, 
suggesting the role of IL-23 signalling towards disease pathology (Brown et al., 2016, Chou et al., 
2006, Danoy et al., 2010). Additionally, the serum level of IL-12p70 was significantly elevated in 
AS patients compared to healthy controls (HCs) (Yang et al., 2007). While AS-derived CD1c+ DCs 
have been demonstrated to promote allogenic MLR in vitro, its cytokine production capabilities 
have yet to be addressed (Wright et al., 2016). Having demonstrated that CD1c+ DCs derived from 
HC secrete substantial amounts of IL-1β, IL-6, IL-12p70 and IL-23 in response to LPS plus R848 
stimulation, we proceeded to investigate whether the cytokine secretory profile would be altered in 
AS patients. To this end, CD1c+ DCs and monocytes were isolated from peripheral blood of active 
AS patients and stimulated them with LPS plus R848 to induce cytokine production. AS patients 
included in our study treated only with non-steroidal anti-inflammatory drugs (NSAID) but not with 
anti-TNFα treatment, which allowed characterisation of unmodulated, CD1c+ DCs.  
We firstly determined the baseline levels of co-stimulatory molecules on freshly isolated CD1c+ 
DCs and monocytes from both groups. Freshly isolated CD1c+ DCs from both groups expressed 
low levels of CD80, CD83 and CD86 (Figure 3.9). The level of HLA-DR expression on CD1c+ 
DCs from both patient groups was similar. Upon overnight culture, CD1c+ DCs from both groups 
spontaneously up-regulated expression of CD86, CD83 and HLA-DR while CD80 remained low 
(Figure 3.9). Of note, AS-derived CD1c+ DCs displayed large variance in CD83 and HLA-DR 
expression. The expression of HLA-DR and CD83 on AS-derived CD1c+ DCs stimulated with LPS 
plus R848 remained unchanged compared to CD1c+ DCs cultured in media without TLR agonists 
(Figure 3.9). Notably, AS-derived CD1c+ DCs stimulated with LPS plus R848 expressed 
significantly higher CD80 (p < 0.0001) and CD86 (p < 0.05) compared to CD1c+ DCs from HC.  
Similarly, freshly isolated monocytes from both patient groups expressed low levels of CD80, 
CD83, CD86 and HLA-DR (Figure 3.10). Upon culture, monocytes from both patient groups 
spontaneously up-regulated the expression of all co-stimulatory molecules. We observed a large 
variance in CD80, CD83 and HLA-DR expression by AS-derived monocytes upon culture. Of note, 
monocytes from one AS patient failed to up-regulate HLA-DR and CD83 upon culture. Similarly, 
monocytes from one HC did not up-regulate CD83 expression following culture. Upon stimulation 
with LPS plus R848, AS-derived monocytes significant up-regulated CD83 expression compared to 
those cultured in media only (p < 0.05, Figure 3.10). Interestingly, AS-derived monocytes 
expressed significantly higher CD83 expression compared to monocytes from HC in response to 
LPS plus R848 stimulation (Figure 3.10, p < 0.05).  
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We did not observe further up-regulation of CD80 and CD86 on monocytes from both patient 
groups upon stimulation with LPS plus R848. Monocytes from both patient groups down-regulated 
HLA-DR expression in response to LPS plus R848 stimulation. Taken together, AS-derived CD1c+ 
DCs displayed increased CD80 and CD86 expression upon dual TLR stimulation in comparison 
with HCs; while AS-derived monocytes had expressed higher CD83 levels compared to monocytes 
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Figure 3.9: Expression of co-stimulatory molecules on CD1c+ DCs from both patient groups 
upon stimulation with a combination of TLR agonists. CD1c+ DCs isolated from both patient 
groups were stimulated with LPS plus R848 for 20 hours, washed and stained with CD80, CD83, 
CD86, HLA-DR and analysed using flow cytometry with Cyan ADP Cytometer. (a) Gating strategy 
to determine the expression of co-stimulatory molecules on CD1c+ DCs. MFI value of each co-
stimulatory molecule was determined using Flow Jo version 8.8.7. (b) ΔMFI was calculated by 
subtracting MFI value of each staining antibody with its matching isotype control Each plot denotes 
data obtained from one patient with a total of six AS patients (red plots) and six HCs (blue plots). 
Data were analysed with two-way ANOVA with Bonferroni post-test and presented as mean with 
**p < 0.01, ***p < 0.0001.   
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Figure 3.10: Expression of co-stimulatory molecules on monocytes from both patient groups 
upon stimulation with a combination of TLR agonists. Monocytes isolated from both patient 
groups were stimulated with LPS plus R848 for 20 hours, washed and stained with CD80, CD83, 
CD86, HLA-DR and analysed using flow cytometry with Cyan ADP Cytometer. (a) Gating strategy 
to determine the expression of co-stimulatory molecules on monocytes. MFI value of each co-
stimulatory molecule was determined using Flow Jo version 8.8.7. (b) ΔMFI was calculated by 
subtracting MFI value of each staining antibody with its matching isotype control Each plot denotes 
data obtained from one patient with a total of six AS patients (red plots) and six HCs (blue plots). 
Data were analysed with two-way ANOVA with Bonferroni post-test and presented as mean with 
*p < 0.05. 
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To study the functional properties of CD1c+ DCs and monocytes derived from AS patients in 
comparison to CD1c+ DCs and monocytes from HCs, we evaluated their cytokine production in 
response to TLR stimulation. To this end, we employed a customised multiplex bead assay to 
simultaneously detect IL-1β, IL-6, IL-12p70, IL-18 IL-23, IL-10, IL-27, CCL5, IFN-α, CXCL9, 
CXCL10, CXCL11 and TNF-α from our culture supernatants. In response to dual TLR stimulation, 
IL-23, IL-1β, IL-6, TNF-α and IL-10 levels produced by AS-derived CD1c+ DCs were not 
significantly different compared to CD1c+ DCs from HCs. Upon LPS plus R848 stimulation, the 
levels of IL-12p70 produced by AS-derived CD1c+ DCs were elevated compared to the levels 
produced by CD1c+ DCs from HCs; however, it did not achieve statistical significance (Figure 
2.11, p = 0.0766, one-way ANOVA). These data suggested that IL-12p70 production by CD1c+ 
DCs between both patient groups was not statistically different.  
The levels of IL-1β (p > 0.999), IL-6 (p > 0.999) and IL-23 (p > 0.999) being produced by CD1c+ 
DCs were not significantly different between groups (Figure 3.11). Notably, CXCL10 levels were 
significantly increased in AS-derived monocytes compared to monocytes from HCs (Figure 3.11, p 
< 0.05, one-way ANOVA). Furthermore, AS-derived monocytes produced significantly higher 
TNF-α levels compared to monocytes from HCs (p < 0.05). Of note, CCL5, IFN-α, CXCL9, 
CXCL11, and IL-27 were undetectable by both cell types from AS patients and HCs in response to 
LPS plus R848 stimulation. Taken together, IL-12p70 production by CD1c+ DCs from both patient 
groups was not significantly different, while AS-derived monocytes produced significantly higher 
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Figure 3.11: Cytokine secretion by CD1c+ DCs and monocytes from patient groups in response to 
dual TLR stimulation. AS-derived CD1c+ DCs and monocytes (red plots), HC-derived CD1c+ DCs 
and monocytes (blue plots) were stimulated with LPS plus R848 for 20 hours. Post-incubation, 
supernatants were harvested for cytokine analysis using a customised human DC LegendPlex assay 
(Biolegend). Raw data was analysed with VigeneTech software Version7.0 (Biolegend). Each plot 
denotes one data obtained from one patient with a total of six AS patients. Data presented as pg/ml 
per 1 x 104 cells. Data were analysed with one-way ANOVA with Bonferroni post-test and 
presented as mean ± s.d. 
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3.4) Discussion 
With its broad TLR expression profile, stimulation of CD1c+ DCs with TLR 3, 4, 7 and 8 agonists 
result in cytokine production (Acosta-Rodriguez et al., 2007a, Hemont et al., 2013, Jongbloed et al., 
2010, Napolitani et al., 2005, Nizzoli et al., 2013). Stimulation of TLR 3 results in IL-1β and IL-6 
(Hemont et al., 2013, Jongbloed et al., 2010), stimulation of TLR 4 induces minimal IL-1β, IL-6 
and IL-12p70 (Acosta-Rodriguez et al., 2007a, Hemont et al., 2013, Napolitani et al., 2005, Nizzoli 
et al., 2013), while stimulation of TLRs 7 and 8 induces IL-1β, IL-6 and IL-12p70 (Acosta-
Rodriguez et al., 2007a, Hemont et al., 2013, Napolitani et al., 2005, Nizzoli et al., 2013). IL-12p70 
plays a role at priming Th1 responses, while the combination of IL-1β, IL-6 and IL-23 play role at 
activating Th17 responses. Stimulation of CD1c+ DCs with LPS plus R848 combination results in 
IL-23 production (Acosta-Rodriguez et al., 2007a); however, its conditions remained to be fully 
established. In this chapter, we determined the conditions that would induce peripheral blood 
CD1c+ DCs to produce IL-12p70 and IL-23; and compared the responses with peripheral blood 
monocytes, CD141+ DCs and pDCs. We demonstrated that the production of IL-1β, IL-6, IL-12p70 
and IL-23 by CD1c+ DCs was induced in response to R848 stimulation. Production of these 
cytokines by CD1c+ DCs was further enhanced in the presence of either LPS alone or PIC alone. 
The combination of LPS plus PIC did not enhance levels of IL-1β, IL-12p70 and IL-23. Here, we 
identified that CD1c+ DCs were capable of producing both IL-12p70 and IL-23 in response to the 
following agonist combinations: LPS plus R848, R848 plus PIC and LPS plus R848 plus PIC. We 
further demonstrated that CD1c+ DCs were highly efficient at producing IL-1β, IL-6, IL-12p70 and 
IL-23 when compared with donor-matched CD141+ DCs and pDCs. The production of IL-12p70 by 
CD1c+ DCs derived from active, AS patients was not statistically different compared to CD1c+ DCs 
from HCs in response to TLR stimulation. Finally, AS-derived monocytes produced significantly 
higher levels of TNF-α and CXCL10 compared to monocytes from HCs in response to TLR 
stimulation.  
Consistent with a previous report (Acosta-Rodriguez et al., 2007a), we demonstrated that CD1c+ 
DCs produced IL-1β and IL-6 in response to LPS plus R848 stimulation. Yu et al. previously 
reported that pDCs up-regulated IL-1β mRNA in response to R837 (a strictly TLR 7 agonist) 
stimulation; however, secretion of its IL-23 protein remains to be determined (Yu et al., 2010). 
Here, we observed that stimulation of pDCs with CpG or R848, either alone or in combination 
failed to induce IL-1β production. Lozza et al. reported that pDCs do not produce IL-1β in response 
to Mycobacterium tuberculosis (Lozza et al., 2014b). Guarda et al. recently reported that Type I 
IFNs suppressed IL-1β production by human monocytes (Guarda et al.). As pDCs are able to 
produce Type I IFNs in response to TLR 7 and 9 ligations, the lack of IL-1β production could be 
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attributed to Type I IFN-mediated suppression. We observed IL-6 production by pDCs in response 
to TLR 7 and 9 stimulations, which was consistent with previous literature (Heil et al., 2004, 
Jarrossay et al., 2001, Kreutz et al., 2015). Our study demonstrated that pDCs produced IL-6 in 
response to dual TLR stimulation, albeit to a lesser extent compared to CD1c+ DCs which was 
consistent with a previous report (Kreutz et al., 2015).  
CD141+ DCs have been reported to produce low levels of IL-1β and IL-6 compared to CD1c+ DCs 
upon stimulation of PIC alone or R848 alone (Haniffa et al., 2012, Hemont et al., 2013, Jongbloed 
et al., 2010). Using R848 plus PIC combination, we next demonstrated that CD141+ DCs were able 
to produce both IL-1β and IL-6, albeit to a lesser extent compared to CD1c+ DCs. Unlike CD1c+ 
DCs, stimulation of CD141+ DCs with dual TLR agonists did not enhance production of IL-1β and 
IL-6 compared to single TLR agonist. Given the low levels of IL-1β and IL-6 being produced by 
CD141+ DCs, this DC subset may not play an important role at priming Th17 responses. CD141+ -
DCs were previously reported to produce IFN-β upon stimulation with PIC (Hemont et al., 2013). 
While the production of IFN-β by CD141+ DCs in response to R848 plus PIC remains to be 
determined, the lack of IL-1β observed from CD141+ DCs could be attributed to Type I IFN-
mediated suppression.  
We demonstrated that monocytes were capable of producing IL-1β and IL-6 but lacked IL-12p70 
and IL-23 in response to LPS plus R848 stimulation, which was consistent with a previous report 
(Acosta-Rodriguez et al., 2007a). The release of IL-1β is mediated by the activation of a multimeric 
protein complex known as the inflammasome. The release of IL-1β the triggers pyroptosis, a rapid 
form of programmed cell death approximately 4 hours after the initial priming step (Sester et al., 
2015, Tschopp and Schroder, 2010). The assembly of inflammasome complex requires an initial 
priming step, which usually involves the recognition of TLR ligands; followed by an activation 
signal such as potassium efflux and generation of reactive oxygen species (Tschopp and Schroder, 
2010). With the exception of PIC, we consistently observed that monocytes produced higher levels 
of IL-1β compared to CD1c+ DCs in response to LPS and R848 stimulation, either alone or in 
combination. These findings may indicate inflammasome activation in monocytes. Furthermore, IL-
12p35 and IL-23p19 mRNA which encodes for IL-12p70 and IL-23, respectively have been 
demonstrated to peak between 9 to 12 hours post-TLR stimulation (Napolitani et al., 2005). 
Therefore, activation of pyroptosis in monocytes may have preceded the up-regulation of IL-12p35 
and IL-23p19 mRNA. Monocytes are known to not express TLR 3 (Matsumoto et al., 2003, Muzio 
et al., 2000, Visintin et al., 2001); however, we observed that stimulation of monocytes with PIC 
resulted in IL-6 production. This could be attributed to their expression of other intracellular PRRs 
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including RIG-I and MDA-5 which upon stimulation, triggers the MAPK and NF-κB pathways 
(Lech et al., 2010).  
Jefford et al. previously reported that the lack of IL-12p70 production by CD1c+ DCs was due to the 
lack of IL-12p35 and IL-12p40 expression (Jefford et al., 2003). In that study, CD1c+ DCs were 
stimulated with CD40L, E. coli and a combination consisting of TNF-α, IFN-α and PGE2. 
Furthermore, the previous study from our group demonstrated the lack of IL-12p70 production by 
CD1c+ DCs in response to an activation cocktail consisting of IL-1β, PIC, TNF, IFN-γ and IFN-α 
(Jongbloed et al., 2010). Consistent with the literature, we observed that CD1c+ DCs stimulated 
with LPS lacked production of IL-1β, IL-6, IL-12p70 and IL-23 (Acosta-Rodriguez et al., 2007a, 
Hemont et al., 2013, Napolitani et al., 2005, Nizzoli et al., 2013). However, production of IL-12p70 
by CD1c+ DCs in response to LPS plus R848 has been widely recognised (Acosta-Rodriguez et al., 
2007a, Napolitani et al., 2005, Nizzoli et al., 2013). We confirmed these previous findings and 
showed that CD1c+ DCs produced IL-12p70 in response to LPS plus R848 combination. We 
extended these observations and further demonstrated that IL-12p70 was induced in CD1c+ DCs in 
response to R848, which was enhanced in the presence of PIC. These findings highlighted that the 
stimuli employed in the aforementioned studies were not optimal at inducing IL-12p70. Our results 
confirmed that the production of IL-12p70 by CD1c+ DCs is mediated via TLR signalling and 
requires multiple stimuli acting in synergy. Importantly, this feature was not observed in 
monocytes.  
To effectively compare IL-12p70 production between CD1c+ DCs and CD141+ DCs, the 
combination of R848 plus PIC was employed; given the lack of TLR 4 expression on latter DC 
subset. We firstly showed that CD1c+ DCs produced significantly higher IL-12p70 to CD141+ DCs 
(p = 0.0340, Figure 3.8a, measured using human DC LegendPlex). In a separate set of 
experiments, we also compared the ability of CD1c+ DCs and CD141+ DCs at producing IL-12p70 
in response to LPS plus R848 plus PIC combination (Figure 3.8, measured using ELISA). We 
observed that CD1c+ DCs produced significantly higher IL-12p70 compared to CD141
+ DCs upon 
stimulation with LPS plus R848 plus PIC (Figure 3.8b, p = 0.0245). The levels of IL-12p70 
produced by CD1c+ DCs and CD141+ DCs in response to R848 plus PIC combination or LPS plus 
R848 plus PIC combination could not be directly compared, as the assays used to quantify IL-
12p70 were different, (i.e ELISA vs DC LegendPlex) which may have different sensitivities. We 
observed that the levels of IL-12p70 produced by CD1c+ DCs in Figure 3.8a and Figure 3.8b were 
markedly different. This was most likely due to the sensitivities of the assays being used to detect 
IL-12p70. For example, the detection limit for IL-12p70 ELISA was 31pg/ml, while the detection 
limit for the human DC LegendPlex was 2.44pg/ml. This indicated that the human DC LegendPlex 
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was far more sensitive than a commercial ELISA. Furthermore, we cannot exclude the fact that the 
data obtained for Figure 3.8a and Figure 3.8b were from different patient cohorts. Nonetheless, our 
data highlighted that CD1c+ DCs were superior than CD141+ DCs in IL-12p70 production, in 
response to TLR stimulation. Given its ability to produce IL-12p70, future experiments should 
confirm the ability of CD1c+ DCs to prime Th1 responses in response to LPS plus R848 
stimulation. Mouse CD11b+ DCs are known to induce Th2 and Th17 responses but not Th1 
responses (Larson et al., 2013, Persson et al., 2013, Plantinga et al., 2013, Schlitzer et al., 2013, 
Vander Lugt et al., 2014), our data along with others highlight possible interspecies differences in 
DC function.  
In the mouse system, the CD8+ DCs but not the CD11b+ DCs are the major producers of IL-12p70 
in response to CpG and PIC stimulation (Hochrein et al., 2001). The counterpart of the mouse 
CD8+/CD103+ DCs are the human CD141+ DCs (Haniffa et al., 2012, Robbins et al., 2008). 
However, human CD141+ DCs do not express TLR 9 (Hemont et al., 2013, Jongbloed et al., 2010). 
Therefore, we would not expect to CD141+ DCs to produce IL-12p70 in response to CpG. Our 
group along with others previously reported that CD141+ DCs produce minimal levels of IL-12p70 
in response to R848 alone or PIC alone (Haniffa et al., 2012, Hemont et al., 2013, Jongbloed et al., 
2010, Nizzoli et al., 2013). Our data suggested that CD1c+ DCs displayed increased capacity in IL-
12p70 production upon R848 plus PIC stimulation compared to CD141+ DCs. The lower level of 
IL-12p70 production by CD141+ DCs was not attributed to their viability or activation status, as we 
demonstrated that CD141+ DCs excelled at IFN-λ production compared to CD1c+ DCs in response 
to R848 plus PIC combination. However, it remains a possibility that CD141+ DCs may induce IL-
12p70 in response to a yet, unknown factor which may be TLR-independent. Next, we observed the 
lack of IL-12p70 production by pDCs in response to CpG plus R848 combination; which was 
consistent with a previous report (Nizzoli et al., 2013). The lack of IL-12p70 production by pDCs 
was most likely attributed to the absence of IL-12p40 subunit (Koopman et al., 2013). We showed 
that the lower levels of IL-12p70 being produced by CD141+ DCs and pDCs were not attributed to 
their viability or activation status, given their ability to maintain co-stimulatory molecule expression 
and production of signature cytokines (i.e IFN-λ by CD141+ DCs, IFN-α by pDCs).  
Both CD1c+ and CD141
+
 DCs express TLR 8; however, the responses observed in our study were 
different. Previously, Napolitani et al. reported that TLR 8 activation requires endosomal 
acidification (Napolitani et al., 2005). Thus, it is possible that both DC subsets display different 
capacity at inducing endosomal acidification. However, recent studies have reported that freshly 
isolated blood or tonsillar CD141+ and CD1c+ DCs were equivalent at maintaining endosomal pH 
(Cohn et al., 2013, Segura et al., 2013a). One other possibility could be that TLR 8 ligation in 
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CD1c+ DCs may trigger a ‘temporal window’ for stimulation of other TLRs, which intensifies DC 
activation as well as transcription of genes. For example, TLR synergy in human MoDCs results in 
sustained c-Jun phosphorylation and AP-1 formation, both crucial at cytokine expression 
(Napolitani et al., 2005). These findings, however remain to be established in CD1c+ DCs and 
CD141+ DCs.  
Yu et al. reported that stimulation of pDCs with R837 lead to IL-23p19 mRNA up-regulation; 
however, IL-23 protein expression was not determined (Yu et al., 2010). We demonstrated that 
pDCs lacked IL-23 production in response to CpG and R848 stimulation, either alone or in 
combination. Furthermore, we showed that pDCs produce IFN-α in response to CpG which was 
previously reported (Heil et al., 2004, Kadowaki et al., 2001, Marshall et al., 2007). Interestingly, 
the combination of CpG plus R848 resulted in diminished IFN-α production which was previously 
reported (Marshall et al., 2007). R848 has been reported to interfere with the induction of IFN-α and 
IRF7 mRNA by CpG (Marshall et al., 2007). Of note, pDCs remained viable and expressed co-
stimulatory molecules after TLR stimulation. Taken together, these data suggested that the lack of 
IFN-α and IL-23 production by pDCs in response to dual TLR stimulation was not a result of cell 
toxicity induced by TLR agonists or loss-of-function from cell sorting. Previously, Schlitzer et al. 
demonstrated that lung CD141+ DCs lack of IL-23p19 mRNA expression compared to CD1c+ DCs 
(Schlitzer et al., 2013). Furthermore, Haniffa et al. previously reported that interstitial CD141+ DCs 
produced minimal amounts IL-23p19 in response to LPS alone or PIC alone (Haniffa et al., 2012). 
It is important to note that for active IL-23 protein to exert its function, it needs to form its 
heterodimeric complex with IL-12p40 (Oppmann et al., 2000). By stimulating CD141+ DCs using 
R848 plus PIC combination, we demonstrated that CD141+ DCs were capable of producing IL-23 
in response to TLR engagement albeit to a lesser extent compared to CD1c+ DCs. We demonstrated 
that CD141+ DCs characteristically secreted significant amounts of IFN-λ in response to PIC 
stimulation which ascertained their viability and function (Lauterbach et al., 2010); further 
demonstrating their functionality upon TLR activation. Previous studies have argued that CD1c+ 
DCs do not express IL-23p19 and are incapable of producing IL-23 compared to MoDCs in 
response to GM-CSF, IL-4 and CD40L (Jefford et al., 2003) or Mycobacterium tuberculosis 
(Gerosa et al., 2008). Gerosa et al. reported the lack of IL-23 production by CD1c+ DCs in response 
to R848 (Gerosa et al., 2008). In that study, however CD1c+ DCs were pre-treated with IL-4 prior to 
R848 stimulation, whereby IL-4 has been reported to inhibit IL-23 production (Guenova et al., 
2015). Here, we identified that CD1c+ DCs were highly proficient at producing both IL-23 and IL-
12p70; their production was induced in response R848, and significantly enhanced in the presence 
of LPS or PIC. These data are in contrast with murine DCs, as IL-12p70 is known to be produced 
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by mouse CD8+ DCs (Hochrein et al., 2001), while IL-23 is produced by mouse CD11b+ DCs 
(Kinnebrew et al., 2012, Satpathy et al., 2013).  
Th17 cells are reputedly known to arise from naïve CD4+ T cells under inflammatory environment 
given the presence of IL-1β and IL-6 (Manel et al., 2008, Yang et al., 2008a, Zhou et al., 2008) and 
the major mouse DC subset at driving this mechanism are the CD11b+ DCs (Kinnebrew et al., 2012, 
Persson et al., 2013, Schlitzer et al., 2013, Vander Lugt et al., 2014). The human CD1c+ DCs have 
been identified as the respective counterpart of the mouse CD11b+ DCs (Haniffa et al., 2012, 
Robbins et al., 2008); however, their role in activating Th17 cells has yet to be addressed. Acosta-
Rodriguez et al. argued that CD1c+ DCs stimulated with LPS failed to prime Th17 responses 
compared to monocytes under identical conditions and this process was highly mediated by IL-1β 
and IL-6 (Acosta-Rodriguez et al., 2007a). In agreement with these findings, our data along with 
others showed that monocytes produced significantly higher IL-1β and IL-6 compared to CD1c+ 
DCs in response to LPS stimulation. (Acosta-Rodriguez et al., 2007a, Acosta-Rodriguez et al., 
2007b, LeibundGut-Landmann et al., 2007). Moreover, CD1c+ DCs but not MoDCs stimulated with 
peptidoglycan were able to prime Th17 responses (Acosta-Rodriguez et al., 2007a, van Beelen et 
al., 2007). CD1c+ DCs reputedly produce IL-12p70 in response to LPS plus R848 stimulation, and 
that IL-12p70 is known to inhibit Th17 responses (Acosta-Rodriguez et al., 2007a, Acosta-
Rodriguez et al., 2007b). Our data along with others suggest that CD1c+ DCs may not play a role in 
priming Th17 responses in response to LPS plus R848 (Acosta-Rodriguez et al., 2007a, Acosta-
Rodriguez et al., 2007b). Interestingly, Dillon et al. reported that CD1c+ DCs derived from the gut 
lamina propria produce IL-23 but not IL-12p70 in response to LPS plus R848 stimulation (Dillon et 
al., 2010), although their ability to prime Th17 responses has yet to be demonstrated. These findings 
suggested that the ability of CD1c+ DCs at priming Th17 responses may be mediated by 
environmental stimuli or possibly, a tissue-specific effect.  
The mechanism of CD1c+ DCs to synergistically enhance their cytokine production remains 
unknown. It is known that TLR 8 is able to cooperate with TRIF-coupled TLRs including TLR 3 
and 4 at enhancing cytokine production. While the mechanisms have yet to be fully described, 
stimulation of CD1c+ DCs with TLR agonists may result in up-regulation of TLRs 3, 4 and 8 
expressions on a protein level. This, in turn, would intensify TLR signalling (i.e NF-κB, MyD88, 
IRF7) leading to cytokine enhancement. In support of this notion, data from our group demonstrated 
that injection of R848 plus PIC combination into humanised mice model resulted in specific up-
regulation of TLR 3, 4 and 8 mRNA in CD1c+ DCs, but not in other DC subsets or unstimulated 
controls in vivo (Yoshihito Minoda, personal communication). While its protein expression 
remains to be determined, these data suggested that the up-regulation of TLRs 3, 4 and 8 on CD1c+ 
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DCs would intensity cytokine signalling and production. Recently, Kreutz et al. reported that using 
PIC plus R837 (a strictly TLR 7 agonist) synergistically enhanced IL-6 production by CD1c+ DCs 
which was hypothesised to be mediated by IFN-α (Kreutz et al., 2015). However, our study 
consistently showed that LPS plus R848 combination does not induce CD1c+ DCs to produce IFN-
α. These data indicated that other factors might mediate the synergistic response by CD1c+ DCs.  
Unlike the human TLR 8, TLR 8 in the mouse system is not functional and does not recognise 
ssRNA ligands, RNA viruses or any agonists which engages human TLR 8 (Heil et al., 2004, 
Hemmi et al., 2002). Following that, the role of human TLR 8 in autoimmune diseases largely 
derived from on work performed on mouse TLR 7 (Deane et al., 2007, Walsh et al., 2012). 
Therefore, current mouse models of autoimmunity may not fully represent the role of human TLR 
8. There is circumstantial evidence pointing a role of TLR 8 in human autoimmunity including RA, 
IBD and Still’s Disease (Guiducci et al., 2013, Prinz et al., 2011, Sacre et al., 2008). Notably, the 
role of TLR 8 in mediating autoimmunity via recognition of self-RNA autoantibody complexes was 
previously noted (Ganguly et al., 2009, Vollmer et al., 2005). Given the potency of IL-12p70 and 
IL-23 in activating Th1 and Th17 responses respectively, its expression must be kept under strict 
control to prevent generation of harmful effector cells. Therefore, from a biological standpoint, 
synergistic TLR stimulation in DCs may represent a ‘two-step’ security system that ensures a potent 
immune response only in the presence of invading pathogens. In the context of autoimmunity, the 
recognition of self-nucleic acids released from damaged tissues or necrotic cells would consistently 
trigger CD1c+ DCs to produce substantial amounts of IL-12p70 and IL-23, leading to activation of 
pathogenic Th responses.  
While a direct role of TLRs in AS pathology remains to be established, TLR signalling results in 
activation of NF-κB pathway, leading to the production of inflammatory cytokines is undisputed. 
We purified CD1c+ DCs from peripheral blood of AS patients and evaluated their cytokine 
production as well as their activation status upon TLR stimulation. Due to lack of cell numbers, the 
conditions performed with CD1c+ DCs were limited to untreated controls and LPS plus R848 
combination. AS-derived monocytes produced higher levels of TNF-α (detection limit = 9.77pg/ml) 
and CXCL10 (detection limit = 156.25pg/ml) upon stimulation compared to monocytes from HCs. 
Increased levels of TNF-α and CXCL10 by monocytes may indirectly indicate the role of activation 
and recruitment of Th1 lymphocytes (Wang et al., 2016). Increased IL-18 gene signature has been 
previously reported in AS patients (Palomo et al., 2015). This finding was interesting given that IL-
18 is known to induce Th1 responses as well as mucosal-associated invariant T (MAIT) cell 
activation [229,242]. Of note, CXCL10 was previously reported as a chemoattractant for Th1 cells 
and have been reported to be elevated in AS patients [230]. CXCL10 has been reported to be 
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elevated in AS patients (Wang et al., 2016, Zeng et al., 2011). Here, we showed that at least in 
response to TLR stimulation, AS-derived monocytes but not CD1c+ DCs produced CXCL10. Here, 
we observed up-regulated co-stimulatory molecule expression of AS-derived CD1c+ DCs and 
monocytes in response to TLR stimulation compared to HCs. As co-stimulatory molecules are 
involved in T cell proliferation, activated CD1c+ DCs and monocytes may promote increased T cell 
proliferation and activation in AS patients.  
Of note, IL-12p70 levels were elevated in AS-derived CD1c+ DCs compared to CD1c+ DCs from 
HCs; however, significance was not reached at a p < 0.05 level (p = 0.0766). Due to time 
constraints in recruiting age-, sex- and ethnicity-matched controls, our study was conducted with 
informed consent from HCs aged between 40-60 years old with both males and females with mixed 
ethnicities. In contrast, our AS patients were Caucasian males aged between 19 – 33 years old. 
Matching (age, sex, ethnicity) controls should be taken into consideration to remove any 
confounding effects; therefore, providing a more accurate comparison in DC functions between 
patient groups. To this end, we performed a power analysis and calculated that we require 22 more 
individuals from each group in order to achieve statistical significance. This finding may hint at a 
potential role for CD1c+ DCs at activating Th1 responses in AS patients. 
The role of IL-23 in AS pathology is yet to be understood. Our study investigated only the effects of 
TLR stimulation on IL-23 production by CD1c+ DCs and monocytes. Here, we report that IL-23 
levels from AS patients were not significantly different compared to HCs. A similar observation 
was noted by Prevosto et al., whereby in vitro-derived human MoDCs produced similar levels of 
IL-23 in response to PIC plus CL075 (TLR 7 and 8 agonists) compared to MoDCs derived from 
HCs stimulated under identical conditions (Prevosto et al., 2012). Furthermore, very low levels of 
IL-23 have been reported in other forms of spondyloarthropathies (Brentano et al., 2009, Hillyer et 
al., 2009). However, it is certainly possible that the main influence of IL-23 may be acting locally 
within the synovial tissue rather than systemically. It is important to note that AS patients recruited 
in our study are currently treated with NSAIDs which could potentially modulate cytokine 
production by myeloid lineages. Page et al. recently reported that monocytes derived from RA 
patients exhibited increased TNF-α production in response to NSAIDs in vitro (Page et al., 2010). 
The effects of NSAIDs on augmenting cytokine production by myeloid lineages from AS patients 
remains to be established.   
Other cell types including MoDCs could produce IL-23 in response to CD40L, PamCSK and LPS 
plus R848 (Prevosto et al., 2012, Segura et al., 2013b). Therefore, we can’t conclude that CD1c+ 
DCs were the dominant source of IL-23 in AS patients in vivo. Previous studies in RA patients have 
revealed that CD1c+ DCs derived from the synovial fluid are considerably more activated compared 
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to their peripheral blood counterparts (Jongbloed et al., 2006, Moret et al., 2013). Similarly, CD1c+ 
DCs have been reported to be enriched in the synovial fluid of AS patients (Wright et al., 2016). 
CD1c+ DCs derived from synovial fluid potently induced Th17 and Th1 responses compared to 
their blood counterparts in RA patients (Moret et al., 2015). Thus, future studies should aim to 
isolate CD1c+ DCs from synovial fluid of AS patients and determine its functional characteristics, 
which is feasible. However, the marker CD1c does not exclusively identify the CD1c+ DCs, as it is 
also expressed on MoDCs (Segura et al., 2013b). Notably, MoDCs express higher levels of early 
growth responses protein (EGR) 1, EGR2 and CSF1R (all involved in macrophage development) 
compared to CD1c+ DCs (Segura et al., 2013b). Future experiments should incorporate these 
markers, to fully distinguish CD1c+ DCs from MoDCs.  
3.5) Conclusion 
We demonstrated that in response TLR agonists with following combinations: LPS plus R848, 
R848 plus PIC and LPS plus R848 plus PIC, CD1c+ DCs excelled in the secretion of IL-1β, IL-6, 
IL-12p70 and IL-23. CD1c+ DC is the only DC subset that produced both IL-12p70 and IL-23, 
compared to other cell types. Importantly, we demonstrated that the levels of IL-12p70 and IL-23 
production by CD1c+ DCs were enhanced in the presence of LPS or PIC. We observed that AS-
derived CD1c+ DCs expressed significantly higher levels of CD80 and CD86 compared to the ones 
from HC upon TLR stimulation. We observed an insignificant difference in IL-12p70 production 
from CD1c+ DCs from both patient groups. Furthermore, AS-derived monocytes expressed 
significantly higher CD83 compared to HC upon TLR stimulation. Elevated levels of IL-12p70 
from AS-derived CD1c+ DCs, TNF-α and CXCL10 from AS-derived monocytes may indicate the 
potential activation of Th1 cells in AS patients. In addition to IL-12p70, memory Th17.1 cells are 
known to respond towards IL-IL-23 and IL-1β (Annunziato et al., 2007, Basdeo et al., 2015, Duhen 
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Chapter 4 - The role of TLR-activated human CD1c+ DCs on CD4+ T cell activation 
4.1) Introduction 
In addition to Ag-specific CD4+ T cell responses, CD11c+ cDCs play role in mediating homeostatic 
memory CD4+ T cell pool independent of MHC:TCR interactions (Geginat et al., 2001, McKinlay 
et al., 2007). This process is mediated by DC-derived cytokines. In the previous chapter, we 
demonstrated that CD1c+ DCs produced IL-12p70 and IL-23 in response to combination stimulation 
including LPS plus R848, R848 plus PIC and LPS plus R848 plus PIC. While the role of CD1c+ 
DCs at reactivating memory CD4+ T cell responses has yet to be fully established, the cytokine 
profile of TLR-activated CD1c+DCs would suggest their role at reactivating human memory Th17.1 
cells (Annunziato et al., 2007, Duhen et al., 2013, Nistala et al., 2010, Ramesh et al., 2014). While 
the combination of TGF-β and IL-6 is known to prime murine Th17 responses (Bettelli et al., 2006, 
Mangan et al., 2006, Veldhoen et al., 2006), this combination does not induce human Th17 
differentiation (Manel et al., 2008, Yang et al., 2008a, Zhou et al., 2008). Furthermore, it has been 
reported that IL-1β synergises with IL-12p70 or IL-23 alone promotes reactivation of memory 
Th17.1 cells leading to the production of IFN-γ and IL-17A (Duhen et al., 2013, Ramesh et al., 
2014).  
It is now widely appreciated that human effector memory T cells are not terminally differentiated 
and display functional plasticity, especially Th17 cells. Human memory Th17 cells have been 
reported to transition towards Th1 phenotype, providing them with the capability to produce IFN-γ 
(Annunziato et al., 2007, Boniface et al., 2010, Cosmi et al., 2011, Duhen et al., 2013). These cells 
are known as Th17/Th1 or Th17.1 cells. Importantly, the transition from Th17 to Th17.1 is 
mediated by several soluble factors including IL-12p70 (Annunziato et al., 2007, Basdeo et al., 
2015), IL-1β (Duhen et al., 2013) and IL-23 (Duhen et al., 2013, Ramesh et al., 2014). Moreover, 
human memory Th17 cells have been reported to express high levels of IL-23R mRNA (Duhen et 
al., 2013, Maggi et al., 2012, Ramesh et al., 2014) and display polyfunctional cytokine producing 
capacity including IFN-γ, IL-17A, IL-17F, IL-21, IL-22 and GM-CSF (Annunziato et al., 2007, 
Basdeo et al., 2015, Duhen et al., 2013, Ramesh et al., 2014). Human memory Th17.1 cells have 
been reported in multiple human disease pathologies including rheumatoid arthritis (RA), Crohn’s 
Disease (CD) and inflammatory bowel disease (IBD) (Basdeo et al., 2015, Cosmi et al., 2011, 
Cosmi et al., 2008, Duhen et al., 2013, Maggi et al., 2014, Nistala et al., 2010, Ramesh et al., 2014). 
Pathogenic human Th17.1 cells also selectively express P-glycoprotein, (MDR1) (Ramesh et al., 
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2014). The activity of MDR1 can be evaluated in vitro using its substrate, rhodamine 123 (Rh123) 
(Ludescher et al., 1992). Ludescher et al. previously reported that leukemic cells expressing MDR1 
are able to expel Rh123, and this process was inhibited in the presence of MDR inhibitors 
(Ludescher et al., 1992). Given their specific MDR1 expression, pathogenic Th17.1 cells, but not 
other Th subsets are able to expel Rh123 as well as rendering them resistant to corticosteroid 
treatment (Ramesh et al., 2014).  
IL-23 signals through STAT3 leading to the production of several cytokines including IL-17A, IL-
17F, IL-21 and IL-22 (Isailovic et al., 2015). In addition to memory CD4+ T cells, several human 
immune populations including γδ T cells and NK cells are reported to express IL23R mRNA 
(Moens et al., 2011, Parham et al., 2002). In the previous chapter, we demonstrated that peripheral 
blood CD1c+ DCs were the major producers of IL-12p70 and IL-23 in response to TLR stimulation. 
We demonstrated that CD1c+ DCs also produced IL-6 and IL-10 which are known to trigger STAT3 
phosphorylation (Kane et al., 2014, Hemont et al., 2013, Jongbloed et al., 2010, Kassianos et al., 
2012). Here, we predict that supernatants derived from LPS plus R848-stimulated CD1c+ DCs 
which contain IL-6, IL-10 and in particular, IL-23 might affect IL-23R-expressing cells. This can be 
measured by evaluating STAT3 phosphorylation. By evaluating STAT3 phosphorylation using flow 
cytometry, this will provide us with a practical way to examine whether CD1c+ DCs are capable of 
activating these cell types.   
In this chapter, we firstly determined the ability of CD1c+ DCs to promote autologous, memory 
CD4+ T cell proliferation in the presence of IL-7 plus IL-15 in comparison with donor-matched 
monocytes. To determine the ability of CD1c+ DCs and their soluble factors to reactivate memory 
Th17.1 cells, CD1c+ DCs were stimulated with TLR agonists (as detailed in Chapter 2) and co-
cultured with autologous memory CD4+ T cells in comparison with monocytes. Given the dual 
production of IL-12p70 and IL-23 by CD1c+ DCs in response to LPS plus R848 stimulation, we 
hypothesised that this DC subset can reactivate memory Th17.1 cells leading to the production of 
IL17A, IL-17F, IFN-γ, IL-21, IL-22 and GM-CSF. We next determined the contribution of CD1c+ 
DC- and monocyte-derived soluble factors on γδ T cells and NK cells by evaluating STAT3 
phosphorylation.   
4.2) Aim 
Determine the cell types which can be influenced by the dual production of IL-12p70 and IL-23 by 
TLR-activated CD1c+ DCs 
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4.2.1) Sub-aims 
1) Determine the expression of IL-23R on immune cell populations including γδ T cells, NK cells, 
B cells, memory CD4+ T cells and DCs. 
2) Compare the ability of CD1c+ DCs and monocytes to drive memory CD4+ T cell proliferation 
3) Determine how TLR-activated CD1c+ DCs and monocytes augment production of IFN-γ, IL-6, 
IL-17A, IL-17F, IL-21, IL-22 and GM-CSF by memory CD4+ T cells  
4) Determine downstream activation of IL-23R-expressing cells in response to CD1c+ DC- and 
monocyte-derived soluble factors, using STAT3 phosphorylation as readout.  
4.3) Results 
4.3.1) Detection of IL-23R on immune cells subsets within human PBMCs 
IL-23R mRNA has been reported to be expressed in γδ T cells, NKT cells, memory CD4+ T cells, 
CD8+ T cells as well as mucosal-associated invariant T (MAIT) cells (Awasthi et al., 2009, 
Billerbeck et al., 2010, Kenna et al., 2012, Oppmann et al., 2000, Shen et al., 2013, Wilson et al., 
2007). To determine the IL-23R expression on a protein level using flow cytometry, we employed a 
fluorescent-labelled IL-23R antibody which was previously reported (Kenna et al., 2012). By 
employing a matching isotype control, IL-23R expression on each cell type was calculated as 
percentage of IL23R+ minus the percentage of IL-23R+ in our isotype staining. Using the same 
antibody at its optimal concentration and in comparison with its matching isotype control, we 
observed a proportion of CD3+ T cells expressed IL-23R. Next, we showed that IL-23R was present 
on memory CD4+ T cells (Figure 4.1). However, the staining percentage was relatively lower 
compared to the ones previously reported (Wilson et al., 2007). We next determined the expression 
of IL-23R on Th17 (CD3+ CD4+ CD45RO
+ CCR6+ CXCR3- CCR4+) and Th17.1 (CD3+ CD4+ 
CD45RO+ CCR6+ CXCR3+ CCR4-) cells as both subsets were reported to express IL-23R mRNA 
(Maggi et al., 2012, Ramesh et al., 2014). We observed a low percentage of Th17 (~0.19%) and 
Th17.1 (~0.15%) cells expressing IL-23R (Figure 4.2). This result was unexpected given that IL-23 
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Figure 4.1: Characterisation of IL-23R on human memory CD4+ T cells. 5 x 105 freshly isolated 
PBMCs were stained with CD3, CD4 and CD45RO to identify memory CD4+ T cells. Memory 
CD4+ T cells were identified as CD3+ CD4+ CD45RO+. Blue arrows represent progressive gating 
strategy. Expression of IL-23R on memory CD4+ T cells was determined by staining with IL-23R-
PE in comparison with its matching isotype control. Data were analysed using flow cytometry with 
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Figure 4.2: Characterisation of IL-23R on numerous Th subsets. 2 x 106 freshly isolated PBMCs 
were stained with CD3, CD4 and CD45RO to identify memory CD4+ T cells. Th subsets were 
segregated by staining with the following: Th1 cells (CXCR3+), Th2 cells (CXCR3- CCR6- 
CCR4+), Th17 cells (CCR6+) and Th17.1 cells (CXCR3+ CCR6+). Blue arrows represent 
progressive gating strategy. Expression of IL-23R on each Th subset was determined by staining 
with IL-23R-PE in comparison with its matching isotype control. Data were analysed using flow 
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Next, we characterised the expression of IL-23R on various innate immune cells. We observed 
strong IL-23R staining on a percentage of human γδ T cells (CD3+ CD56- γδ TCR+) (Figure 4.3). 
We also showed a strong IL-23R staining on a percentage of NK cells (CD3- CD56+ CD161+) 
(Figure 4.4). However, it is worth noting that only a small percentage of γδ T cells (~2%) and NK 
cells (~0.34%) of their total parent population expressed IL-23R (Figure 4.6). In addition to the 
high percentage of IL-23R staining, γδ T cells and NK cells displayed the highest median 
fluorescence intensity (MFI) compared to other cell types. IL-23R was absent on both naïve (CD19+ 
CD27- and memory B (CD19+ CD27+) cells (Figure 4.5). Both CD11c+ cDCs (Lin- HLA-DR+ 
CD11c+ CD123-) and pDCs (Lin- HLA-DR+ CD123+ CD11c-) lacked IL-23R expression (Figure 
4.5). Within the CD11c+ DC population, we consistently observed negative IL-23R staining. 
Therefore, there was not a strong rationale to analyse IL-23R expression on CD141+ DCs. 
However, we were unable to obtain sufficient numbers of natural killer T (NKT – CD3+ CD56- 
Vα24-Jα18 TCR+) cells to characterise IL-23R expression. This was due to its low frequency in 
peripheral blood which is approximately 0.001 – 0.2% of total CD3+ T cells (Sakamoto et al., 
1999). NKT cells can also be identified using CD1d tetramers loaded with lipid antigen α-
galactosylceramide (α-Galcer) (Benlagha et al., 2000, Sharma et al., 2011). As an alternative, we 
firstly enriched CD3+ T cells from peripheral blood via depletion of other lineage cells. However, 
we did not observe any distinct IL-23R staining (Figure 4.5). Next, we tried expanding NKT cells 
from PBMC using their prototypical antigen, α-Galcer and cultured them either in the presence of 
IL-7 plus IL-15. We only managed to obtain minimal NKT cell expansion and IL-23R expression 
data was inconclusive (Figure 4.5). Taken together, our flow analysis managed to identify and 
confirm IL-23R expression on γδ T cells, memory CD4+ T cells as well as NK cells (Figure 4.6).  
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Figure 4.3: IL-23R expression on human γδ T cells. Using 1 x 106 freshly isolated PBMCs, γδ T 
cells were identified by staining for CD3 and γδ TCR. Blue arrows represent progressive gating 
strategy. Percentage of γδ T cells expressing IL-23R was determined by staining with IL-23R, 
compared to its matching isotype. Data were analysed using flow cytometry with CyAN ADP 
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Figure 4.4: IL-23R expression on human NK cells. Using 1 x 106 freshly isolated PBMCs, NK 
cells were identified by staining for CD3, CD56 and CD161. Blue arrows represent progressive 
gating strategy. Percentage of NK cells expressing IL-23R was determined by staining with IL-23R, 
compared to its matching isotype. Data were analysed using flow cytometry with CyAN ADP 
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Figure 4.5: IL-23R expression on human B cells, naive CD4+ T cells, CD8+ T cells, DCs, NKT 
cells. Using freshly isolated PBMCs, B cells, naive CD4+ cells, CD8+ T cells, NKT cells and DCs 
were identified. Blue arrows represent progressive gating strategy. a) Gating strategy identifying 
different cell subsets. b) The percentage of IL-23R+ expressing cells compared to its matching 
isotype control. Data were analysed with flow cytometry using CyAN ADP Cytometer. 







































































Figure 4.6: Percentage of IL-23R positive cells in each cell population. Freshly isolated PBMCs 
were stained with a combination of flow antibodies specific for each cell type (detailed above) in 
the presence of α-IL-23R PE antibody. Flow cytometric data were compiled and analysed using 
GraphPad Prism 5. Data presented as a percentage of IL-23R+ cells in each cell type that were 
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Given the high IL-23R expression on γδ T cells and NK cells, we asked if IL-23R could be up-
regulated in response to human recombinant IL-23 stimulation. After three days of culture, we 
observed IL-23R up-regulation on γδ T cells in response to IL-23 stimulation compared to untreated 
controls in two out of three human donors; however, no significance was achieved (Figure 4.7). In 
NK cells, we observed down-regulation of IL-23R in response to IL-23 stimulation in all three 
human donors (Figure 4.7). Due to the inconsistency of the data and lack of sufficient replicates, 
we were unable to conclude that γδ T cells and NK cells were able to up-regulate IL-23R expression 
upon stimulation with human recombinant IL-23. Taken together, we observed the highest IL-23R 
percentage in unstimulated γδ T cells, NK cells and memory CD4+ T cells (Figure 4.6). 
Furthermore, we noted that γδ T cells and NK cells displayed higher IL-23R MFI compared to other 
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Figure 4.7: IL-23R expression on γδ T and NK cells in response to recombinant IL-23. PBMCs 
were cultured at a concentration of 1 x 106 cells/ml either in media alone or in the presence of 
20ng/ml human recombinant IL-23 for 3 days. On day 3, cells were harvested, washed and the IL-
23R expression on γδ T cells (red squares) and NK cells (blue squares) cells were determined. 
Data analysed with flow cytometry using CyAN ADP Cytometer. Cumulative data from three 
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4.3.2) Optimisation of CFSE-labelling of memory CD4+ T cells and flow cytometry panel 
A key feature of the adaptive immune response is the rapid proliferation of T cells into effector 
cells. Therefore, in order to monitor the proliferation of T cells both in vivo and in vitro, several 
tools have been developed. One such tool is the intracellular fluorescent dye, carboxyfluorescein 
diacetate succinimidyl ester (CFSE) [242]. CFSE dye allows stable labelling of lymphocytes, with 
each cell division results in a sequential halving of fluorescence. Using appropriate human 
antibodies labelled with different fluorochromes, we assessed the proliferation of CD4+ T cells as 
well as their production of cytokine via intracellular staining. Firstly, we optimised the CFSE-
labelling concentration to successfully label a fixed number of PBMCs (i.e 2 x 106 cells). Initial 
experiments were conducted by labelling frozen human PBMCs with three CFSE doses, 5, 1 and 
0.2µM. Post 20-hour culture, PBMCs were harvested and stained with anti-human CD3 which 
allowed visualisation of successful CFSE incorporation by total T cells. As shown in Figure 4.8, 
we observed a reduction in the percentage of forward scatter (FSC) versus side scatter (SSC) which 
indicated a reduction of cell viability as a result of CFSE labelling. However, CFSE was 
successfully incorporated by T cells and was consistent for all three doses (≥ 99%). PBMCs labelled 
with 0.5µM CFSE displayed lower fluorescence compared to other CFSE doses. As CFSE is prone 
to bleaching, it is possible that the 0.5µM mixture may have been subjected to prolonged light 
exposure.  Having optimised compensation settings on the instrument using single colour stains, we 
further validated the viability of CFSE-labelled T cells. We labelled purified memory CD4+ T cells 
with 0.2µM CFSE and stained them using live/dead aqua dye (Invitro Technologies), as well as co-
cultured them in the presence of 0.05µg plate-bound αCD3 plus 1µg/ml soluble αCD28 for 7 days. 













Figure 4.8: Optimisation of CFSE labelling and viability of T cells post-CFSE labelling was 
evaluated by live/dead aqua dye. (a) Frozen PBMCs were labelled with CFSE (1, 0.5, 0.2µM) and 
cultured overnight for 20 hours at 37oC. Post-incubation, PBMCs were harvested, washed and 
stained with anti-human CD3. CFSE incorporation by total T cells was evaluated by gating total 
CD3+ cells. Blue arrows represent progressive gating strategy. Representative plot from two 
experiments. (b) Purified memory CD4+ T cells were labelled with 0.2µM CFSE were cultured 
overnight for 20 hours at 37oC. Post-incubation, cells were harvested, washed and stained with 
live/dead aqua dye. Representative plot from two independent experiments. (c) Proliferation of 
Memory CD4+ T cells in response to plate-bound αCD3 (0.05µg) plus 1µg/ml αCD28 compared to 
unstimulated controls. Data were analysed with flow cytometry using LSR FortessaX20. 
Representative plot from three independent experiments. 
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4.3.3) CD1c+ DCs and monocytes were equivalent at driving proliferation and reactivation of 
memory CD4+ T cells to produce IL-17A and IFN-γ 
Having optimised the CFSE labelling of CD4+ T cells as well as the flow cytometry panel, we next 
aimed to determine the ability of CD1c+ DCs to promote memory CD4+ T cell proliferation. 
Homeostatic cytokines including IL-7 and IL-15 maintain memory CD4+ T cell numbers by driving 
their proliferation, which can be potently boosted in the presence of DCs (Geginat et al., 2001, 
McKinlay et al., 2007). In the presence of recombinant IL-7 and IL-15, CD11c+ cDCs displayed 
superior capacity at driving the proliferation of autologous memory CD4+ T cells compared to 
monocytes and MoDCs (McKinlay et al., 2007). By employing this assay, we assessed the ability of 
CD1c+ DCs activated with various TLR agonists on augmenting the proliferation of memory CD4+ 
T cells as well as their cytokine profile. IFN-γ+ IL-17A+ double producers comprise between 1 to 
4% of memory Th17.1 cells (Ramesh et al., 2014). Preliminary experiments were conducted to 
determine the optimal time course for memory T cell proliferation, thus allowing us to characterise 
this population. We noted that higher T cell proliferation on day 7 compared to day 5. Therefore, 
subsequent experiments were conducted on day 7. Human memory CD4+ T cells can be effectively 
identified on day 7 by staining with anti-human CD4. The proliferation of memory CD4+ T cells on 
day 7 was visualised by staining the cells with anti-human CD4 and CFSE dilution was evaluated. 
Highly proliferative memory CD4+ T cells were identified as CD4+ CFSElow cells (Figure 4.9a).  
Firstly, we observed no difference in CD4+ T cell proliferation between unstimulated CD1c+ DCs 
and monocytes (Figure 4.9b). We observed no significant difference between CD1c+ DCs activated 
with LPS or R848, either alone or in combination in the percentage of CD4+ CFSElow cells 
compared to unstimulated controls (Figure 4.9b). Notably, memory CD4+ T cell co-cultured with 
LPS-stimulated CD1c+ DCs had increased percentage CD4+ CFSElow compared to monocytes under 
identical conditions, although significance was not achieved. Similarly, we did not observe any 
significant difference in T cell proliferation induced by monocytes activated with different TLR 
agonists or when compared to its untreated controls (Figure 4.9b). These data suggested that TLR-
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Figure 4.9: CD1c+ DCs and monocytes were equivalent at inducing proliferation of memory 
CD4+ T cells. CD1c+ DCs and monocytes were activated with 100ng/ml LPS and 2µg/ml R848, 
either alone or in combination. Cells were washed and co-cultured with purified memory CD4+ T 
cells at 1:10 (APC:T ratio) in the presence of 25ng/ml IL-7 and IL-15 for 7 days. On day 7, cells 
were harvested and stained with anti-human CD4. Blue arrows represent progressive gating 
strategy. a) Representative plot showing proliferation of memory CD4+ T cells by gating CD4+ 
CFSElow. b) Percentage of CD4+ CFSElow cells gated from total CD4+ T cells induced by TLR-
activated CD1c+ DCs (red circles) in comparison with monocytes (blue squares). Data were 
analysed with repeated measures, two-way ANOVA and presented as mean ± SEM from a total of 
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By gating on CD4+ CFSElow T cells, we aimed to evaluate the ability of TLR-stimulated CD1c+ 
DCs or monocytes at augmenting the proportion of IFN-γ and IL-17A producing CD4+ T cells 
(Figure 4.10a). In all conditions tested, we observed IFN-γ+ (Th1 cells), IL-17A+ (Th17 cells), IFN-
γ+ IL-17A+ (Th17.1 cells) and IL-17A- IFN-γ- memory CD4+ T cells upon restimulation with PMA 
and ionomycin. These data therefore, indicated that pre-existing memory CD4+ T cells in our 
culture readily reactivated to produce IFN-γ and IL-17A.  
Memory Th17.1 cells are known to respond towards IL-1β, IL-12p70 and IL-23 which reactivate 
IFN-γ and IL-17A production (Annunziato et al., 2007, Cosmi et al., 2011, Duhen et al., 2013, 
Ramesh et al., 2014). We hypothesised that CD1c+ DCs would play an important role at reactivating 
memory Th17.1 cells, given the ability of this DC subset to produce IL-1β, IL-12p70 and IL-23 
when stimulated with LPS plus R848 combination. Firstly, we observed that LPS-stimulated CD1c+ 
DCs did not augment the proportion of IL-17A-, IFN-γ- or IFN-γ+ IL-17A+-producing CD4+ T cells 
compared to unstimulated controls (Figure 4.10b). While we observed that the proportion of IL-
17A+-producing CD4+ T cells decreased in response to R848- and LPS plus R848-activated CD1c+ 
DCs; however, the proportion IFN-γ+ IL-17A+-producing CD4+ T cells was not significantly 
different compared to unstimulated controls (Figure 4.10b). Furthermore, the proportions of IFN-
γ+-producing CD4+ T cells were not significantly different between CD1c+ DCs stimulated with 
R848 alone or in combination with LPS or monocytes under identical conditions (Figure 4.10b). 
CD1c+ DCs stimulated with R848 alone or in combination with LPS did not significantly alter the 
proportion of IFN-γ+ IL-17A+ producing CD4+ T cells compared to unstimulated controls. CD1c+ 
DCs activated with LPS did not increase the proportion of IFN-γ+ IL-17A+-producing CD4+ T cells 
compared to unstimulated controls.  
Next, monocytes activated with LPS alone or R848 alone lead to an increase in IL-17A+-producing 
CD4+ T cells compared to untreated controls (Figure 4.10b). Monocytes activated with LPS alone 
or R848 alone reactivated similar proportions of IFN-γ+ IL-17A+ producing CD4+ T cells when 
compared to LPS plus R848-activated CD1c+ DCs. Taken together, the reactivation of IFN-γ+ IL-
17A+-producing CD4+ T cells by CD1c+ DCs occurred upon stimulation with R848 alone or in 
combination with LPS, while the reactivation of this memory population by monocytes occurred in 
response to LPS or R848 alone.   
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Figure 4.10: CD1c+ DCs and monocytes were equivalent at reactivating memory CD4+ T cells to 
produce IFN-γ and IL-17A. CD1c+ DCs and monocytes were activated with 100ng/ml LPS and 
2µg/ml R848, either alone or in combination. Cells were washed and co-cultured with purified 
memory CD4+ T cells at 1:10 (APC:T ratio) in the presence of 25ng/ml IL-7 and IL-15 for 7 days. 
On day 7, intracellular staining for IFN-γ and IL-17A was performed. Blue arrows represent 
progressive gating strategy. a) Representative plot from four independent experiments illustrating 
the proportions of IFN-γ+ and IL-17A+ producing T cells. Gates were set based on the isotype 
control. Numbers in each quadrant represent the percentage of CD4+ CFSElow cells. b) Proportions 
of double negative, IFN-γ+, IL-17A+ and IFN-γ+ IL-17A+ production by CD4+ CFSElow T cells 
primed by monocytes (top) or CD1c+ DCs (bottom). Cumulative data from four independent 
experiments 
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4.3.4) TLR-activated CD1c+ DCs and monocytes did not alter MDR1 activity of memory CD4+ 
T cells 
While IFN-γ+ IL-17A+ Th17.1 cells exist in healthy individuals (Duhen et al., 2013, Ramesh et al., 
2014), only a small proportion of this Th subset is pathogenic. Truly pathogenic Th17.1 cells have 
been reported to selectively express MDR1 mRNA (CD243) (Ramesh et al., 2014). In a preliminary 
experiment, we aimed to determine MDR1 protein on purified Th17.1 cells (CD3+ CD4+ CD45RO+ 
CCR6+ CXCR3+ CCR4low) via flow cytometry using an α-CD243 antibody (clone – UIC2, 
Biolegend). However, we did not observe MDR1 staining on Th17.1 cells. As Th17.1 cells are 
known to respond towards IL-1β, IL-12p70 and IL-23 (Annunziato et al., 2007, Duhen et al., 2013, 
Ramesh et al., 2014), we hypothesised that CD1c+ DCs would specifically activate pathogenic 
Th17.1 cells. To evaluate MDR1 activity, we co-cultured CD1c+ DCs or monocytes with 
autologous memory CD4+ T cells as described above for 7 days. On day 7, memory T cells were 
labelled with rhodamine 123 (Rh123), a fluorescent MDR1 substrate (Ludescher et al., 1992) and 
evaluated Rh123 efflux via flow cytometry. As shown in Figure 4.11, we did not observe any 
significant difference in Rh123 efflux by memory CD4+ T cells co-cultured with TLR-activated 
CD1c+ DCs or monocytes. Our data suggested that the presence of inflammatory cytokines as well 
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Figure 4.11: Percentage of Rh123low memory CD4+ T cells. CD1c+ DCs and monocytes were 
activated with LPS or R848, either alone or in combination. Cells were washed and co-cultured 
with purified memory CD4+ T cells at 1:10 (APC:T ratio) in the presence of 25ng/ml IL-7 and IL-
15 for 7 days. On day 7, T cells were washed and loaded with 1µg/ml Rh123 for 30 minutes on ice 
and allowed to efflux for 60 minutes at 37oC. T cells were then stained with CD4, washed and 
analysed using flow cytometry with LSR FortessaX20. Blue arrows represent progressive gating 
strategy. a) Representative gating strategy on day 7 illustrating the percentage of CD4+ Rh123low 
cells. b) Collated data from three independent experiments illustrating the percentage of CD4+ 
Rh123low cells induced by TLR-activated CD1c+ DCs or monocytes at day 7. Each donor is 
represented by a different symbol. Data were analysed with repeated measures, two-way ANOVA, 
with Bonferroni post-test and presented as mean ± s.d.  
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4.3.5) CD1c+ DCs induced higher levels of pathogenic cytokines from memory CD4+ T cells 
As previously demonstrated, both CD1c+ DCs and monocytes were equivalent at reactivating IFN-
γ+ IL-17A+-producing memory CD4+ T cells. Human pathogenic Th17.1 and mouse pathogenic 
Th17 cells have been reported to display polyfunctional cytokine production capabilities including 
IL-21, IL-22, IL-17A, IL-17F, GM-CSF and IFN-γ (Annunziato et al., 2007, Basdeo et al., 2015, 
Cosmi et al., 2008, Duhen et al., 2013, Nistala et al., 2010, Ramesh et al., 2014). Induction of the 
aforementioned cytokines by human pathogenic Th17.1 cells have yet to be fully elucidated; 
however, IL-1β, IL-12p70 as well as IL-23 are known to play a role in their induction (Annunziato 
et al., 2007, Duhen et al., 2013, Ramesh et al., 2014). We consistently demonstrated that CD1c+ 
DCs upon TLR 8 stimulation, along with LPS produce substantial amounts of these cytokines. 
Given the cytokine profile of CD1c+ DCs upon TLR stimulation, we predicted that this DC subset 
would reactivate IFN-γ+ IL-17A+ memory CD4+ T cells to produce higher levels of IL-21, IL-22, 
IL-17A, IL-17F, GM-CSF and IFN-γ compared to monocytes.  
We employed a multiplex cytokine bead assay which enabled the simultaneous detection of the 
following cytokines: IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-
γ and TNF-α, while the detection of GM-CSF was performed using ELISA from the supernatants 
harvested from the 7-day culture. As shown in Figure 4.12, monocytes stimulated with LPS or 
R848, either alone or in combination lead to a significant increase in IL-6 production by memory 
CD4+ T cells compared to unstimulated controls (LPS – p < 0.01, R848 – p < 0.05, LPS plus R848 
– p < 0.05). CD1c+ DCs stimulated either with LPS alone or in combination with R848 led to 
significant increase in IL-6 production compared to unstimulated controls (LPS – p < 0.05, LPS 
plus R848 – p < 0.01). We observed elevated IL-6 levels in memory CD4+ T cell cultures in the 
presence of TLR-stimulated CD1c+ DCs or monocytes compared to unstimulated controls, although 
significance was not achieved.  
Next, we observed monocytes stimulated with either LPS or R848, either alone or in combination 
did not significantly enhanced IL-17A production by memory CD4+ T cells compared to 
unstimulated controls (Figure 4.12). Compared to unstimulated controls, LPS plus R848-stimulated 
CD1c+ DCs reactivated memory CD4+ T cells to produce significantly higher IL-17A (p < 0.05). 
While the production of IL-17A by memory CD4+ T cells was enhanced in the presence of LPS 
plus R848-stimulated CD1c+ DCs compared to monocytes, no significance was observed (Figure 
4.12, repeated measures, two-way ANOVA, p = 0.1029).  
In all conditions tested, monocytes did not enhance IFN-γ production by memory CD4+ T cells. LPS 
plus R848-stimulated CD1c+ DCs reactivated memory CD4
+
 T cells to produce significantly higher 
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IFN-γ compared to unstimulated controls (p < 0.05). Notably, LPS plus R848-stimulated CD1c+ 
DCs reactivated memory CD4+ T cells to produce significantly higher IFN-γ (p < 0.05) compared to 
monocytes under identical conditions. Compared to unstimulated controls, LPS plus R848-
stimulated CD1c+ DCs reactivated memory CD4+ T cells to produce significantly higher IL-22 (p < 
0.05). In all conditions tested, CD1c+ DCs and monocytes were equivalent at reactivating memory 
CD4+ T cells to produce IL-22. Compared to unstimulated controls, we observed that LPS plus 
R848-stimulated CD1c+ DCs reactivated memory CD4+ T cells to produce significantly higher 
levels of IL-17F (p < 0.05). We observed elevated IL-17F production by memory CD4+ T cells 
reactivated by LPS plus R848-stimulated CD1c+ DCs compared to monocytes under identical 
conditions; however, significance was not reached at the p < 0.05 level (p = 0.0720, repeated 
measures, two-way ANOVA). Pathogenic Th17.1 cells express high levels of CSF2 which encodes 
for GM-CSF (Ramesh et al., 2014). As shown in Figure 4.12, GM-CSF was detected from memory 
CD4+ T cells in all conditions tested (detection limit = 62.5pg/ml); however, the presence of TLR-
activated monocytes or CD1c+ DCs did not enhance its production. While memory CD4+ T cells did 
not produce GM-CSF during the 7-day culture, we noted that memory CD4+ T cells from all 
conditions except the negative control were highly capable of producing GM-CSF upon 
restimulation with PMA and ionomycin. Similarly, we did not observe any detectable levels of 
other cytokines tested including IL-2, IL-4, IL-5, IL-9, IL-10 and IL-13 from our cultures. This 
indicated that LPS plus R848-stimulated CD1c+ DCs did not reactivate Th2 or Treg responses. 
Taken together, CD1c+ DCs upon dual TLR stimulation reactivated memory CD4+ T cells to 
produce significantly higher levels of IFN-γ compared to monocytes under identical conditions. It is 
worth mentioning that using R848 as stimulus, our preliminary experiment (n = 1) demonstrated 
elevated levels of IFN-γ, IL-21 and IL-22 production by polyclonal memory CD4+ T cells in 
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Figure 4.12: Detection of pathogenic cytokines produced by memory CD4+ T cells. Levels of IL-
17A, IL-17F, IL-22, IFN-γ, IL-6 and GM-CSF produced by memory CD4+ T cells during the 7-day 
culture with TLR-activated CD1c+ DCs (red) or monocytes (blue) were quantified using 
LegendPlexTM bead-based immunoassay and analysed using LSR FortessaX20. Quantitative levels 
of each cytokine were computed using Vigene Tech software version 7.0 (Biolegend). Levels of 
GM-CSF from culture supernatant were quantified using ELISA. Unstimulated CD1c+ DCs and 
monocytes co-cultured with memory CD4+ T cells were setup as negative controls. Data were 
analysed with repeated measures, two-way ANOVA and presented as mean. Each plot represents 
one donor. Cumulative data from four independent experiments (three experiments with LPS), with 
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4.3.6) CD1c+ DC-derived soluble factors induced STAT3 phosphorylation in γδ T and 
CD3negative cells 
Given the importance of IL-23R/STAT3 signalling in autoimmune disease pathologies (Danoy et 
al., 2010, Duerr et al., 2006), and having demonstrated the expression of IL-23R on γδ T cells and 
NK cells, we asked if TLR-activated CD1c+ DCs would play a role in their activation. As these cell 
types are logistically difficult to isolate due to their rarity in peripheral blood, the first step was to 
examine whether CD1c+ DC or their soluble factors could induce activation of these innate cells by 
analysing STAT3 phosphorylation in total PBMCs as a functional readout.  
To this end, we stimulated CD1c+ DCs and monocytes overnight (day 0 for 20 hours) with LPS plus 
R848 combination, harvested the supernatant which was subsequently used to stimulate autologous 
PBMCs and evaluated STAT3 phosphorylation intracellularly via flow cytometry (day 1). To 
examine whether STAT3 phosphorylation in innate cells was mediated via cell contact or soluble 
factors or both, experiments were setup by stimulating autologous PBMCs in the presence of 
soluble factors alone or in combination with activated cells. γδ T cells were gated as CD3+ γδ TCR+, 
while NK cells were gated as CD3- CD56+ CD161+ (Figure 4.13a, b). Using flow cytometry, we 
demonstrated that soluble factors from LPS plus R848-stimulated CD1c+ DCs but not monocytes 
induced significantly higher STAT3 phosphorylation in γδ T cells (p < 0.0001, Figure 4.13d). We 
observed a loss in CD56 and possibly CD161 expression, therefore we were unable to determine the 
presence of NK cells within our PBMC pool. However, we observed CD1c+ DC-derived soluble 
factors induced significantly higher STAT3 phosphorylation in CD3negative population compared to 
monocyte-derived soluble factors (Figure 4.13b). We demonstrated that STAT3 phosphorylation in 
γδ T cells and CD3negative population does not require cell-to-cell interaction (Figure 4.13c). Taken 
together, these data suggested that STAT3 phosphorylation in γδ T and CD3negative cells was induced 
by CD1c+ DC-specific soluble factors and the presence of cell-to-cell contact did not enhance 
STAT3 phosphorylation. Therefore, subsequent STAT3 experiments were conducted using cell-
derived soluble factors. 
 


































































3 * * * *
d )
 
112 | P a g e  
 
Figure 4.13: Intracellular STAT3 phosphorylation induced by CD1c+ DCs in γδ T cells and 
CD3negative population. CD1c+ DCs or monocytes were cultured overnight in the presence of 
100ng/ml LPS plus 2µg/ml R848 to induce cytokine production. Post-incubation, supernatants of 
activated CD1c+ DCs were harvested and co-cultured with PBMCs for 15 minutes to induce STAT3 
phosphorylation in γδ T cells and CD3negative cells. Blue arrows represent progressive gating 
strategy. (a) Gating strategy to identify γδ T cells and CD3negative cells. (b) Induction of STAT3 
phosphorylation in γδ T cells and CD3negative population by supernatants from activated CD1c+ DCs 
or monocytes was evaluated using flow cytometry with Cyan ADP Cytometer. STAT3 antibody 
(red), isotype control from activated supernatants (blue), supernatants from activated CD1c+ DCs 
or monocytes stained with isotype control antibody (green). (c) STAT3 phosphorylation in 
response to either supernatant from activated cells (red) or in the presence of both supernatants and 
activated cells (blue) or activated CD1c+ DCs or monocytes stained with isotype control antibody 
(green). Data were analysed using flow cytometry with Cyan ADP Cytometer. (d) Cumulative data 
from six independent experiments analysed with repeated measures, two-way ANOVA with **** p 
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We next investigated other potential cell types that might up-regulate phosphorylated STAT3 (p-
STAT3) in response to CD1c+ DC-derived soluble factors. To further delineate what other cell 
types that expressed p-STAT3 in response to CD1c+ DC-derived soluble factors, we analysed the 
markers being expressed by gated on p-STAT3+ cells using flow cytometry (Figure 4.14). By 
gating on the p-STAT3+ cells, we further segregated them using the CD3 marker. In this gate, we 
observed three different cell populations: a CD3high population which represented conventional and 
non-conventional T cells; a CD3low population with high SSC profile which represented monocytes; 
and a CD3negative population which is represented by NK cells, B cells and DCs. Within the CD3high 
population, p-STAT3 was expressed by CD3high γδ TCRnegative cells which represented conventional 
T cells such as CD4+ and CD8+ T cells (Figure 4.14). p-STAT3 was also expressed in CD3high γδ 
TCR+, which represented the γδ T cells, thus confirming our previous observation. Next, p-STAT3 
was also induced in CD3lowpopulation which may represent monocytes given their high SSC 
profile. Finally, p-STAT3 was also expressed by CD3negative population which contain NK cells, 
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Figure 4.14: Induction of STAT3 phosphorylation in multiple cell populations in the presence of 
CD1c+ DC-derived soluble factors. CD1c+ DCs or monocytes were cultured overnight in the 
presence of 100ng/ml LPS plus 2µg/ml R848 to induce cytokine production. Post-incubation, 
supernatants of activated CD1c+ DCs were harvested and co-cultured with PBMCs for 15 minutes 
to induce STAT3 phosphorylation in total responding PBMCs. Blue arrows represent progressive 
gating strategy. Gating strategy to identify multiple cell populations directly from cells expressing 
phosphorylated STAT3 in response to supernatant from activated CD1c+ DCs. Gate was set from 
PBMCs stimulated with supernatants of activated CD1c+ DCs stained with isotype control antibody. 












In the previous chapter, we demonstrated that peripheral blood CD1c+ DCs were the major 
producers of IL-12p70 and IL-23 in response to LPS plus R848 stimulation. In this chapter, we 
sought to identify the cell types which can be influenced by the dual production of IL-12p70 and 
IL-23 production by TLR-activated CD1c+ DCs. We observed IL-23R expression on memory CD4+ 
T cells, γδ T cells, CD8+ T cells and NK cells, but absent on naïve CD4+ T cells. Notably, γδ T cells 
and NK cells displayed higher IL-23R MFI compared to other cell types. We demonstrated that 
TLR-stimulated CD1c+ DCs and monocytes were equivalent at driving memory CD4+ T cell 
proliferation. Notably, we demonstrated that LPS plus R848-activated CD1c+ DCs reactivated 
memory CD4+ T cells to produce significantly higher IFN-γ compared to monocytes under identical 
conditions. We observed an elevated production of IL-17F by memory CD4+ T cell reactivated with 
LPS plus R848-stimulated CD1c+ DCs in comparison with monocytes; however, significance was 
not achieved. LPS plus R848-stimulated CD1c+ DCs and monocytes were equivalent at reactivating 
memory CD4+ T cells to produce IL-6, IL-17A, IL-22 and GM-CSF. pSTAT3 was observed in a 
wide range of cells including γδ T cells, CD3high T cells, CD3internediate cells and CD3negative cells in 
response to CD1c+ DC-derived soluble factors.  
In the mouse system, 40% of cells that constitutively express IL-23R are γδ T cells (Awasthi et al., 
2009). Consistent with this finding, our study confirmed that human γδ T cells represent the major 
IL-23R+ expressing cells. In humans, numerous methods have been adopted to identify IL-23R 
expression including the use of a fluorescent IL-23R antibody (Kenna et al., 2012), fluorescent 
polyclonal IgG antibody (Wilson et al., 2007) or PCR (Billerbeck et al., 2010, Chognard et al., 
2014, Rachitskaya et al., 2008, Shen et al., 2013). Using these strategies, human γδ T cells, memory 
CD4+ and CD8+ T cells have been reported to express IL-23R (Kenna et al., 2012, Oppmann et al., 
2000, Shen et al., 2013, Wilson et al., 2007). Using the fluorescent IL-23R antibody from Kenna et 
al. (Kenna et al., 2012), our study observed that IL-23R protein was expressed on γδ T cells, 
memory CD4+ T cells and CD8+ T cells which were consistent with previous studies (Kenna et al., 
2012, Shen et al., 2013, Wilson et al., 2007). While memory CD4+ T cells were positive for IL-23R 
staining, the number of IL-23R+ cells and staining pattern in our study was considerably lower 
compared to Wilson et al. (Wilson et al., 2007). This was most likely due to the difference in 
antibody sources (i.e the one used in our study was a monoclonal IgG vs polyclonal goat IgG used 
by Wilson et al.). Monoclonal antibodies recognise a single epitope while polyclonal antibodies 
recognise multiple epitopes of a protein. Thus, the use of polyclonal goat IgG may have intensified 
the IL-23R staining on memory CD4+ T cells. Recently, Chognard et al. reported that human NK 
cells (CD3- CD19- CD56+) do not express IL-23R mRNA (Chognard et al., 2014). NK cells in our 
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study were identified as CD3- CD56+ CD161+, whereby CD161 is a marker of NK cells (Lanier et 
al., 1994) and we observed IL-23R staining on a small percentage of NK cells. While we observed 
IL-23R staining on γδ T which was consistent with a previous report (Kenna et al., 2012), the 
proportion of IL-23R+ cells were lower in our study. Differences may be attributed to different 
cohorts of healthy individuals or handling of blood samples. The IL-23R expression profile 
obtained in our study was consistent with published literature (Billerbeck et al., 2010, Kenna et al., 
2012, Shen et al., 2013, Wilson et al., 2007), we concluded that the fluorescent antibody used in our 
study was optimal. IL-23R expression was absent on both CD11c+ DCs and pDCs. Due to the lack 
of CD141+ DC numbers, we were unable to determine its respective IL-23R expression. 
Furthermore, any available CD141+ DCs were prioritised for experiments in Chapter 2. Future 
experiments should confirm the expression of IL-23R on CD141+ DCs.  
The IL-23R expression on human NKT cells remains to be determined. Human NKT cells represent 
0.001 – 0.2% of total CD3+ T cells in peripheral blood of healthy adults (Sakamoto et al., 1999). In 
our experiments, the IL-23R expression on NKT cells was determined directly from freshly isolated 
PBMCs. However, the number of NKT cells was considerably low which could be attributed to the 
lower number of events acquired in our study. Furthermore, NKT cell expansion using its 
prototypical antigen, α-Galcer in the presence of IL-7 plus IL-15 was minimal. It is certainly 
possible that the concentration of α-Galcer and/or recombinant cytokines used in our expansion 
studies was not optimal. Alternatively, NKT cells can be expanded in vitro with multiple rounds of 
α-Galcer stimulation in the presence of human recombinant IL-2 (Motohashi et al., 2006) or 
cultivated in the presence of irradiated donor antigen presenting cells (Sharma et al., 2011). It is 
however, important to note that the proportion of human NKT cells and their proliferative capacity 
are known to decrease with age (Jing et al., 2007, Ladd et al., 2010). NKT cells can be purified ex 
vivo by employing a fluorescent-labelled CD1d tetramer and address IL-23R expression on this cell 
population (Sharma et al., 2011). Human memory T cells mature from CCR7high central memory 
(TCM) to CCR7
low effector memory T cells (TEM) (Sallusto et al., 1999). TCM cells populate the 
peripheral blood, while TEM cells localise within peripheral tissues which serve as sites of active 
inflammation (Sallusto et al., 1999). Ramesh et al. reported that human Th17.1 effector memory 
cells displayed higher IL-23R mRNA expression compared to Th17 effector memory cells (Ramesh 
et al., 2014). In our study, the IL-23R expression on Th17 and Th17.1 cells was characterised using 
peripheral blood mononuclear cells which are populated with TCM. To confirm the previous finding 
by Ramesh et al. on a protein level, the IL-23R expression should be determined on tissue-resident 
Th17.1 and Th17 in comparison with their peripheral blood counterparts. Increased IL-23/IL-23R 
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signalling within tissues may result in heightened cytokine production including IL-17A, IL-17F, 
IL-21 and IL-22, further elevating inflammatory responses.  
The current understanding of why the percentage of IL-23R positive cells varies between 
individuals remains to be established. As IL-23 is known to promote autoimmune diseases, IL-23R 
expression may be limited to a small proportion of Th cells, which may be a preventative measure 
against prolonged or enhanced inflammatory response which could lead to harmful effects on the 
host. Furthermore, the contribution of IL-23/IL-23R towards disease pathology has been highly 
characterised in human tissues, including the skin and gut (Capon et al., 2007, Cargill et al., 2007, 
Chognard et al., 2014, McGovern et al., 2009, Silverberg et al., 2009, Zwiers et al., 2012). 
Therefore, IL-23R expression on peripheral blood cells may be less pronounced compared to its 
expression in human tissues (Kleinschek et al., 2009). If so, future experiments should be conducted 
to compare the percentage of IL-23R+ cells within tissues in comparison with their peripheral blood 
counterparts. While there is no evidence of IL-23R being recycled within a cell, a previous report 
has highlighted that multiple variants exist within the IL23R gene (Kan et al., 2008). These variants 
are categorised into four groups: 1) a full-length IL-23R with a truncated extracellular domain; 2) 
short premature IL-23R peptides; 3) soluble IL-23R without intracellular domains and 4) a non-
responsive IL-23R. While the significance of these variants remains to be established, this study 
suggested that those multiple regulatory mechanisms exist within the host to constrain the aberrant 
effects of IL-23R signalling. In the murine system, IL-23R can be up-regulated in response to 
transforming growth factor (TGF)-β, IL-1 and IL-6 (Lee et al., 2009, Morishima et al., 2009); 
however, it remains to be determined how these factors influence IL-23R expression in the human 
system. However, IL-23R up-regulation in humans may be a functional consequence of SNPs. 
SNPs in the IL-23R gene, including rs10889677 in IBD, CD (Duerr et al., 2006, Zwiers et al., 2012) 
have been demonstrated to relieve regulatory pathways resulting in increased IL-23R protein 
expression on PBMCs and CD4+ T cells in response to αCD3/CD28 stimulation (Zwiers et al., 
2012). Other SNPs including p.Arg381Gln, p.Arg86Gln (Duerr et al., 2006, McGovern et al., 2009, 
Momozawa et al., 2011) were reported to confer protection, their contribution towards IL-23R 
expression and mechanism of resistance has yet to be established. However, the protective allele, 
p.Arg381Gln was previously demonstrated to confer loss of IL-23R function in response to human 
recombinant IL-23 without impairing Th17 differentiation from naive CD4+ T cells (Di Meglio et 
al., 2011, Di Meglio et al., 2013, Pidasheva et al., 2011). We demonstrated in our study that γδ T 
and NK cells expressed IL-23R using the fluorescent monoclonal antibody. To follow up on these 
findings, γδ T and NK cells can be purified and IL-23R protein expression can be confirmed via 
Western Blot and the IL-23R expression can be up-regulated in the presence of soluble factors.  
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Geginat et al. previously reported that human DCs maintain memory CD4+ T cells in the presence 
of IL-7 and IL-15, which occurs independently of TCR:MHC interactions (Geginat et al., 2001). 
Furthermore, McKinlay et al. reported that CD11c+ cDCs are superior at driving memory CD4+ T 
cell proliferation in the presence IL-7 plus IL-15 (McKinlay et al., 2007). Notably, Th17.1 cells are 
to known produce IFN-γ and IL-17A in the presence of IL-12p70 and IL-23, respectively (Duhen et 
al., 2013, Ramesh et al., 2014). Given the substantial production of both IL-12p70 and IL-23 by 
LPS plus R848-activated CD1c+ DCs, we hypothesised that CD1c+ DCs would play a major role at 
reactivating memory Th17.1 cells. Here, we demonstrated that CD1c+ DCs and monocytes were 
equivalent driving memory CD4+ T cells in the presence of IL-7 plus IL-15 in vitro. These findings 
were in contrast to the previous report (McKinlay et al., 2007). McKinlay et al. utilised total 
CD11c+ cDCs in their co-culture experiments which contains both CD1c+ DCs and CD16+ 
monocytes, whereas our assay was performed using highly purified CD1c+ DCs. The presence of 
both cell types in their culture system may have enhanced memory CD4+ T cell proliferation by 
providing additional co-stimulatory signals. A previous report highlighted that memory CD4+ T 
cells respond directly towards R848 leading to proliferation and production of IFN-γ, due to their 
expression of TLR 8 (Caron et al., 2005). To rule out the direct activation of memory CD4+ T cells 
by TLR agonists, TLR-stimulated CD1c+ DCs and monocytes were washed twice with PBS and co-
cultured with purified memory CD4+ T cells was setup using a new plate. Here, we managed to 
demonstrate that CD1c+ DCs were able to drive memory CD4+ T cell proliferation. 
In our study, we demonstrated that TLR-stimulated CD1c+ DCs and monocytes were equally 
capable at reactivating memory CD4+ T cells to produce both IL-17A and IFN-γ. These findings 
suggested that the reactivation by memory CD4+ T cells by both cell subsets may occur 
independently of IL-12p70 and IL-23, given monocytes lacked the ability in producing these 
cytokines. While memory CD4+ T cells were able to produce IFN-γ and IL-17A upon reactivation, 
we also observed a double negative memory CD4+ T cell population within our cultures. These 
double negative memory CD4+ T cells did not produce IL-4, IL-5, IL-13 or IL-10 during the 7-day 
culture period or upon restimulation with PMA and ionomycin, suggesting that these T cells are not 
Th2 or Tregs. IL-1β has been reported to induce STAT4 phosphorylation as well as up-regulation of 
the Th1-associated transcription factor, T-bet in memory CD4+ T cells (Duhen et al., 2013). Thus, 
the production of IL-1β by TLR-stimulated CD1c+ DCs and monocytes reactivated IFN-γ 
production by memory CD4+ T cells. Of note, IL-1β has been reported to synergise with IL-12p70 
to enhance T-bet and STAT4 expression in memory Th17 cells, leading to enhanced production of 
IFN-γ and IL-17A (Duhen et al., 2013). Our intracellular cytokine data showed no difference in the 
proportion of IL-17A and IFN-γ producing CD4+ T cells. However, we observed that LPS plus 
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R848-stimulated CD1c+ DCs but not monocytes reactivated memory CD4+ T cells displayed 
elevated levels of IFN-γ (p < 0.01), IL-17A (p = 0.1029) and IL-17F (p = 0.072) in the day-7 
culture supernatant. Thus, the production of IFN-γ, IL-17A and IL-17F by Th17.1 cells were 
transiently induced in the presence of IL-1β, IL-12p70 and IL-23. To test this hypothesis, memory 
CD4+ T cells should be cultured in the presence of IL-1β, IL-12p70 and IL-23, either alone or in 
combination at physiological concentrations secreted by CD1c+ DCs or monocytes in response to 
LPS plus R848; and levels of IFN-γ, IL-17A and IL-17F produced should be quantified.  
While IL-17A levels were increased from memory CD4+ T cells in response to LPS plus R848-
stimulated CD1c+ DCs, significance was not observed when compared to monocytes under identical 
conditions. Memory CD4+ T cells reactivated by LPS plus R848-stimulated monocytes produced 
2035pg/ml while LPS plus R848-stimulated CD1c+ DCs from the matching donor reactivated 
memory CD4+ T cells to produce 89pg/ml IL-17A. The assay was setup in duplicates, thus it is 
certainly possible that the supernatants used for analysis may be an outlier. IL-6 can be produced by 
activated memory T cells (Morishima et al., 2009). We initially hypothesised that CD1c+ DCs 
would reactivate memory CD4+ T cells to produce higher levels of IL-6 compared to monocytes; 
given the cytokine profile of this DC subset. Cultures containing memory CD4+ T cells with TLR-
stimulated CD1c+ DCs or monocytes had higher levels of IL-6 compared to unstimulated controls. 
IL-6 produced by TLR-stimulated CD1c+ DCs and monocytes may still persist within the culture 
supernatant. However, IL-6 was previously reported with a half-life of 10 minutes (Castell et al., 
1988), while the half-life of its signalling components such as IL-6Rα and gp130 is approximately 3 
hours (Siewert et al., 1999). Therefore, the cellular source of IL-6 post-7 day cultures was most 
likely derived from reactivated memory CD4+ T cells themselves.   
As previously reported, IL-1β, IL-12p70 and IL-23 reactivate Th17.1 cells to produce IL-6, IFN-γ, 
IL-17A, IL-17F and IL-22 ex vivo (Annunziato et al., 2007, Duhen et al., 2013, Ramesh et al., 
2014). We initially hypothesised that the production of IL-1β, IL-12p70 and IL-23 by LPS plus 
R848-stimulated CD1c+ DCs can reactivate pathogenic, memory Th17.1 cells. We noted that in 
most cases, the levels of IL-6, IL-17A, IL-17F, IL-22 and IFN-γ was not significantly enhanced in 
the presence of LPS plus R848 combination compared to LPS or R848 alone. Ramesh et al. 
previously reported that pathogenic Th17.1 effector memory cells that express MDR1 display 
higher levels of IL17A, IL17F, IL22 and IFNG compared to its MDR1- nonpathogenic counterparts 
(Ramesh et al., 2014). Thus, it is possible that our study which uses polyclonal memory CD4+ T 
cells may not provide an accurate model for investigating the role of CD1c+ DCs at reactivating 
pathogenic memory Th17.1 cells. Future experiments should reinvestigate the role of CD1c+ DCs 
and its soluble factors on FACS-sorted MDR1+ effector memory Th17.1 cells.  
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In mouse models of autoimmunity, GM-CSF has been determined as one of the crucial pathogenic 
factors by sustaining IL-23 production by CD11c+ myeloid cells (Codarri et al., 2011). GM-CSF 
production in the murine system has been heavily associated with Th17/STAT3 axis, given their 
induction in the presence of both IL-1β, IL-6 and IL-23 (Codarri et al., 2011, El-Behi et al., 2011). 
However, GM-CSF production in humans is not induced by IL-1β, IL-6 and IL-23 but rather in 
response to IL-12p70. Indeed, Noster et al. and Reynolds et al. demonstrated that GM-CSF 
production by reactivated memory CD4+ T cells was suppressed by IL-1β, IL-6 or IL-23; while IL-
12p70 significantly enhanced GM-CSF production (Noster et al., 2014, Reynolds et al., 2015). 
While GM-CSF production by memory CD4+ T cells was not enhanced during the 7-day culture, we 
noted that memory CD4+ T cells were highly capable of producing it upon restimulation with PMA 
and ionomycin, with the exception of the T cell alone control. However, GM-CSF production by 
human memory CD4+ T cells could also be induced by IL-15 and IL-2 in a STAT5-dependent 
manner (Noster et al., 2014, Reynolds et al., 2015). While we were unable to conclude that IL-1β 
and IL-6 derived from CD1c+ DCs and monocytes actively suppressed GM-CSF induction, our data 
suggested that CD1c+ DC-derived soluble factors did not induce GM-CSF production by peripheral 
blood memory CD4+ T cells. As pathogenic Th17.1 effector memory cells express higher CSF2 
compared to its nonpathogenic counterparts, the role of CD1c+ DCs at inducing GM-CSF 
production from the former T cell population remains an open question. Finally, the propensity of 
GM-CSF production by human T cells may be regulated by the ratio of IL-1β, IL-6 and IL-23 to IL-
12p70, IL-15 and IL-2.  
It is however, important to note that not all Th17.1 cells display pathogenic profile. In fact, 
pathogenic Th17.1 cells stably express MDR1 compared to its non-pathogenic counterparts 
(Ramesh et al., 2014). Therefore, pathogenic Th17.1 can be truly defined by the following markers: 
CD3+ CD4+ CD45RO+ CXCR3+ CCR4low CCR6+ MDR1+. While a fluorescent MDR1 antibody is 
available, its validity in human studies has yet to be established. In our preliminary experiments, we 
attempted to identify MDR1 protein expression on purified memory Th17.1 cells using flow 
cytometry. However, no discernable difference in MDR1 expression was observed on Th17.1 cells 
in comparison to Th1, Th2 and Th17 cells. Our data suggested that MDR1 activity was not 
augmented in the presence of activated DCs or DC-derived soluble factors. MDR1 activity in 
healthy individuals is low due to the low precursor frequency of pathogenic Th17.1 cells. Indeed, 
Ramesh et al. previously reported that PBMCs derived from inflamed gut tissue of CD patients 
displayed up to four-fold increase in MDR1 activity, evaluated by Rh123 efflux assay compared to 
PBMCs from healthy controls (Ramesh et al., 2014). Importantly, MDR1 activity was restricted to a 
subset of CD161+ memory CD4+ T cells. This is an important finding given that pathogenic Th17.1 
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cells express CD161 and MDR1 activity renders them resistant to corticosteroid treatment (Basdeo 
et al., 2015, Ramesh et al., 2014). However, CD161 is also expressed by Th17 cells as well as 
MDR1negative Th17.1 cells (Ramesh et al., 2014). Given the specificity of MDR1 activity on 
pathogenic Th17.1 cells, these cells can be effectively purified by performing an initial Rh123 assay 
and co-stained with fluorescent antibodies and purified as the following: CD3+ CD4+ CD45RO+ 
CXCR3+ CCR4low CCR6+ Rh123low. However, the evaluation of MDR1 activity ex vivo in disease 
setting is challenging due to the requirement of high cell numbers to purify pathogenic Th17.1 
effector memory T cells. Alternatively, the MDR1 activity can be evaluated by comparing Rh123 
efflux using PBMCs isolated from diseased patients compared to PBMCs from HCs.  
IL-23R signalling promotes STAT3 phosphorylation, which has been associated with disease 
pathologies. In alignment with our IL-23R expression data, we sought to determine the effects of 
CD1c+ DC- and monocyte-derived soluble factors in STAT3 phosphorylation in γδ T cells and NK 
cells. We managed to demonstrate that CD1c+ DC- but not monocyte-derived soluble factors 
induced this process in all cell types; however, NK cells could not be accurately identified given the 
possibility of cell death or down-regulation of CD56 marker. As previously highlighted, both 
CD1c+ DCs and monocytes were stimulated overnight (20 hours) to induce maximal cytokine 
production. During the stimulation process, autologous PBMCs were stored at 4oC in complete AB 
medium. Therefore, there is a possibility whereby NK cells down-regulated CD56 expression. 
Indeed, this phenomenon has been previously documented (De Maria et al., 2011, Navabi et al., 
2015). Furthermore, our experiments also showed that the expression of CD56 and CD161 was 
down-regulated upon fixation. Several ways can be employed to accurately identify NK cells in our 
assay. CD56dim NK cells comprise 90% of total peripheral blood NK cells and known to express 
CD16 and CD57 marker (De Maria et al., 2011, Lopez-Verges et al., 2010). However, it is 
important to note that CD16 is also expressed by a subset of monocytes, while CD57 is expressed 
on conventional T cells (Brenchley et al., 2003). To exclude CD16+ monocytes, lymphocytes can be 
initially gated with CD3 vs CD57. As CD16+ monocytes lack CD3 and CD57 expression, NK cells 
can be initially identified as CD3negative CD57+ cells; thus, excluding conventional T cells this 
process. Finally, bonafide NK cells can further be identified from CD3negative CD57+ cells by gating 
for CD16 expression. Alternatively, NK cells can be purified using CD56 microbeads which are 
commercially available and routinely employed for human NK cell studies (De Maria et al., 2011). 
While there may be a possibility that these markers can be down-regulated upon fixation, future 
experiments should consider using flow antibodies which are not affected by fixation.  
Upon further analysis, CD1c+ DC-derived soluble factors induced widespread p-STAT3 expression 
in CD3high, CD3intermediate and CD3negative populations. Within the CD3high population, p-STAT3 was 
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expressed in CD3high γδ TCR+ which represented γδ T cells, confirming our previous finding. p-
STAT3 was also expressed in CD3high γδ TCRnegative cells, which may correspond to conventional 
CD4+ and CD8+ T cells, as well as unconventional T cells including MAIT cells. Wilson et al. 
previously reported that STAT3-deficient patients exhibit significantly reduced levels of circulating 
MAIT cells (Wilson et al., 2015). MAIT cells are CD3+ γδ TCRnegative CD161high, specifically 
express Vα7.2 TCR and comprise approximately 10% of total CD3+ T cells (Sattler et al., 2015, 
Ussher et al., 2014). Thus, MAIT cells can be identified in PBMCs and future experiments should 
confirm whether CD1c+ DC-derived soluble factors are capable of inducing STAT3 
phosphorylation in this cell population. Interestingly, p-STAT3 was also induced in CD3low cells 
with high SSC profile, which indicated that these cells most likely corresponded to monocytes. 
Human blood monocytes can be segregated into three subsets based on the expression of CD16 and 
CD14, the CD14high CD16negative (classical), CD14high CD16+ (intermediate) and CD14intermediate 
CD16+ (non-classical) subsets (Wong et al., 2012). Thus, future experiments should incorporate 
CD14 and CD16 markers to further confirm which monocyte subset expresses p-STAT3 in 
response to CD1c+ DC-derived soluble factors. Finally, CD1c+ DC-derived soluble factors induced 
p-STAT3 in CD3negative population which might correspond to NK cells, B cells and DCs.  
STAT3 phosphorylation is known to be triggered by IL-6, IL-10, IL-21, IL-23 and IL-27 (Kane et 
al., 2014, Jones et al., 2016, Morandi et al., 2012). In the previous chapter, we consistently 
demonstrated that in response to LPS plus R848 stimulation, CD1c+ DCs produced IL-6, IL-10, IL-
23 but lacked IL-27. Under identical conditions, monocytes produced only IL-6 but not IL-10, IL-
23 or IL-27. IL-21 is primarily produced by activated CD4+ T cells, NK and NKT cells (Spolski and 
Leonard, 2008a), however its production by monocytes or human DCs has not been confirmed. 
Given the significant levels of STAT3 phosphorylation being induced in γδ T cells by CD1c+ DC-
derived soluble factors, this process may be mediated by IL-6, IL-10 and IL-23, either alone or in 
combination. Of note, IL-10R protein has been reported to be expressed on human NK (Cai et al., 
1999, Carson et al., 1995), while the expression of IL-10R on γδ T cells has yet to be confirmed. 
Previously, Kassianos et al. reported that CD1c+ DCs were capable of producing IL-10 in response 
to LPS (Kassianos et al., 2012). While significance was not achieved, we observed an elevated 
levels of IL-10 being produced by CD1c+ DCs derived from healthy individuals compared to 
monocytes in response to LPS plus R848 stimulation (Figure 3.16, p = 0.06). To confirm the ability 
of CD1c+ DC-derived IL-10 on inducing STAT3 phosphorylation in γδ T and NK cells, initial 
experiments should aim to validate IL-10R expression on both these cell types. Human NK cells 
have been reported to express functional IL-21R (Burgess et al., 2006), however its expression on 
human γδ T cells has not been established. Furthermore, the production of IL-21 by CD1c+ DCs in 
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response to LPS plus R848 stimulation requires clarification. Once confirmed, this would permit us 
to investigate the possibility of STAT3 activation in these cell types in response to human 
recombinant IL-10, IL-21 and IL-23. Furthermore, it would be interesting to evaluate whether the 
induction of STAT3 in these cells types is dependent on one cytokine or synergistically enhanced in 
the presence of multiple cytokines. To test this, PBMCs can be stimulated with human recombinant 
IL-6, IL-10, IL-21 and IL-23 either alone or in combinations and STAT3 phosphorylation will be 
evaluated in comparison to PBMCs stimulated with supernatants derived from LPS plus R848-
stimulated CD1c+ DCs. Given the importance of IL-23/STAT3 signalling in autoimmune diseases, 
we hypothesised that CD1c+ DC-derived IL-23 may be the major contributor in triggering STAT3 
phosphorylation in IL-23R-expressing cells. IL-23 is composed of IL-23p19 and IL-12p40 subunits, 
where the former signals through STAT3. Moreover, neutralising antibodies against IL-6, IL-10, 
IL-21 and IL-23 should also be taken consideration to help determine the factors within the CD1c+ 
DC-derived soluble factors at triggering STAT3 phosphorylation in innate and adaptive cell 
populations. 
In our assay, monocytes and CD1c+ DCs were stimulated with LPS in combination with R848 
overnight to induce cytokine production. These supernatants were subsequently used to trigger 
STAT3 phosphorylation in total, autologous PBMCs. These supernatants may contain residual LPS 
and R848. The presence of these TLR agonists may trigger the responding PBMCs to produce IL-6, 
IL-10, IL-21 and IL-23, which in turn could potentiate STAT3 phosphorylation. While that may 
present as a possibility, we consistently showed that the levels of STAT3 phosphorylation induced 
by CD1c+ DC-derived soluble factors were significantly higher compared to monocytes under 
identical conditions. Therefore, our findings suggested that the high levels of STAT3 
phosphorylation may not be attributed to the feedback loop induced by free floating TLR agonists, 
but rather triggered in response to CD1c+ DC-specific factors. To address this, future experiments 
should incorporate an additional control with PBMCs stimulated with LPS and R848. STAT3 
phosphorylation assay was conducted by stimulating responding PBMCs with soluble factors 
derived either from CD1c+ DCs or monocytes for 15 minutes. An increase in STAT3 
phosphorylation was observed in γδ T cells, CD3+, CD3low and CD3negative cells. Increased 
phosphorylated STAT3 may be due to an increase in total STAT3 protein; however, due to the short 
time of incubation, this was unlikely. To confirm whether the increase in p-STAT3 is due to an 
overall increase in STAT3; future experiments should quantify both total STAT3, and p-STAT3 to 
understand the mechanism behind cytokine production.  
In addition to STAT3 phosphorylation, future experiments should aim to determine the activation 
status of γδ T and NK cells by measuring CD69 up-regulation; a marker associated with T cell 
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activation (Kunzmann et al., 2004). γδ T cells have been reported to be activated by type I IFNs 
derived from CD11c+ cDCs in response to PIC stimulation (Kunzmann et al., 2004). Cytokine data 
from Chapter 1 revealed that CD1c+ DCs do not produce IFN-α in response to PIC stimulation. 
Furthermore, data from our group demonstrated that CD1c+ DCs lacked the ability to produce IFN-
β (Jongbloed et al., 2010). Therefore, the activation of γδ T cells by CD1c+ DCs requires further 
clarification. The activation of NK cells by CD1c+ DCs is driven by IL-12p70, leading to CD69 up-
regulation as well as IFN-γ (Gerosa et al., 2005, Perrot et al., 2010). These findings are further 
supported by a recent report that human NK cells express high levels of IL12Rβ1 and IL-12Rβ2, 
which encodes for IL-12R (Chognard et al., 2014). Having demonstrated that NK cells express IL-
23R, the next step is to demonstrate their capability in IL-17A and IFN-γ production in the 
concurrent presence of IL-12p70 and IL-23. To demonstrate the effects concordant IL-23 and IL-
12p70 in γδ T and NK cell cytokine production, intracellular cytokine staining could be performed 
on PBMCs in the presence of CD1c+ DC-derived soluble factors. With our optimised flow 
cytometry antibody panel, this experiment would allow evaluation of CD69 up-regulation, as well 
as the proportion of IFN-γ and IL-17A producing γδ T and NK cells.  
NK cells express high levels of TLR 3, with minimal expression of TLRs 4, 7 and 8, while human 
γδ T cells express TLRs 3 and 7 (Dar et al., 2014, Della Chiesa et al., 2014). Direct stimulation of 
NK cells and γδ T cells with PIC results in IFN-γ secretion (Morandi et al., 2006, Wesch et al., 
2006). Notably, direct TLR 8 stimulation of human NK cells enhanced IFN-γ production (Alter et 
al., 2007). The activation of human γδ T cells in response to direct TLR 7 ligation requires 
clarification. Thus, to fully evaluate the effects of CD1c+ DC-derived soluble factors on γδ T and 
NK cell activation, the following controls should be setup: 1) PBMCs only, 2) PBMCs in the 
presence of LPS and R848, 3) PBMCs in the presence of activated CD1c+ DC supernatant and 4) 
PBMCs in the presence of activated monocyte supernatant.  
4.5) Conclusion 
IL-23R was found to be expressed on a small percentage of memory CD4+ T cells, NK cells and γδ 
T cells, but not on naïve CD4+ T cells. γδ T cells and NK cells expressed the highest IL-23R MFI 
compared to other cell types. TLR-activated CD1c+ DCs and monocytes were equivalent at driving 
the proliferation of polyclonal memory CD4+ T cells, LPS plus R848-stimulated CD1c+ DCs 
reactivated polyclonal memory CD4+ T cells to produce significantly higher levels of IFN-γ in the 
7-day culture supernatant; along with an elevated level of IL-17F compared to monocytes under 
identical conditions; however, significance was not reached at the p < 0.05 level (p = 0.0720). 
However, CD1c+ DCs may not be reactivating pathogenic Th17.1 responses given the lack of GM-
CSF induction from memory CD4+ T cells, as well as being equivalent to monocytes at reactivating 
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memory CD4+ T cells to produce IL-6, IL-17A, IL-21 and IL-22. We showed that the CD1c+ DC- 
but not monocyte-derived soluble factors induced p-STAT3 expression in γδ T cells, as well as in 
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Chapter 5 - General discussion and future directions 
We demonstrated the production of IL-12p70 and IL-23 by CD1c+ DCs was induced upon R848 
stimulation, and further enhanced by LPS or PIC. This feature was absent in the monocytes, 
CD141+ DCs and pDCs, thus confirming a CD1c+ DC-specific effect. We demonstrated that 
CD141+ DCs secreted IL-23 protein in response to TLR stimulations, albeit to a lesser extent 
compared to CD1c+ DCs while pDCs were unable to do so. In the mouse system, murine CD8+ DCs 
are the major producers of IL-12p70 (Hochrein et al., 2001), while murine CD11b+ DCs represent 
the obligate source of IL-23 (Kinnebrew et al., 2012, Satpathy et al., 2013). While CD141+ DCs 
were able to produce IL-12p70 in response to R848 plus PIC combination as well as LPS plus R848 
plus PIC combination, CD1c+ DCs were far superior under identical conditions. These data 
suggested both CD1c+ DCs were superior than CD141+ DCs at producing IL-12p70 in response to 
TLR stimulations. Our data showed that peripheral blood CD1c+ DCs were capable of producing 
both IL-12p70 and IL-23 in response to TLR stimulations compared to other myeloid lineages. We 
concluded that CD1c+ DCs were certainly capable at producing IL-12p70 in response to the 
following conditions: LPS plus R848 combination, R848 plus PIC combination and LPS plus R848 
plus PIC combination. Having confirmed the production of IL-12p70 by CD1c+ DCs in response to 
LPS plus R848 stimulation, its role at priming Th1 responses remains to be explored. Given the 
importance of Th1 cells in the clearance of intracellular pathogens and tumours, future studies 
should determine the ability of CD1c+ DCs to prime naïve CD4+ T cells into Th1 cells upon 
stimulation with LPS plus R848 combination. CD1c+ DCs were reported to prime Th17 responses 
in the presence of peptidoglycan, which was attributed to the production of IL-1β and IL-6 (Acosta-
Rodriguez et al., 2007a). Similarly, stimulation of CD1c+ DCs with Mycobacterium tuberculosis 
lead to the induction of IL-1β, IL-6 and IL-23, but not IL-12p70; thus indicating the activation of 
Th17 responses (Lozza et al., 2014a, Acosta-Rodriguez et al., 2007a). We demonstrated that 
stimulation of CD1c+ DCs with LPS plus R848 resulted in the production of IL-1β, IL-6, IL-23 and 
more importantly, IL-12p70. As IL-12p70 is known to inhibit Th17 differentiation, our data along 
with others suggested that CD1c+ DCs stimulated with LPS plus R848 combination may not be able 
to prime Th17 responses (Acosta-Rodriguez et al., 2007a, Acosta-Rodriguez et al., 2007b, 
LeibundGut-Landmann et al., 2007). Gut CD1c+ DCs were previously demonstrated to produce IL-
23 but not IL-12p70 in response to LPS plus R848 stimulation (Dillon et al., 2010), although its role 
at priming Th17 responses remains to be determined. Therefore, future experiments can be 
conducted by stimulating gut CD1c+ DCs with LPS plus R848 and determine their ability to prime 
naïve CD4+ T cells towards Th17 phenotype in compassion with their peripheral counterparts.  
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Our study demonstrated IL-23R expression on small percentage of γδ T cells, NK cells, memory 
CD8+ T cells, Th17 cells and Th17.1 cells. Given the production of IL-23 by CD1c+ DCs and the 
importance of IL-23R signalling in autoimmune pathologies, our data suggested a possible crosstalk 
between CD1c+ DCs and these innate cell populations. γδ T cells have been reported to be elevated 
in AS patients and produced higher levels of IL-17A compared to the γδ T cells from HCs in 
response to recombinant IL-23 (Kenna et al., 2012). γδ T cells can also produce IFN-γ in response 
to IL-12p70 (Chien et al., 2014). NK cells are reputedly known to respond towards IL-12p70 
leading to IFN-γ production (Fauriat et al., 2010, Ferlazzo and Morandi, 2014, Ferlazzo et al., 2004, 
Gerosa et al., 2005). The expression of IL-23R on NK cells suggests a possibility of IL-17, IL-21 
and IL-22 production in response to IL-23 stimulation. While IL-23R signalling is involved in 
autoimmunity, its functional consequences seem to be localised within the tissues including the gut 
(Duerr et al., 2006, McGovern et al., 2014, Rueda et al., 2008). Thus, it would be interesting to 
compare the expression of IL-23R on gut-derived γδ T cells and NK cells with their peripheral 
blood counterparts. However, the logistics of isolating γδ T cells and NK cells from patient tissues 
for accurate detection of IL-23R will be challenging. Thus, future experiments can be performed by 
isolating lamina propria mononuclear cells and IL-23R expression can be investigated using an IL-
23R flow antibody. IL-23R signalling promotes the production of IL-17. Murine mouse models of 
autoimmunity have hypothesised the importance of IL-17:IFN-γ ratio in promoting pathogenesis; 
where IL-17 plays a pathogenic role while IFN-γ plays a protective role (Korn et al., 2009). Our 
data warrants future investigations to determine the precise role of CD1c+ DC-derived soluble 
factors at augmenting the IL-17:IFN-γ ratio in γδ T cells and NK cells in contributing towards 
autoimmunity.  
In our AS study, we demonstrated that CD1c+ DCs significantly up-regulated CD80 and CD86 
expression upon TLR stimulation compared to CD1c+ DCs from HCs. Additionally, AS-derived 
monocytes significantly up-regulated CD83 expression compared to monocytes from HCs. The 
priming of T cell responses requires three signals, presentation of Ag in the context of MHC 
molecules (signal one), up-regulation of co-stimulatory molecules (signal two) and production of 
cytokines by APCs (signal three). Notably, signals two and three are induced upon recognition of 
PAMPs or DAMPs via PRRs. In the context of autoimmunity, the recognition of DAMPs by APCs 
would result in up-regulation of co-stimulatory molecules leading to increased cytokine production, 
and ultimately, priming of T cell responses. The types of Th responses contributing towards AS 
pathology remain conflicting. For example, the prevalence of Th1 responses have been reported 
(Duftner et al., 2006, Wang et al., 2015), while others have reported increased percentages of Th17 
cells (Jandus et al., 2008, Shen et al., 2009). We observed elevated IL-12p70 levels being produced 
by AS-derived CD1c+ DCs compared to CD1c+ DCs from HCs; indicating the activation of Th1 
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cells in AS patients. Interestingly, AS-derived monocytes produced significantly higher TNF-α and 
CXCL10 compared to monocytes from HCs. TNF-α and CXCL10 have been reported to be 
elevated in AS patients (Wang et al., 2016) and given their importance in recruitment and activation 
of Th1 cells (Rotondi et al., 2004), our data suggested that monocytes may be involved in activating 
Th1 responses in AS patients. Taken together, elevated IL-12p70 levels along with significant TNF-
α and CXCL10 levels may suggest Th1 cell activation in AS patients. Moret et al. recently reported 
that CD1c+ DCs derived from RA patients were able to drive proliferation and reactivation memory 
CD4+ T cells in the presence of recombinant IL-7 to produce IL-17 and IFN-γ (Moret et al., 2015). 
Having demonstrated an increased IL-12p70 production by AS-derived CD1c+ DCs in response to 
LPS plus R848 stimulation, future studies should determine the ability of this DC subset at 
augmenting Th1 cell activation using IFN-γ production as a readout in AS patients. Th1 cell 
activation results in the production of IFN-γ, which has been reported to up-regulate STAT1 
expression in macrophages derived from RA patients (Hu et al., 2002). This is an important finding 
as STAT1 phosphorylation in macrophages leads to the production of Type I IFNs (Hu et al., 2002). 
Furthermore, increased IFN-γ as well as TNF-α has been reported to skew macrophages towards an 
M1 phenotype (otherwise known as classically activated macrophages). The surface markers of M1 
macrophages have yet to be fully characterised; however, M1 macrophages are reputedly known to 
produce IL-1, IL-6 and IL-23, which have been hypothesised to contribute to autoimmune 
pathology (Mosser and Edwards, 2008). Thus, future experiments should determine the expression 
of STAT1 in macrophages derived from AS patients, along with the levels of IL-1, IL-6 and IL-23 
being produced, which may indicate a role of M1 macrophages in contributing to AS pathology. 
Additionally, MAIT cells have been hypothesised to contribute towards AS pathology (Kenna and 
Brown, 2013b). Stimulation of human peripheral blood MAIT cells triggers STAT3 and STAT4 
phosphorylation in response to recombinant IL-23 and IL-12p70, respectively (Wilson et al., 2015). 
In addition to pathogenic Th17.1 cells, MAIT cells have been reported to express MDR1 which 
renders them resistant to corticosteroid treatment (Dusseaux et al., 2011). Having demonstrated that 
peripheral blood CD1c+ DCs were the major producers of IL-12p70 and IL-23 in response to TLR 
stimulation, our data suggested a potential crosstalk between CD1c+ DCs and MAIT cells. To 
ascertain this hypothesis, future experiments should determine the effects of IL-12p70 and IL-23 
derived from CD1c+ DCs at augmenting MAIT cell activation as well as their cytokine secretory 
profile, notably IL-17A and IFN-γ. Along with its polyfunctional cytokine secretory profile, the 
survivability and persistence of MAIT cells within inflammatory sites may potentially be harmful to 
the host.   
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In the mouse system, TLR 8 does not recognise ssRNA ligands, RNA viruses, bacterial RNA or any 
agonists which engage human TLR 8 (Heil et al., 2004, Hemmi et al., 2002). Furthermore, TLR 8 
deficient mice showed increased TLR 7 up-regulation as well as increased serum levels of 
autoantibodies, further suggesting a regulatory role of TLR 8 (Demaria et al., 2010). Therefore, the 
propensity of TLR 8 to induce autoimmunity is specific towards the human system. In the context 
of autoimmunity, the recognition of self and foreign nucleic acids, as well as necrotic cells from 
damaged tissues by CD1c+ DCs would consistently be triggered to produce substantial amounts of 
IL-1β, IL-12p70 and IL-23 which affects reactivation memory pathogenic Th17.1 cells. We 
hypothesised that CD1c+ DCs can potentiate autoimmune diseases upon TLR 8 ligation and 
reactivate pathogenic Th17.1 cells within peripheral blood. Our data demonstrated that CD1c+ DCs 
stimulated with LPS plus R848 reactivated polyclonal memory CD4+ T cells to produce 
significantly higher IFN-γ, along with elevated levels of IL-17F compared to monocytes under 
identical conditions. Our intracellular cytokine staining data revealed no difference in the 
proportion of IFN-γ memory T cells, suggesting that the reactivation of Th17.1 cells by IL-1β, IL-
12p70 and IL-23 is may be a transient process. IFN-γ plays an important role in activating Th1 
responses, host defence against intracellular pathogens and tumour surveillance (Hu and Ivashkiv, 
2009). Moreover, enhanced IFN-γ signalling has been reported to suppress production of anti-
inflammatory cytokines IL-10; which further fuels the production of inflammatory cytokines 
(Mosser and Edwards, 2008, Zielinski et al., 2012). In the context of autoimmune diseases, IFN-γ 
was recently reported to stimulate APCs to promote the migration of Th17 cells into psoriatic 
lesions via production of CCL20 as well as synergising with IL-17 leading over-expression of 
human β-defensin 2 by keratinocytes (Kryczek et al., 2008). These findings indicated that IFN-γ 
may regulate Th17 responses leading to exacerbation of disease pathology. IL-17F is known to 
promote neutrophil migration to sites of inflammation (Moseley et al.). In the context of 
autoimmunity, aberrant IL-17F signalling results in the triggering of the NF-κB pathway, leading to 
increased production of inflammatory cytokines including TNF, IL-1 and IL-6. However, we were 
unable to conclude that CD1c+ DCs were specifically reactivating pathogenic Th17.1 cells due to 
the lack of GM-CSF induction, as well as being equivalent to monocytes at reactivating memory 
CD4+ T cells to produce IL-6, IL-17A, IL-21 and IL-22. Pathogenic Th17.1 cells however, display 
reduced expression of regulatory genes including SOCS3 and FOXP3. Future experiments should 
consider analysing their protein expression in memory CD4+ T cells upon co-culture with CD1c+ 
DCs or monocytes. CD161 is not exclusively expressed on pathogenic Th17.1 cells. However, 
pathogenic Th17.1 effector memory cells can be effectively purified as the following: CD3+ CD4+ 
CD45RO+ CXCR3+ CCR6+ CCR4low Rh123low. Ramesh et al. previously reported that MDR1+ 
memory CD4+ T cells isolated from the inflamed gut of CD patients displayed increased expression 
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of CSF2, IFNG, IL23R and IL22 compared to its MDR1negative counterparts (Ramesh et al., 2014). 
As CD1c+ DCs have been reported to localise within human gut (Dillon et al., 2010, Watchmaker et 
al., 2014), future studies should aim to investigate the role CD1c+ DCs at reactivating Th17.1 
effector memory responses within gut tissues, which is feasible. TLR 7 is expressed by CD1c+ DCs 
and pDCs, while TLR 8 is expressed in CD1c+ DCs and CD141+ DCs (Hemont et al., 2013, 
Jongbloed et al., 2010, Kadowaki et al., 2001). Using R848 as stimulus, our preliminary experiment 
(n = 1) demonstrated elevated levels of IFN-γ, IL-21 and IL-22 production by polyclonal memory 
CD4+ T cells in response to CD1c+ DCs but not CD141+ DCs. Like CD1c+ DCs, CD141+ DCs were 
able to produce IL-1β, IL-12p70 and IL-23 in response to R848 plus PIC combination (Figure 
3.8a). Constrained by low numbers of CD141+ DCs, we were unable to compare the reactivation of 
memory CD4+ T cells by CD141+ DCs with CD1c+ DCs using R848 plus PIC as our stimulus. To 
obtain sufficient numbers of human CD141+ DCs, future experiments should aim to purify this DC 
subset from leukapheresis products. These findings will provide an understanding if the reactivation 
of Th17.1 memory responses is shared by all cell types upon production of IL-1β, IL-12p70 and IL-
23.  
Our data demonstrated that CD1c+ DC- but not monocyte-derived soluble factors induced generic 
expression of p-STAT3 in γδ T cells, along with CD3low and CD3high populations. These data 
indicated that induction of p-STAT3 in these immune cells was not limited to IL-23 only. The next 
step would be to incorporate additional markers including CD4, CD8, CD45RO, CD14, CD16, 
CD19, CD57, Vα7.2 TCR to accurately delineate the cell types that expressed p-STAT3 including 
NK cells, subsets of monocytes, B cells, conventional CD4+ and CD8+ T cells as well as MAIT 
cells. Danoy et al. identified STAT3 as a disease susceptibility locus shared between AS and CD 
patients (Danoy et al., 2010). Having observed p-STAT3 induction in multiple cell populations 
within PBMCs from healthy individuals, future experiments should characterise the expression of 
p-STAT3 in cell populations using PBMCs isolated from AS patients in response to CD1c+ DC-
derived soluble factors as well as its effects on downstream cytokine production including IL-17A, 
IL-17F, IL-21 and IL-22.  
During the last 5 years, enormous progress has been made in the characterisation of human DC 
subsets. pDCs, as the major inducers of Type I IFNs play a crucial role in anti-viral immunity, while 
CD141+ DCs excel at anti-tumour immunity as well as the generation of CTL responses via cross-
presentation. The role of human CD1c+ DCs however, remains to be established. Our study 
suggests that peripheral blood CD1c+ DCs may play a role at activating Th1 responses given their 
propensity to produce higher IL-12p70 compared to other DC subsets. We showed that R848 plus 
PIC combination induced peripheral blood CD1c+ DCs were major producers of both IL-12p70 and 
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IL-23 compared to other DC subsets. Our clinical study also showed that CD1c+ DCs produced 
elevated levels of IL-12p70 as well as increased levels of TNF-α and CXCL10 being produced by 
monocytes, further suggesting Th1 activation in AS patients. CD1c+ DCs reactivated polyclonal 
memory CD4+ T cells to produce IFN-γ, which is known to skew macrophages towards an M1 
phenotype. Finally, the cytokine secretory profile of CD1c+ DCs suggested the potential crosstalk 
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Appendices  
A) Flow cytometry antibodies used in this thesis 
Antibody Manufacturer Catalogue number Fluorophore Clone 
CD1c Abcam Ab27336-1 FITC B-B5 
CD1c Biolegend 331506 PE L161 
CD3 Biolegend 317314 PB OKT3 
CD3 BD Pharmingen 555333 PE UCHT1 
CD4 Biolegend 300518 APC Cy7 RPA-T4 
CD4 Biolegend 300514 APC RPA-T4 
CD11c BD 559877 APC B-ly6 
CD14 Biolegend 325616 PB HCD14 
CD14 Biolegend 325608 APC HCD14 
CD16 Biolegend 302032 PB 3G8 
CD19 Biolegend 302232 PB HIB19 
CD20 Biolegend  302320 PB 2H7 
CD27 BD 337169 APC L128 
CD34 Biolegend 343512 PB 581 
CD45RA Biolegend 304108 PE HI100 
CD45RO Biolegend 304210 APC UCHL1 
CD56 Biolegend 318326 PB HCD56 
CD56 BD 557747 PeCy7 B159 
CD69 BD 555533 APC FN50 
CD80 BD 557227 PE L307.4 
CD83 BD 551073 APC HB15e 
CD86 BD 555657 FITC 2331 
CD123 BD 340545 PE 9F5 
CD123 Biolegend 306016 Percp Cy5.5 6H6 
CD141 Biolegend 344106 APC M80 
HLA-DR Biolegend  307616 PeCy7 L243 
CD161 Biolegend 339908 Percp Cy5.5 HP-3G10 
MDR1 (CD243) Biolegend 348611 Percp Cy5.5 UIC2 
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γδ TCR Biolegend 331208 FITC B1 
Vα24- Jα18 Biolegend 342908 APC 6B11 
IL-23R RnD Systems FAB14001P-100 PE 218213 
Mouse IgG2b RnD Systems IC0041P PE 133303 
CCR4 Biolegend L291H4 Pecy7 359410 
CCR6 Biolegend GO34E3 BV605 353420 
CXCR3 BD Biosciences IC6 FITC 558047 
IgG1, κ (isotype control) BD Pharmingen 556649 FITC MOPC-21 
IgG1, κ (isotype control) BD Pharmingen 555749 PE MOPC-21 
IgG1, κ (isotype control) BD Pharmingen 555751 APC MOPC-21 
IgG2a, κ (isotype control) Biolegend 400231 PeCy7 MOPC-173 
 





pSTAT3 (pY705) BD Biosciences 612569 PE 4/P-STAT3 
IgG2a, κ (isotype 
control) 
BD Biosciences 558595 PE MOPC-173 
IL-17A APC eBioscience 17-7179-42 APC eBio64DEC17 
IgG1 κ isotype control eBioscience 17-4714-42 APC  P3.6.2.8.1 
IFN-γ PE BD Pharmingen 562016 PE B27 
IgG1 κ isotype control BD Pharmingen 559320 PE MOPC-21 
 
Other fluorescent reagents used 
Reagent  Manufacturer Catalogue number Fluorophore 
CFSE Molecular Probes  C1157 FITC 
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B) Cell purities 
 
i) Monocyte (CD14) purity  
 
Figure 5.1: Purity of isolated peripheral blood CD14+ monocytes. CD14+ monocytes were isolated 
from peripheral blood mononuclear cells using CD14 isolation kit (Miltenyi). Monocytes were 
positively selected using AutoMACS (Miltenyi) with the Possel program. The purity of monocytes 
was evaluated using flow cytometry by staining them with CD14-APC (Biolegend) and analysed 
using flow cytometry via Cyan ADP Cytometer. Blue arrows represent progressive gating strategy.   
ii) CD1c+ DC purity 
 
Figure 5.2: Purity of isolated peripheral blood CD1c+ DCs. CD1c+ DCs were isolated from 
peripheral blood mononuclear cells using BDCA-1 isolation kit (Miltenyi). CD19+ B cells were 
initially depleted using AutoMCS (Miltenyi) with the Depletes program. CD1c+ DCs were 
positively selected from the CD19negative-containing suspension using AutoMACS (Miltenyi) with 
the Posseld2 program. The purity of CD1c+ DCs was evaluated using flow cytometry by staining 
them with CD1c-PE, HLA-DR-PEcy7, CD19-PB and CD14-APC (all from Biolegend) and 
analysed using flow cytometry via Cyan ADP Cytometer. Blue arrows represent progressive gating 
strategy. Percentage of contaminating B cells were gated as CD1c- HLA-DR+ CD19+.   
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iii) Memory CD4+ T cell purity 
 
Figure 5.3: Purity of isolated peripheral blood memory CD4+ T cells. Memory CD4+ T cells were 
isolated from fresh PBMCs with human Memory CD4+ T cell Enrichment Kit (StemCell 
Technologies) according to manufacturer’s instructions, which depleted CD8, CD14, CD16, CD19, 
CD20, CD36, CD45RA, CD56, CD123, TCRγ/δ, glycophorin A-expressing cells. The purity of 
memory CD4+ T cells was evaluated by staining with anti-human CD3-PB (clone – OKT3), CD4-
APC Cy7 (clone – RPA-T4), CD45RO-APC (clone – UCHL1) and CD45RA-PE (clone – HI100) 
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iii) CD141+ DC, CD1c+ DC and pDC sorting strategy 
 
Figure 5.4: Sorting strategy to isolate CD1c+ DCs, CD141+ DCs and pDCs. Total lymphocytes 
were initially gated from the FSC vs SSC gate, followed by the removal of cell doublets. Total live 
lymphocytes were gated as live/dead aquaneg. Total DCs were identified as lineageneg HLA-DR+. 
pDCs were sorted as lineageneg HLA-DR+ CD123+. From the lineageneg HLA-DR+ CD123neg 
population, CD141+ DCs were sorted as lineageneg HLA-DR+ CD141+, while CD1c+ DCs were 
sorted as lineageneg HLA-DR+ CD1c+. All three DC subsets were sorted using MoFlo Astrios 
(Beckman Coulter) into their respective polypropylene tubes cushioned with 500µl of 10% heat-
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pDC purity post-sorting 
 
Figure 5.5: Purity of pDCs post-sorting. Using the gating strategy depicted above, an aliquot of 
sorted pDCs were reanalysed using the MoFlo Astrios (Beckman Coulter). The diagram above is a 
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CD141+DC purity post-sorting 
 
Figure 5.6: Purity of CD141+ DCs post-sorting. Using the gating strategy depicted above, an 
aliquot of sorted CD141+ DCs were reanalysed using the MoFlo Astrios (Beckman Coulter). The 
diagram above is a representative plot of CD141+ DC purity. The percentage of shown within the 
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CD1c+ DC purity post-sorting 
 
Figure 5.7: Purity of CD1c+ DCs post-sorting. Using the gating strategy depicted above, an aliquot 
of sorted CD1c+ DCs were reanalysed using the MoFlo Astrios (Beckman Coulter). The diagram 
above is a representative plot of CD1c+ DC purity. The percentage of shown within the R10 gate 
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C) LSR Fortessa X20 colour compensations 
 
Figure 5.8: Single colour compensation setup on the LSR Fortessa X-20 using CFSE-labelled 
PBMCs. Frozen PBMCs were thawed, labelled with 0.2µM CFSE and cultured overnight (20 
hours) at 37OC. Post-culture, CFSE-labelled PBMCs were harvested, washed and analysed on LSR 
Fortessa X-20. a) CFSE-labelled PBMCs were gated from FSC vs SSC, and bleeding of CFSE 
signal into other flow cytometer channels was evaluated. b) CFSE-labelled PBMCs were stained 
with anti-human CD3-PE (Biolegend) and bleeding of CFSE signal into PE detector was evaluated. 
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D) AS patient details 
Table 5.1: AS patient characteristics including age, sex, erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP) levels, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
scores as well as treatment regime. All AS patients recruited in our study were treated with 
nonsteroidal anti-inflammatory drugs (NSAIDs) but naïve for TNF-α antagonist treatment.  
 
 
